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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Gastric Cancer: Seeking the
Chance to Cure
The diagnosis of cancer of the stomach
generally causes despair in the heart of the
victim and despondency and a sense of
futility in the mind of the physician. Few
cancers are viewed with such overriding
gloom. The reasons for this endemic pes
simism are clear: 30% of patients are not
even surgically explored; in only one third
will a curative resection be feasible, and
even for this less-unfortunate minority the
5-year survival is, at best, only 30%.
These depressing figures are made even
more discouraging by the widely held opi
nion that none of our efforts over the past
few decades has made the slightest
impression on the ultimate outcome.
Cady and associates,1 describing the
Lahey Clinic experience with 403 patients
seen during the period 1957 through 1966,
reported that although 44% had a cura
tive resection, only 24% of this group sur
vived 5 years, and of these long-term sur
vivors about 25% died of disease in the

ensuing 10 years. They concluded that no
progress in the surgical management of
this disease had been made since 1950
despite a generally aggressive surgical
approach. They recommended more con
servative management of focal gastric
cancer, rejected routine total gastrectomy
and advised that subtotal gastrectomy be
performed taking “ a modest amount of
surrounding omentum and whatever
adjacent tissue is required to encompass
gross tumour” . More recently, Diehl and
colleagues2 reported on 164 patients seen
during the period 1970 to 1980 at the
Cleveland Clinic. Except for a reduction
in operative mortality (from 10.3% to
4%), there was no change in overall prog
nosis compared with that achieved at the
same institution during the period from
1950 to 1972. They therefore “ do not
recommend radical resections for small
favorable cancers” . The very large series
of 1024 cases seen in Montreal between
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1941 and 1983 reported by Moore (Can
J Surg 1986; 29: 25-28) provides a strik
ingly similar picture: 81% of patients
underwent laparotomy, but only 24% of
the 1024 patients underwent curative
resection; of these, 34% survived 5 years
and only 21% survived 10 years. Despite
a substantial increase in overall resecta
bility (from 47% in the first decade to
65% in the third decade) there was no
change in the survival rate. Moore con
cluded that possible improvement will
come only from other treatment modal
ities.
Are we condemned to rely on improve
ments in radiotherapy and chemotherapy
(neither notably effective in gastric
cancer) for future advances? The future
may not be quite so bleak as it appears.
There are two glimmers of hope. The first
relates to etiology and the second to diag
nosis. Moore reported a decline in the
number of cases seen at the Royal Vic-
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toria Hospital during the study period.
While this may, in part, be explained by
a change in referral pattern, it also reflects
a real decline in the incidence of gastric
cancer on this continent. This is in con
trast to areas of high prevalence (e.g., in
Japan, where cancer of the stomach is the
cause of almost half of all cancer deaths)
where the incidence remains quite
steady.3 Other changes are occurring
too. There is a relatively greater reduc
tion in antral cancers (especially in men)
compared with proximal tumours, the age
at diagnosis has increased and, perhaps
most interestingly, there appears to be a
substantial increase in the number of
signet-ring carcinomas.4 These changes
may provide important clues to the etiol
ogy of gastric cancer and certainly merit
closer study.
Second, why are the Japanese able to
rep o rt5 that early gastric cancer
represents about one third of their cases
and that the 5-year survival rate is greater
than 90%. It is unlikely that early gastric
cancer is different in Japan. Those few
cases that are recognized in North
America (5% of all cases) appear to be
indistinguishable in terms of histologic
characteristics, growth patterns, co
existent lesions in the stomach and cura
bility by surgical resection6 from those
reported by the Japanese. The explana
tion for the discrepancy clearly lies in
earlier diagnosis.
Perhaps we cannot hope to find gas
tric cancer as early as Japanese physicians
do. In a society in which gastric cancer

is substantially less common and is also
on the decline, it would not be costeffective to mount mass endoscopic
screening programs. But there seems lit
tle doubt that earlier and more ready
recourse to endoscopy in symptomatic
patients would identify many more cases
of early gastric cancer. The accuracy of
endoscopy has improved greatly. Moore
reported only 76% accuracy in the
30-years ending in 1970, but current tech
niques would yield a tissue diagnosis in
more than 95% of patients.7 This means
that we have an obligation to identify
high-risk patients and to investigate them
aggressively for even minor gastric symp
toms. Such patients include those with
atrophic gastritis, pernicious anemia and
hypergastrinemia from any cause. If gas
tric polyps are found they should be
removed and regular surveillance estab
lished. The finding of intestinal metapla
sia or severe dysplasia also merits care
ful observation and regular reassess
ment.8 It is doubtful if the suggested
regular endoscopie examination of all
patients following gastric surgery for
benign disease would be cost-effective.
What is desperately needed is a reliable
serologic tumour marker.
As long as we continue to see gastric
cancer at a stage when only 30% of
patients can undergo resection for cure,
arguments about the best operation are
senseless. But if we can learn to detect
gastric cancer early — and a group at
McMaster University has shown that we
can do much better9 — then as surgeons

we can return to the challenging question
of what is the most effective curative
operation.
M ax M . Coh en,

m b , fr c s (e d in ), frcsc

Member,
Editorial Board
Professor o f Surgery,
University o f Toronto,
Toronto, Ont.
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A Tale of Two Women: the Concept
of Good and Bad Disease in Breast Cancer
To know the natural progress o f disease is to
know more than half of medicine.

A rmand T rousseau

The treatment of breast cancer remains
one of today’s greatest medical controver
sies, and clinicians are in a state of great
uncertainty about proper treatment. If
cancer statistics are to be improved then
the riddle of breast cancer must be solved.
The disease has a thousand different
faces, and no two patients suffer in
exactly the same way. How do we sort out
the different kinds of cancer and assess
our results? It is insufficient to measure
the quantity of life using 5 or 10-year
yardsticks. The quality of life is equally
important, but it is difficult to measure
and is rarely reported.
78

The medical literature contains more
reports on breast cancer than on any
other tumour. Imhotep wrote the first
treatise on breast cancer in 3000 BC. In
the last 5 years there have been 13 662
publications on breast cancer, with 5175
discussing treatment and 2197 experimen
tal approaches. Overall, they have done
little to help the clinician in deciding how
to investigate and treat his next new
patient. Many reports relate to what hap
pened to patients in a clinical trial, but
provide little guidance as to whether the
findings can be extrapolated to practice.
Over the years I have participated in
both retrospective studies and prospective
randomized controlled clinical trials.1'3
Twenty years ago, I knew, or thought that

I knew, how to manage the disease. There
have been many changes and advances in
investigation and treatment, but I am now
at a greater loss than ever to define
optimal care in the many different phases
of the illness. Improved survival rates are
reported with more conservative local
treatment and aggressive adjuvant ther
apies.2'4,5 A patient’s problems, how
ever, and what can be done to alleviate
them, have not changed. Where should
I put my efforts in the next decade? What
constitutes optimal cost-effective investi
gation and treatment? What about clini
cal trials? What research should I do?
A recent mini-sabbatical gave me the
opportunity to shift my mental gears and
to review my own frontline oncologic
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practice. Experienced clinicians have
always known that they can learn more
about life and death from their patients
than from any book or lecture. Glancing
through old notes, I became aware of the
importance of the natural history of the
disease. It was exemplified by tjie histo
ries of two women. Survival, whatever the
treatment, was clearly related to the
tum our’s degree of malignancy, or
growth rate. From my records I rediscov
ered the concept of “ good” and “ bad”
breast cancer (not that there is such a
thing as good cancer). Bad tumours are
highly malignant and metastasize early;
all treatments fail and the patient dies
usually within a few months. Good
tumours are of low-grade malignancy and
metastasize only months or years after
their initiation. The disease follows a
chronic course during which the patient
lives a relatively normal life with little or
no treatment.
The first patient, with bad breast
cancer, was a 28-year-old nurse who had
had a complete physical examination just
2 months earlier. She found a large lump
in her left breast while bathing, and
immediately sought medical advice. A
mass- measuring 8 cm was present in an
inflamed breast with peau d ’orange skin.
The axillary nodes were not palpable and
distant metastases were not detected. Fol
lowing a course of irradiation to the
breast and regional nodes, the tumour
resolved. Widespread bone metastases
developed, however, and she died within
5 months of her first symptom. The
second woman, illustrating good breast
cancer, was 37 years old when she noticed
a thickening in her left breast. A partial

mastectomy was performed, but 8 months
later the tumour recurred at the primary
site and was treated with a radium
implant. For the next 32 years the patient
was lost to follow-up. Then, she came
back complaining of “ spots on the chest”
and backache (Fig. 1). The chest wall
showed recurrent nodules and roentgeno
grams revealed widespread osteolytic and
osteoblastic bone metastases. Palliative
irradiation and hormones were given, but
she died 2 years later aged 72 years, 35
years after diagnosis. Both women died
of breast cancer, but one lived with the
cancer and without symptoms for half of
her life.
The influence of treatment on survival
can only be truly assessed in the light of the
natural history of breast cancer.6 When
did the cancer really start and is it “good”
or “ bad” ? Since survival is intimately
related to the degree of malignancy or
growth rate, the length of history, the
clinical stage and especially the status of
the axillary lymph nodes, and the
presence or absence of estrogen and
progesterone receptors provide the best
clues to its malignant potential. Estimates
of tumour growth from serial measure
ments of cutaneous nodules and pulmo
nary metastasis suggest that fast-growing
tumours double within 90 days, but slowgrowing ones take more than 450 days. 4-7
Such tumours might have originated from
a single cell 8 and 42 years before diag
nosis. An average tumour would appear
to have a doubling time of 100 days, and
so when the tumour is 1 cm in diameter
and barely palpable it would contain 109
cells and have been present for 10 years.4
My two patients had very different
tumours (Fig. 2). It seems reasonable to
assume that the woman with bad breast
cancer had a very short preclinical phase
with metastases seeded almost immedi
ately. In the other woman with good
breast cancer, the tumour probably
started some 15 years earlier, with

metastases developing 6 years before diag
nosis. Alternatively, the metastases may
have been seeded 20 to 30 years after
treatment or at the time of the local recur
rence. But what factors controlled the
tumour for so many years, and what
other factors upset the balance and
unleashed overt disease?
Breast cancer is a biologically predeter
mined disease. Its characterization is
essential in order to determine optimal
treatment. The growth rate and metastatic
potential vary enormously and depend on
numerous tumour-host variables. About
one third of patients, those who live
longer than 5 years, could be considered
to have good breast cancer. The spectrum
of disease makes it difficult to assess
treatment, and as any stratification will
contain good and bad tumours a bias one
way or another could account for the
differences in the reports of clinical trials.
Current research on treatment is being
directed along biologic concepts rather
than anatomic or mechanistic ones, which
formed the basis for radical mastectomy
and other aggressive treatment.5
Toronto can be proud of the major role
that it has played in the now goldstandard treatment for stage I and II
breast cancer, segmental mastectomy fol
lowed by breast irrad iatio n .1-2 This
philosophy was developed from clinical
observation and careful retrospective
studies and, as already stated, the
experienced clinician knows that his
patients teach him more than he can learn
from any other source.

P.J. Fitzpatrick, mb,

bs, frcpc , frcr

Professor of Radiology (Oncology),
The Princess Margaret Hospital,
University of Toronto,
500 Sherbourne St.,
Toronto, Ont.
M4X 1K9
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Acalculous Cholecystitis
in Burned Patients
To the editors.—The recent report by
M.W. McDermott and colleagues (Can J
Surg 1985; 28: 529-533) on the occurrence
of acute acalculous cholecystitis in burned
patients prompts me to make several com
ments regarding this insidious and poten
tially lethal condition in critically ill
patients with no gastrointestinal disease.
Acalculous cholecystitis is common to
all patients receiving intensive care regard
less of the admitting diagnosis. Invaria
bly, in my experience and that of
others,' these patients have a number of
factors in common. They are: prolonged
narcotic requirements, mechanical venti
lation, recent surgery, multiple blood
transfusions, a source of sepsis remote
from the gallbladder and hyperalimenta
tion. Certainly these factors were present
in all the p atien ts described by
McDermott.
The diagnosis of acalculous cholecysti
tis is not as straightforward as McDer
mott and colleagues suggest. I disagree
with their summary, regarding diagnosis.
This is a slowly progressive disease with
abdominal findings that are nonspecific
and invariably misleading. These critically
ill patients often have local injuries (such
as a burn), have been given narcotics
intravenously, have incisions, have
enlarged livers due to intravenous alimen
tation and have altered mentation secon
dary to sepsis, all of which make the
interpretation of any finding almost
impossible.
The biochemical picture is similarly
confusing, especially in the patient with
sepsis receiving intravenous hyperalimen
tation. Radiologic investigations provide
the only reliable method of making the
diagnosis. In critically ill patients, bedside
ultrasonography should be the initial
investigation. If an abnormality is found
(transverse diameter of the gallbladder
greater than 5 cm, wall thickness greater
than 4 mm, presence of sludge or stones,
or air in the gallbladder wall),2 then
there are several options for either treat
ment or further investigation. Stones or
emphysematous findings within the gall

bladder wall require surgical therapy. The
remaining nonspecific ultrasonographic
findings common to patients with acal
culous cholecystitis are consistent with
either a diagnosis of acalculous chole
cystitis or the fasting state. Hydroxydiaminoacetic acid (HIDA) or paraisopropyliminodiacetic acid (PIPIDA) scanning
should then be performed. If positive (no
gallbladder visible in 2 hours) then surgi
cal intervention is again required. I recog
nize that the patient must be moved to the
nuclear medicine department for this
procedure, but this can be done safely if
certain physical and staff requirements
are met.3 The morbidity and mortality
associated with this trip out of the inten
sive care unit are far less than those of
an unwarranted surgical exploration of
the right upper quadrant either under
local or general anesthesia. In some cases
the radioisotope for these scans can be
injected into the patient in the intensive
care unit and the patient transported some
time later.
Acalculous cholecystitis is lethal if left
untreated. Acute awareness of the con
dition and appropriate investigations are
needed for early diagnosis and manage
ment. I agree with the suggestions made
by McDermott and colleagues regarding
the surgical therapy.
M urray J. G irotti, md , frcsc
Co-director,
Surgical Intensive Care Unit,
Toronto General Hospital,
Toronto, Ont.
M5G 2C4
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To the editors.—We thank Dr. Girotti
for his comments on our article. Dr.
Girotti makes the statement that “ this is
a slowly progressive disease with non

specific abdominal findings” . We think
this disease is likely a part of the syn
drome of multisystem organ failure and
usually presents as other organs fail.
Acalculous cholecystitis may have a more
acute course in patients suffering from
multiple traum a or when oral feeding is
reinstated.1-3
With reference to the investigation of
the condition, Dr. Girotti states, “ Radi
ologic investigations provide the only
reliable method for making the diagno
sis...” . We believe that the development
of the new finding of tenderness in the
right upper quadrant that is localized to
the region of the gallbladder should alert
the clinician to the possibility of acute
acalculous cholecystitis. One of our
patients had in fact been burned in this
area, but this did not obscure the fact that
right upper-quadrant tenderness did
develop and did lead us to the diagnosis.
Others3,4 have found that most patients
w ith the diagnosis o f acalculous
cholecystitis who are able to respond have
right upper-quadrant tenderness. U ltra
sonography and HIDA scanning are good
aids in diagnosis. But they, too, have their
sources of error.
It is well known that total parenteral
nutrition and alcoholic liver disease can
affect the results of HIDA scanning.5 In
one of our patients the diagnosis of acal
culous cholecystitis was made from the
findings of ultrasonography alone. After
exploration of the gallbladder through a
3.5-cm incision under local anesthesia, the
gallbladder was judged to be normal.
There was no morbidity attached to the
procedure.
With respect to patients with small
localized burns, we agree that movement
of these patients from the specialized
burn-care unit does not jeopardize the
patient’s welfare. In our series, patients
with acalculous cholecystitis tended to be
those with severe, extensive burns. These
patients often have limbs suspended for
skin grafting and burn-wound care and
are often intubated, compounding the
difficulty and risk of transporting them
out of the special care unit.
We agree with Dr. G irotti that
ultrasonography and HIDA scanning
should be done rather than “ an unwar-
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ranted surgical exploration” , but explo
ration under local anesthesia should be
done if acalculous cholecystitis is
definitely suspected despite negative
results of ultrasonography or HIDA
scanning.
C harles H. Scudamore, md , frcsc
Assistant Professor of Surgery,
University of British Columbia,
3rd Floor,
910 West 10th Avenue,
Vancouver, BC
V5Z 4E3
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The Death of G.B.S.
To the editors.—In his editorial on the
broken hip (Can J Surg 1985; 28:
385-386), Sorbie refers to the terminal ill
ness of George Bernard Shaw.
My brother, L.W. Plewes, FRCS,
CBE, was Shaw’s orthopedic surgeon
after he was admitted to the Luton and
Dunstable Hospital in September 1950, at
the age of 94 years, with a broken hip,
chronic retention of urine and a
hemoglobin value of 250 g/L (he was a
strict vegetarian all his life). A genitouri
nary surgeon arranged treatment for an
enlarged prostate. The fracture was
reduced and fixed with a pin and plate.
He was allowed limited weight bearing the
following day and made steady progress.
When he returned home, he removed the
urinary catheter and refused further treat
ment. He realized what was happening
and said, “ The great G.B.S. was gone
and merely the shell remained.”
George Bernard Shaw did not die of a
broken hip, but of chronic urinary reten
tion, anemia and his own refusal to toler
ate an indwelling catheter.
Burns P lewes, md , ms, frcsc ,
FRCS(EDIN)
245 Beech Ave.,
Toronto, Ont.
M4E 3J1

To the editors.—I was very interested to
read Dr. Plewes’ letter. It reveals infor
mation to which I had no access. 1 am
grateful for the correction and pleased to
have first-h an d know ledge. The
newspapers at the time ascribed Shaw’s
82

death to the consequences of a fractured
hip. It is usual, when compiling statistics
for most clinical reviews, to list all deaths
within 3 months of a fractured hip as
relating to, if not resulting directly from
it. The immediate cause may be, for
example, pulmonary embolism. Jensen
and Tetndevold1 list death rates of 17%
at 3 months and 21.5% at 6 months after
hip fracture.
In the case of G.B.S., I am reliably
informed the sequence of events was as
follows: Sept. 6, 1950 — broken hip,
internal fixation; Sept. 22 — surgery to
urinary tract; Oct. 5 — discharged from
hospital; Nov. 2 — died.
I was a teenager when G.B.S. died and
time can distort memories. I recall that
his hip broke when he fell from a step lad
der while pruning his apple trees. I hesi
tate to repeat this, however, as I risk a
letter from his gardener who may have
more reliable information!
C harles Sorbie , md , frcsc
Professor and Head,
Department of Surgery,
Queen’s University,
Kingston, Ont.
K7L 3N6
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Radiation Exposure to the Surgeon
During Ender’s Nailing
To the editors.—Thurlow’s remarks (Can
J Surg 1986; 29: 9) concerning the need
to keep radiation exposure to a minimum
in the operating room are well taken. A
conventional nail and plate can certainly
be used to treat all intertrochanteric frac
tures, and the procedure does not require
the use of an image intensifier.
Many surgeons now use image intensifiers during hip nailing. Our purpose was
to quantify the exposure the hands of
members of the operating team receive
during Ender’s nailing. The operation
must be done with two image intensifiers
and the hands can’t easily be shielded.
Individual judgement must be used in
deciding whether the operating team can
accept that Ender’s nailing will probably
entail the following exposure: 9 to 20
mrem for the surgeon, 1.3 to 1.7 mrem
for the instrument nurse and 2.8 to 3.0
mrem for the anesthetist.
The 5000 mrem figure quoted by
Thurlow is the annual occupational limit
for exposure to the whole body. The cur
rent limit used by Canadian authorities
for extremities such as the hands is 75 000
mrem/yr. This is the figure that should
be used to put our paper (Can J Surg

1985; 28: 25-26) and Thurlow’s com
ments into perspective.
We did not propose to support or to
challenge the adequacy of the interna
tional standards and those used by Cana
dian authorities.
J.P. Moreau , md , facs, frcsc
Division of Orthopedic Surgery,
University of Alberta,
Edmonton, Alta.

J.P. ASHMORE, PH D
Radiation Protection Bureau,
Department of National Health and Welfare,
Ottawa, Ont.

Splenic Abscess —
Percutaneous Drainage
To the editors.—I read with interest the
report of Stringel and associates (Can J
Surg 1985; 28: 269-270), describing suc
cessful operative drainage of a splenic
abscess. Although splenectomy and
antibiotics are the treatment of choice for
a splenic abscess,1 drainage of the
abscess has been tried in an attempt to
preserve splenic function and thus prevent
overwhelming post-splenectomy infec
tion. Percutaneous drainage of splenic
abscesses is a theoretical option and can
be performed safely using ultrasonogra
phy and computed tomography for
guidance. It results in decreased mor
bidity and shorter hospital stay. Lerner
and Spataro2 successfully managed four
cases of splenic abscess by percutaneous
drainage and referred to four more cases
reported earlier.3,4 Kreel5 reported
another case of splenic abscess treated
successfully by this method.
Percutaneous catheter drainage under
radiologic guidance is a safe and effec
tive method for treating splenic abscess
and is recommended, especially for debili
tated patients.
vinay

Kumar Kapoor , mb, bs, ms

Senior Resident,
Department of Surgery,
All India Institute of
Medical Sciences,
New Delhi — 110029,
India
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Now indicated for the
prevention o f occlusion of the saphenous vein
in coronary bypass procedures.
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know
who's doing what and why. Surgeons are interested in what other surgeons are doing in
research, education, practice and administration. Surgery is a vibrant specialty, and, as
its practitioners, you must be the source as well as the readers of this column.

Liability Insurance: the Costs

While most surgeons in Canada have to
dig into their wallets for almost 100%
more money than last year to cover their
fees for liability insurance, their primary
workplace — the hospital — is searching
its budget for as much as 1000% more.
The increases, according to the insur
ance companies, are simply a reflection
of the rising numbers of writs against doc
tors and hospitals, the increasing dollar
values of awards to patients who can con
vince the courts that someone was to
blame for their injury, and the ever
growing legal fees that accompany actions
no matter what the outcome.
In 1984, the Canadian Medical Protec
tive Association (CMPA) recorded an
increase of about two new actions per
month over the year before, while
monthly payments for damages increased
an average of about $100 000. What’s
more, the CMPA had to pay out about
$150 000 per month more in legal costs
to defend its members. Although tabula
tions for 1985 are not yet complete, says
CMPA associate secretary Stuart Lee,
FRCSC, the trend continues in all the
provinces.
The picture for hospitals is similar: the
Ontario Hospital Association’s Compre
hensive Insurance Programme reported
that for every claim lodged against a
member in 1978 there were 4.5 in 1984,
and awards increased six times during the
same period. Jean-Claude Martin, presi
dent of the Canadian Hospital Associa
tion, says that a survey of brokers is under
way to collect, if possible, nationwide
figures on not only the claims and awards
but also the risks attached to different
types and locations of hospital. “ We are

Contributions to this column are welcome.
Please send your material to: Mrs. Amy
Chouinard, Canadian Journal o f Surgery, PO
Box 8650, Ottawa, Ont. K1G 0G8.

trying to gather the information but
hospitals are not like the doctors who
have only the CMPA; we are dealing with
many insurance brokers. Some of the
hospitals are grouped by region, some by
provincial association and some are deal
ing directly with brokers. Most of the
western provinces — BC, Alberta,
Manitoba — and Ontario are grouped
under the hospital association and they
deal with one broker; in Quebec, they
deal with a consortium of brokers; the
maritime provinces vary. But the legal
contract is with the institution.”
Hospitals are only one area where the
public purse is involved, as liability costs
and insurance coverage have been front
page news since the beginning of the year
when many school boards and municipal
ities attempted to renew their policies and
were faced with unprecedented increases.
Compensating the injured patient

Government intervention is only a mat
ter of time and the medical profession
would like to have some input into the
direction of change, says Richard Railton,
FRCSC, a general surgeon from Welland,
Ont., who chairs the Canadian Medical
Association’s political action committee
and serves on both the CMA Board of
Directors and the Council on Economics.
Railton spoke to CJS after a meeting
on Jan. 26 in which the economics coun
cil heard from a government consultant
on liability, Frank J. Sellers, FRCPC, and
F. Norman Brown, FRCPC, secretarytreasurer of the CMPA. He acknowl
edged both speakers as providing infor
mation that allowed the council to focus
on what can be done to improve the sys
tem and fashion some recommendations
for action by the CMA board and the
medical profession in general.
Some weaknesses, said Railton, lend
themselves readily to change, such as the

amount of time allowed for a patient to
lodge a legal complaint, lump sums as
paym ents instead of annuities for
damages, rules on taxation and uses of
awards, and the current arrangements for
legal aid. Other weaknesses, such as the
emphasis on finding someone at fault for
the injury and the inadmissibility of other
compensation as part of the payment for
damages, are entrenched in the tort
system.
“ Statutes of limitations have been
around since the 1500s at least but are
increasingly being affected by the ‘discov
ery principle’. This means that the
patient’s time limit in bringing an action
against a physician for some alleged
wrongdoing begins at the time that the
person knows or ought to have known
there was a problem. The time limit
doesn’t start running if the person is
under a disability, including being a
minor. So you have the possibility of an
obstetrician being sued for negligence 20
or 30 years after delivering a baby. By this
time, people have forgotten what really
happened, records have disappeared, wit
nesses have moved away or died, and it
becomes terribly difficult to defend an
action.
“ The statute of limitations we feel
should have an absolute cap on it of 6
years as is the case in British Columbia.”
Otherwise, the circumstances are difficult
to reconstruct as are the practices,
knowledge and equipment that were stan
dard at the time. In other words, the
grounds for negligence are no longer firm.
“ Another problem is that a large
amount of the money awarded to a per
son goes to the provincial health plan. In
Ontario, for example, if a court awards
$2 million to someone for a negligent
action by a doctor, perhaps half of it goes
to the health insurance plan to look after
the person. This is called subrogation.
“ Also, to give a person the amount of
money needed to cover future health care
and potential earnings, the court may
double the award because it knows that
the person is going to be taxed on the
money. This is known as ‘grossing up’.
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“ Both subrogation and taxation con
tribute to the high awards but not to the
amount of money given as compensation
to someone. If the idea is to recompense
people for some misadventure, then the
money should go to them .”
“ Subrogation and grossing up of pay
ments have come about in the last 10 or
15 years; they are not enshrined in an act
or a bill, and provincial governments
could make changes to them relatively
easily.”
In contrast, says Railton, “ regulations
on collateral payments [moneys received
as compensation from sources other than
defendants] have long-standing existence
in common law and would be difficult to
change, although I think that the Law

— orm Commission is looking at them.”
If the idea is to ensure that the person
is appropriately compensated for past,
present, and future losses and expenses
caused by an injury, then other compen
sation payments should figure in calcu
lations of how much an injured person
should receive.
Similarly, the onus on patients to show
that someone is to blame for their mis
fortune means that many people receive
no compensation: that is, lawyers are the
only participants in the action who have
any guarantee of success in terms of dol
lars and in most provinces of Canada only
the rich who can afford the fees and the
poor who can qualify for legal aid can
undertake such an action. According to

Malawi Orthopedic Project
Seeks Volunteers

This month marks the official opening of
a $1.4 million project in which orthopedic
surgeons from Canada and elsewhere will
train about 30 parasurgeons in Malawi to
correct the crippling effects of poliomye
litis.
The 4-year project, which is funded
jointly by Canadian Rotary Clubs and the
Canadian International Development
Agency, is headed by Edward J. Blair and
will get under way officially Mar. 10 after
the head of Rotary International, also an
orthopedic surgeon, arrives for a visit to
the country.
Blair left his practice in St. Catharines
to begin work late last year at the Queen
Elizabeth Central Hospital in Blantyre,
Malawi. The first 10 students, selected
from a group of 150 applicants, have
begun their course work, and $100 000
worth of equipment purchased by rotarians for the project has been airlifted to
the area.

Edward J. Blair, FRCSC heads Malawi ortho
pedic project.
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Railton, the structure for legal aid
encourages a patient to continue an action
even though the indications are that he
or she will be unable to show that the phy
sician has been guilty of negligence,
breach of confidence, breach of contract
or battery.
These and other reasons have
prompted some governments to introduce
“ no fault” compensation. New Zealand
and Sweden have fashioned legislation
that will provide compensation for per
sonal injuries or accidents of all sorts
without tying up the courts. However, the
systems are major departures from the
existing setup in Canada, as they deny the
injured person’s right to resort to the
courts for compensation.

BOOKS RECEIVED
This list is an acknowledgement of
books received. It does not preclude
review at a later date.

In 1979, 7 in every 1000 healthy children in
Malawi would have contracted poliomyelitis
and many victims would need a type of
surgical correction that Blair is teaching.

Blair came up with the idea for the
project while putting his skills to work in
an earlier effort between the rotarians and
Malawi Against Polio, a local organiza
tion that is involved in both prevention
and cure of the disease. At present, there
are 60 000 to 70 000 crippled peo
ple in the small southeast African coun
try, which covers about 80 000 km2 and
has a population of about 7 million. Blair
realized that his work and that of his col
leagues would make little impact unless
carried on and expanded by local people.
So he decided to ask other orthopedic sur
geons to volunteer for 3-month stints as
teachers, during which they would receive
a small stipend.
A.M. Adams, a retired food scientist
in St. Catharines, is managing the project
from this end and is overseeing the
money-raising from the 68 rotary clubs
in northeastern North America; the goal
is to come up with about $60 000 to com
plement a donation from Rotary Interna
tional.
Although the project has enough
volunteers for 1986, it is still looking for
assistance during the next 3 years. Ortho
pedic surgeons who are interested are
asked to write to: Malawi Orthopedic
Project, PO Box 512, St. Catharines,
Ont. L2R 6V9.
A my C h o u in a r d

Atlas of Cystoscopy. Jan Schonebeck, Lennart
Hakansson, Poul Buckhoj and Jan Buckhoj. 120 pp. Illust. Grune & Stratton, Inc.,
Orlando, Fla.; Academic Press Canada,
Don Mills, Ont., 1984. $89.50. ISBN
0-8089-1735-8
Congenital Displacement of the Hip Joint.
John A. Wilkinson. 153 pp. Illust.
Springer-Verlag New York, Inc., New York
1985. $96. (US). ISBN 0-387-13947-8.
Differential Diagnosis of Soft Tissue and Bone
Tumors. Steven I. Hajdu. 478 pp. Illust.
Lea& Febiger, Philadelphia, 1986. $146.25.
ISBN 0-8121-0895-7.
Dynamic Electrocardiography. Edited by
R.W.F. Campbell and A. Murray. 135 pp.
Illust. Churchill Livingstone, Edinburgh;
Academic Press Canada, Don Mills, Ont.,
1985. $65.25. ISBN 0-443-02407-3.
Hyperalimentation. A Guide for Clinicians.
Edited by Mitchell V. Kaminski, Jr. 719 pp.
Illust. Marcel Dekker, Inc., New York,
1985. $95. ISBN 0-8347-7375-6.
Invasive Procedures in Critical Care. Edited
by Charles L. Sprung and Ake Grenvik.
294 pp. Illust. Churchill Livingstone, Edin
burgh; Academic Press Canada, Don Mills,
Ont., 1985. $56.75. ISBN 0-443-98337-1.
Manual of Hand Splinting. Nancy M. Cannon,
Rebecca W. Folta, Jan M. Koepfer,
Melanie F. Lauck, Dawn M. Simpson and
Roberta S. Bromley. 117 pp. Illust. Chur
chill Livingstone, Edinburgh; Academic
Press Canada, Don Mills, Ont., 1985.
$26.25, paperbound. ISBN 0-443-08451-3.
1986 Surgery Annual. Volume 18. Edited by
Lloyd M. Nyhus. 385 pp. Illust. AppletonCentury-Crofts, Norwalk, Conn., 1986.
Price not stated. ISBN 0-8385-8725-9.
Nutrition in Clinical Surgery. 2nd ed. Edited
by Mervyn Deitel. 411 pp. Illust. Williams
& Wilkins, Baltimore, 1985. $65. (US).
ISBN 0-683-92450-7.
Occlusive Arterial Diseases of the Lower Limbs
in Young Patients. Serono Symposia Pub
lications from Raven Press, Volume 15.
P. Fiorani, G. Raimondo Pistolese and
Carlo Spartera. 312 pp. Illust. Raven Press,
New York, 1984. $39.50 (US). ISBN
0-88167-090-1.
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W hen you want an effective antibiotic at all costs.
But not at any price.
During the critical 24 to 48
hour wait for susceptibility tests,
you need an antibiotic with a clini
cally proven spectrum of activity.
An antibiotic with an excellent rec
ord of safety. An antibiotic such
as Cefobid*
When cost must also be
considered, Cefobid* remains an
antibiotic of choice. Its realistic

pricing structure and economical
twice-a-day dosage make
Cefobid* cost-effective therapy.12
Cefobid* is an advanced
cephalosporin proven effective
against a wide range of infections.
It is very well tolerated. With a
unique dual pathway of excretion,
Cefobid* at usual dosage requires
no modification of dosage in
patients with renal impairment.
Cefobid* Effective antibiotic
therapy you can well afford to use.
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Prescribing Information
Antibiotic
For Intravenous or Intramuscular Injection
ACTION
In vitro studies indicate that the bactericidal action of CEFOBID (cefoperazone sodium)
results from the inhibition of bacterial cell wall synthesis.
INDICATIONS AND CLINICAL USES
CEFOBID (cefoperazone sodium) may be indicated for the treatment of the following
infections when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae,
Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, Kleb
siella species (including Klebsiella pneumoniae), Pseudomonas aeruginosa, Escheri
chia coli, Proteus mirabilis, indole-positive Proteus species and Enterobacter species.
URINARY TRACT INFECTIONS caused by Escherichia coli, Pseudomonas aeruginosa,
Enterobacter species, Klebsiella species, Enterococcus, Proteus mirabilis, Staphylo
coccus aureus, Staphylococcus epidermidis and indole-positive Proteus species.
Due to the nature of the underlying conditions which usually predispose patients
to Pseudomonas infections of the lower respiratory and urinary tracts, a good clini
cal response accompanied by bacterial eradication may not be achieved despite
evidence of in vitro sensitivity.
ACUTE BILIARY TRACT INFECTIONS ASSOCIATED WITH CHOLECYSTITIS OR CHO
LANGITIS caused by Escherichia coli.
SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Strep
tococcus agalactiae, Escherichia coli and Klebsiella species.
WOUND INFECTIONS (SURGICAL AND TRAUMATIC) caused by Staphylococcus
aureus, Streptococcus pyogenes and Pseudomonas aeruginosa.
GYNECOLOGICAL INFECTIONS (SUCH AS PELVIC INFLAMMATORY DISEASE AND
ENDOMETRITIS) caused by Streptococcus agalactiae, Neisseria gonorrhoeae,
Escherichia coli, Bacteroides species (including Bacteroides fragilis), Peptococcus
species and Peptostreptococcus species.
Specimens for bacteriologic culture should be obtained prior to therapy in order to iden
tify the causative organism and to determine its susceptibility to CEFOBID (cefoperazone
sodium). Therapy may be instituted before results of susceptibility testing are known;
however, modification of the treatment may be required once these results become
available.
CONTRAINDICATIONS: CEFOBID (cefoperazone sodium) is contraindicated in patients
with known allergy to the cephalosporin class of antibiotics.
WARNINGS: Before therapy with CEFOBID (cefoperazone sodium) is instituted, careful
inquiry should be made to determine whether the patient has had previous hypersensi
tivity reactions to cephalosporins, penicillins or other drugs. CEFOBID (cefoperazone
sodium) should be administered with caution to penicillin-sensitive patients or to any
patient who has demonstrated some form of allergy, particularly to drugs. If an allergic
reaction to CEFOBID (cefoperazone sodium) occurs, discontinue administration of
the drug and treat the patient with the usual agents (e.g. epinephrine, antihistamines,
pressor amines or corticosteroids).
Pseudomembranous colitis has been reported to be associated with the use of
CEFOBID (cefoperazone sodium). Therefore, in those patients administered CEFOBID
(cefoperazone sodium) who develop diarrhea, it is important to consider such a
diagnosis.
Treatment with broad-spectrum antibiotics, including CEFOBID (cefoperazone
sodium) alters the normal flora of the colon and may permit overgrowth of Clostridia.
Studies indicate that a toxin produced by Clostridium difficile is one primary cause of
antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe
cases should be managed with fluid, electrolyte, and protein supplementation as indica
ted. When the colitis is not relieved by the discontinuance of CEFOBID (cefoperazone
sodium) or when it is severe, consideration should be given to the administration of oral
vancomycin.
PRECAUTIONS
General: The concomitant administration of aminoglycosides and some cephalosporins
has caused nephrotoxicity. Although transient elevations of BUN and serum creatinine
have been observed, there is no evidence that CEFOBID (cefoperazone sodium) when
administered alone causes significant nephrotoxicity. However, the effect of ad
ministering CEFOBID (cefoperazone sodium) concomitantly with aminoglycosides is not
known.
CEFOBID (cefoperazone sodium) is excreted in both the bile and urine. In normal
volunteers, 19 to 41% of the dose is excreted in the urine, the remainder being excreted
by the hepato-biliary system. The serum half-life of CEFOBID (cefoperazone sodium) is
usually prolonged and urinary excretion of the drug increased in patients with hepatic
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be
monitored in these patients treated with doses in excess of 2 grams daily and dosage
should be adjusted as necessary.
Because renal excretion is not the main route of elimination of cefoperazone, adult
patients with renal failure usually require no adjustment in dosage when daily doses of
2 to 4 grams (1 to 2 grams every 12 hours) are administered. If higher doses of CEFOBID
(cefoperazone sodium) are used, serum concentrations of cefoperazone should
be monitored. If there is evidence of accumulation, dosage should be decreased
accordingly.

In one study in patients with chronic renal failure, the half-life of CEFOBID (cefopera
zone sodium) was reduced from 4.17 to 1.67 hours during hemodialysis. Thus, dosing
should be scheduled to follow a dialysis period.
In patients with both hepatic dysfunction and renal impairment, the initial dosage of
CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and serum con
centrations of cefoperazone should be monitored closely.
Vitamin K deficiency has occurred in a few patients treated with CEFOBID
(cefoperazone sodium). The mechanism is most probably related to the suppression of
gut flora which normally synthesizes this vitamin. Those at risk include patients with
poor diet or malabsorption states (e.g. cystic fibrosis) and patients on prolonged intrave
nous alimentation regimens. Prothrombin time should be monitored in these patients
and exogenous vitamin K administered as indicated.
A reaction characterized by flushing, sweating, headache, and tachycardia has been
reported when alcohol is ingested during and as late as the fifth day after CEFOBID
(cefoperazone sodium) administration. Patients should be cautioned concerning inges
tion of alcoholic beverages in conjunction with administration of CEFOBID (cefoperazone
sodium). For patients requiring artificial feeding orally or parenterally, solutions con
taining ethanol should be avoided.
CEFOBID (cefoperazone sodium) should be administered with caution to individuals
with a history of gastrointestinal disease, particularly colitis.
Overgrowth of nonsusceptible organisms may occur during prolonged use of
CEFOBID (cefoperazone sodium). Patients should be observed carefully during treat
ment. If superinfection occurs, appropriate measures should be taken.
Drug Laboratory Test Interactions
A false-positive reaction for glucose in the urine may occur with Benedict’s or Folding's
solution.
Pregnancy: The safety of CEFOBID (cefoperazone sodium) in pregnancy has not been
established. The use of CEFOBID (cefoperazone sodium) in pregnant women requires
that the likely benefit from the drug be weighed against the possible risk to the mother
and fetus.
Reproduction studies have been performed in mice, rats and monkeys at doses up to
10 times the human dose and have revealed no evidence of impaired fertility or teratoge
nic effects due to cefoperazone sodium. Animal reproduction studies, however, are not
always predictive of human response.
Nursing Mothers: Cefoperazone is excreted in low concentration (0.4 to 0.9 /ig/mL) in
human milk. Caution should be exercised when CEFOBID (cefoperazone sodium) is
administered to a nursing mother.
Children: The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not
been established.
ADVERSE REACTIONS
Hypersensitivity: Maculopapular rash, urticaria, pruritis, eosinophilia, drug fever.
Hematology — Decreases in hemoglobin and/or hematocrit have occurred. Slight
decreases in neutrophil count have been reported, and reversible neutropenia may occur
with prolonged administration. Transient eosinophilia has occurred. Hypoprothrombinemia has been observed. Some individuals have developed positive direct Coombs' test
during treatment.
Liver — Transient elevations in SGOT, SGFT and alkaline phosphatase levels have been
noted. One patient with a history of liver disease developed significantly elevated liver
function enzymes during therapy with CEFOBID (cefoperazone sodium). Clinical signs
and symptoms of nonspecific hepatitis accompanied these increases. After CEFOBID
(cefoperazone sodium) therapy was discontinued, the patient's enzymes returned to pre
treatment levels and the symptomatology resolved.
Kidney — Transient elevations of blood urea nitrogen and serum creatinine have been
noted.
Gastrointestinal — Altered bowel habits (loose stools or diarrhea) have been reported.
Most of these events have been mild or moderate, but some have been severe. In all
cases, these symptoms responded to symptomatic therapy or ceased when
cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.
Pseudomembranous colitis has been reported rarely in patients administered
CEFOBID (cefoperazone sodium). Symptoms of pseudomembranous colitis can appear
during or for several weeks subsequent to antibiotic therapy.
Disulfiram-like Reaction
Disulfiram-like reactions have been reported when alcohol was ingested during and as
late as the fifth day after CEFOBID (cefoperazone sodium) administration.
Central Nervous System — Headache and dizziness occur rarely.
Local Reactions — CEFOBID (cefoperazone sodium) is well tolerated following intra
muscular administration. Occasionally, transient pain may follow administration by this
route. When CEFOBID (cefoperazone sodium) is administered by the intravenous route,
some patients develop phlebitis at the site of administration.
Other — Diaphoresis/chills
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Since no case of overdosage has been reported to date with CEFOBID (cefoperazone
sodium), no specific information on symptoms or treatment of overdosage is available.
Treatment should be symptomatic.
Hemodialysis is not effective in the removal of cefoperazone.
DOSAGE AND ADMINISTRATION
Dosage
CEFOBID (cefoperazone sodium) may be administered intravenously or intramuscularly.
Dosage and route of administration should be determined by severity of infection,
susceptibility of the causative organism, and condition of the patient.
Adult
The recommended daily dose of CEFOBID (cefoperazone sodium) is 2 to 9 grams ad
ministered in equally divided doses every 8 to 12 hours (See table below). The usual
duration of treatment is 7 to 14 days.
Adult Dosage
Frequency and Route
Type of infection
Daily Dose
1 to 2 grams
Mild to moderately severe
2 to 4 grams
every 12 hours
infections such as pneumonia,
I.M. or I.V.
acute urinary tract infection,
wound infection

Severe infections or infections
caused by less sensitive
organisms

4 to 8 grams

2 to 4 grams
every 12 hours
I.V.

Infections commonly requiring
9 grams
3 grams every
antibiotics in higher dosage
8 hours I.V.
(e.g. septicemia and life threatening
infections)
The maximum adult daily dose should not exceed 9 grams.
For infections caused by Streptococcus pyogenes, therapy should be continued for
at least 10 days.
Impaired Renal Function
Because renal excretion is not the main route of elimination of cefoperazone, adult
patients with renal failure usually require no adjustment in dosage when daily doses of
2to4 grams (1 to2 grams every 12 hours) of CEFOBID (cefoperazone sodium) are admin
istered. If higher doses of CEFOBID (cefoperazone sodium) are used, serum concentrationsof cefoperazone should be monitored. If there is evidence of accumulation, dosage
should be decreased accordingly. For patients whose glomerular filtration rate is less
than 18 mL/min orwhose serum creatinine level is greaterthan 3.5 mg/dL, the maximum
CEFOBID (cefoperazone sodium) dosage should be 4 grams per day.
In patients undergoing hemodialysis, dosing should be scheduled to follow a dialysis
period.
Hepatic Disease and Biliary Obstruction
The serum half-life of cefoperazone is increased 2 to 4 fold in patients with hepatic
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be
monitored in patients treated with doses in excess of 2 grams daily and dosage should
be adjusted as necessary.
Hepatic Dysfunction and Renal Impairment
In patients with both hepatic dysfunction and concomitant renal impairment, the initial
dosage of CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and
serum concentrations of cefoperazone should be closely monitored.
Children
The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been
established.
ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular
injection into a large muscle mass such as the gluteus maximus or anteriorthigh. The
maximum dose of CEFOBID (cefoperazone sodium) should be two (2) grams.
Intravenous:
Direct Intravenous (bolus) injection: The reconstituted solution should be injected
slowly over a period of no less than three (3) minutes. The maximum dose of
CEFOBID (cefoperazone sodium) should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a
period of 15 minutes to 1 hour through the tubing of an administration set while any
of the intravenous solutions (See Solutions for I.V. Infusion) are being infused. During
infusion of the solution containing CEFOBID (cefoperazone sodium), it is desirable to
temporarily discontinue administration of the other solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be
administered over a longer period of time.
Note: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination
with an aminoglycoside antibiotic, each should be administered at different sites
because of a physical incompatibility. An aminoglycoside should not be mixed with
CEFOBID (cefoperazone sodium) in the same container.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFOBIO
Proper Name: Cefoperazone sodium
Chemical Name:
Sodium (6R,7R)-7- ( (R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2(p-hydroxyphenyl) acetamido] -3[ [ (1-methyl-1H-tetrazol-5-yl)thio ] methyl]-8-oxo5-thia-1- azabicyclo[4.2.0] oct-2-ene-2-carboxylate

Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(g)____________ (mL)___________Volume (m l)____________(mg/mL)_______
1.0
3.5
4.0
250
2.0 __________ 7 9 ________________ FLO__________________ 250_________
Shake well until dissolved. Solutions should be allowed to stand after reconstitution to
allow any foaming to dissipate in order to permit visual inspection for complete solubili
zation. Vigorous and prolonged agitation may be necessary to solubilize CEFOBID
(cefoperazone sodium).
For Intravenous Use:
Solutions for Reconstitution and Dilution
Sterile Water fo r Injection
or, if required
Bacteriostatic Water for Injection
Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(g)____________ (m y___________ Volume (mL)____________(mg/mL)_______
1
9.5
10.0
100
2____________ 199_______________2 0 0 _________________ 100__________
Shake well until dissolved. The prepared solution may be further diluted to the desired
volume with any of the solutions for I.V. infusion listed below.
For direct intravenous (bolus) injection: Reconstitute as directed above.
For intermittent intravenous infusion: Reconstitute as directed above.
For continuous intravenous infusion: Reconstitute with Sterile Water for Injection. The
reconstituted solution may be added to an appropriate intravenous bottle/bag containing
any of the solutions for I.V. infusion listed below:
Solution for I.V. Infusion
5% Dextrose Injection (USP)
5% Dextrose and Lactated Ringer’s Injection
5% Dextrose and 0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.2% Sodium Chloride Injection (USP)
10% Dextrose Injection (USP)
Lactated Ringer’s Injection (USP)
0.9% Sodium Chloride Injection (USP)
Normosol® M and 5% Dextrose Injection
Normosol® R
Stability of Solutions
Storage:
Reconstituted solutions for intramuscular injection should be used within 24 hours if
kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Reconstituted solutions for I.V. injection or infusion should be used within 24 hours
if kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Incompatibility
CEFOBID (cefoperazone sodium) should not be added to blood products, protein
hydrolyzates, or amino acids. CEFOBID (cefoperazone sodium) should not be mixed
together with an aminoglycoside.
DOSAGE FORMS
Availability:
CEFOBID (cefoperazone sodium) is available as a lyophilized powder:
1.0 g vial — cefoperazone 1.0 g as sodium salt
2.0 g vial — cefoperazone 2.0 g as sodium salt
Storage
CEFOBID (cefoperazone sodium) should be stored protected from light and
refrigerated (2 to 8° C).
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Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol,
poorly soluble in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane.
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The
sodium content of each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion).
The pH of a 25% (w/v) solution is 4 5 to 6 5 and the solution is colorless to straw yellow
depending on the concentration.
RECONSTITUTION
For Intramuscular Use:
Solution for Reconstitution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
05% Lidocaine Hydrochloride Injection
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Transluminal Angioplasty: Indications and Overview
Reasons for the slow acceptance of per
cutaneous transluminal angioplasty over
the past 20 years are multiple and
include the lack of understanding of the
changes in the arterial wall caused by
angioplasty. Factors responsible for the
present popularity of the technique
include a better understanding of the
pathophysiology of catheter dilatation of
an artery, more efficient catheters and
monitors, increasing experience and
competence of angiographers, better
drugs to decrease spasm and thrombo
sis, greater knowledge of the immediate
and long-term results and social pressure
to reduce both cost and time in treating
patients. The indications for percutane
ous transluminal angioplasty are being
standardized, as were the indications for
reconstructive arterial surgery, and now
the role of angioplasty should be under
stood by all physicians treating patients
with arterial disease. The best results of
this procedure are obtained with seg
mental occlusive lesions of the iliac,
superficial femoral, coronary and renal
arteries.
II existe de multiples raisons pour la lente
acceptation, au cours des 20 dernieres
annees, de I'angioplastie transluminale
percutanee, dont I'ignorance des changements causes par I'angioplastie dans la
paroi arterielle. Les facteurs responsables
de Tactuelle popularity de cette techni
que comprennent une meilleur compre
hension de la physiopathologie de ia dila
tation par catheter des arteres, I'arrivee
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de catheters et de systeme de monitorage plus efficaces, ('amelioration de
I'experience et de la competence des
specialistes de I'angiographie, la mise au
point de meilleurs medicaments pour
combattre les spasmes et thromboses,
une meilleure connaissance des resultats
immediats et a long terme et les pressions sociales qui s'exercent en vue de
reduire les couts et la duree de traitement. Les indications de I'angioplastie
transluminale percutanee sont en voie
d'etre standardises, tout comme I'ont
ete celles de la chirurgie arterielle recons
tructive, et maintenant le role de I'angioplastie devrait etre connu de tous les
medecins traitant les maladies arterielles.
Avec cette intervention, les meilleurs
resultats sont obtenus dans les cas de
lesions occlusives segmentaires des arte
res iliaques, femorales superficielles,
coronaires et renales.

The long and controversial history of per
cutaneous transluminal angioplasty has
demonstrated the difficulties most phy
sicians have in accepting this unusual
technique. As one who has watched the
development of transluminal angioplasty,
I have shared the general skepticism, espe
cially strong among vascular surgeons.
However, it appears that percutaneous
transluminal angioplasty has finally
reached the status of an “ idea whose time
has come” . This paper presents the
diverse factors responsible for the erratic
progress of the technique in the 20 years
since its inception and outlines accepta
ble indications for the procedure.
Percutaneous entry techniques initially
were described by Seldinger1in 1953 and
have kept pace with the development of
vascular surgery during the past 30 years.
The publication by Fogarty and
colleagues2 in 1963 of a method for
removing arterial emboli and thrombi
using a balloon catheter is still hailed as
one of the great advances in vascular
surgery.
Dotter and Judkins3 reported in 1964
on the first patients treated by their tech
nique of percutaneous transluminal dila
tation. It is interesting that Fogarty

interned at the University of Oregon and
knew Dotter at that time; it is possible
that their joint ideas were formed by that
early association. Dotter’s first patient
was an 82-year-old woman who presented
with progressive gangrene of three toes.
Angiography demonstrated an adductor
canal thrombosis of the femoral artery
and outflow disease in the lower leg. The
patient refused reconstructive arterial sur
gery or amputation, so Dotter dilated the
area with a tapered radiopaque Teflon
dilating catheter of approximately 25 mm
outer diameter, greatly increasing blood
flow, which relieved the woman of her
rest pain and resulted eventually in spon
taneous amputation of the three toes. The
good result continued until the woman
died 2 Vi years later. Instead of being
acclaimed by his colleagues, Dotter heard
armchair reasons why percutaneous
transluminal angioplasty would not work
and in fact received requests for angio
grams only, specifically requesting him
not to treat the lesion.
In 1964, a three-page photographic
presentation in Life4 featured a picture
of Dotter with the following caption:
“ With a look of impending triumph Dr.
Dotter forces his arterial ‘snake’ — a spe
cially designed catheter — through the
fatty plug blocking the main artery in a
patient’s leg.” Instead of converting his
colleagues, the article gave rise to further
doubts and no referrals were forthcom
ing. However, 500 people wrote to him
after publication of the article and he
eventually performed percutaneous trans
luminal angioplasty on 75 of them.
Why did doctors not accept the role of
transluminal dilatation? Roberts and
Ring5 wrote, “ To those of us who oper
ate upon blood vessels and know the great
variety of lesions that may be encountered
in an obstructed or stenotic artery the
concept of treating such lesions by sim
ple dilatation is not attractive. As one
contemplates the possible problems that
may arise from such an approach, it
would seem reasonable to anticipate the
result would be more often disastrous
than beneficial. As a result, many sur
geons have been unwilling to try the
method despite many recent articles
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pointing out its usefulness for certain
problems.”
Dotter originally believed that the
plaque itself had been compressed and
remoulded by the dilating catheter like a
footprint in the snow. That this seldom
occurs is now apparent and comes as no
surprise to vascular surgeons who know
that most plaques are firm and not
usually compressible. This initial expla
nation hindered the acceptance of his
idea. With lack of North American sup
port, the technique was exported to
Europe where it was refined and used
widely.
Following Dotter’s first publication in
1964,3 interest was slow to develop but,
after the first percutaneous transluminal
coronary angioplasty was performed by
Griintzig6 in Zurich in 1977, interest bur
geoned and 188 publications were listed
in “ Index Medicus” in 1982. Many
reports were from Europe. The majority
reported the results o f coronary
angioplasty, while others reported its role
in peripheral, renal and other arteries.
Griintzig now performs over 100 proce
dures per month in four laboratories at
Emory University in Atlanta, and in the
Soviet Union there are more than 170 spe
cial centres for percutaneous translumi
nal angioplasty.
Reasons for Renewed Interest
in Percutaneous
Transluminal Angioplasty

Factors responsible for this great
upsurge of interest are multiple and
include the following:
• A reasonable explanation, accept
able to surgeons and other clinicians, has
been provided for the pathophysiology of
percutaneous transluminal angioplasty.
The changes produced in the arteri
osclerotic plaques have been attributed to
intimal disruption and splitting,7 stretch
ing of the media of the artery,8 remodel
ling and redistribution of the inelastic core
substance,9 fragm entation o f the
plaque10 and dissection of arterial wall
layers.11 The actual morphologic change
in the artery wall must determine the
immediate and longer term response to
dilatation. Zarins and colleagues12
studied arteries dilated in vivo and sub
sequently examined at autopsy or after
amputation. Fourteen cadaver superficial
femoral arteries were also dilated. All
were assessed by serial angiography and
microscopic sections. These were com
pared to angiograms in 36 patients fol
lowing angioplasty. In all pathological
specimens, the plaque and media were
ruptured with separation of the plaque
and stretching of the adventitia. The usual
postangioplasty angiographic changes are
due to dissection channels and protrusion
of intimal flaps. Restenosis may be due

to inadequate dilatation or extension of
dissection channels. It was concluded that
persistent overstretching of the artery wall
was the reason for successful dilatation,
not change in the plaque or remodelling
of the wall. From a clinical series Zarins
and colleagues12 reported that restenosis,
as determined by measurement of ankle
brachial pressure index, occurred in
approximately 50% of patients within 6
months, and the authors concluded that
successful dilatation depends on medial
and intimal rupture.
• High technology in catheter
development has kept pace with similar
developments in other fields. The initial
catheter used by Dotter was a Teflon
dilating catheter. Griintzig and Hopff13
revolutionized the technique when they
developed a soft, flexible, double-lumen
balloon catheter. The original polyvinyl
chloride catheter was hard to curve and
the balloon would swell into an hour-glass
configuration if too much pressure was
applied. The polyethylene catheter can be
curved and shaped with ease and can
withstand great pressures while maintain
ing a cylindrical shape and the diameter
specified by the manufacturer, thus
preventing inadvertent overdistension and
rupture of the vessel. Monitors have
improved, permitting accurate measure
ment of pressure gradients across the
lesion at the time of angioplasty, while
digital imaging has expanded to improve
the role of radiology.
• The use of drugs as adjunctive ther
apy has improved the immediate and
long-term results and decreased compli
cations of the procedure. Heparin,
usually 5000 units intra-arterially, is used
by most angiographers when the catheter
is passed. Local spasm that will prevent
successful angioplasty has been treated by
nifedipine, tolazoline and papaverine
hydrochloride. Antiplatelet drugs are
started 3 to 4 days before angioplasty and
are usually continued indefinitely. Strep
tokinase, given intra-arterially at the time
of angioplasty, has been used to control
distal acute thrombosis and to expand the
role of this procedure.
• The social pressure to treat patients
faster, better and cheaper is increasing
owing to extensive media dissemination
of information on medical topics, thus
creating more demand on doctors.
Naisbitt14 has followed in the footsteps
of other futurists such as Toffler and
McLuhan by describing 10 new trends
that are transforming our lives.14 His
conclusions are obtained by “ content
analysis” , a method based on intelligence
gathering techniques used in World War
II and arrived at by statistically analys
ing all media information. One such trend
is a loss of faith in medicine’s traditional
treatment of disease by drugs or surgery
and the expectation that much can be
achieved by less-invasive and less-painful

methods, including percutaneous trans
luminal angioplasty. A trend to describe
this technique as an easy alternative to
surgery has been apparent in many
newspaper and magazine articles and
many patients request it.
There is also considerable government
and public pressure to contain the cost of
health care, and percutaneous translumi
nal angioplasty is much less expensive
than arterial surgery, even if it must be
repeated earlier because the long-term
results are not as good. The comparison
of costs for percutaneous transluminal
angioplasty of a stenosed femoral artery
requiring 2 days’ admission to hospital
and femoropopliteal bypass grafting with
10 days in hospital show that the latter
is five times more expensive. A compara
ble ratio exists for coronary artery lesions
treated by percutaneous transluminal
coronary angioplasty and coronary artery
bypass surgery.
An unresolved question is who should
perform angioplasties. The Committee on
Vascular Surgery of the Inter-Society
Commission for Heart Disease Re
sources, formed by the United States
Department o f Health, Education, and
Welfare,15 listed many requirements for
the performance of high-quality vascular
surgery. The committee members con
cluded: “ We believe that the factors most
responsible for the quality of vascular sur
gery are the judgement and technical skill
of the surgeon, both developed through
properly supervised train in g and
experience.” There is no doubt that this
applies equally to a person performing
angioplasty, who must possess a thorough
knowledge o f all aspects of arterial dis
ease and technical competence to perform
the procedure well. Whether that person
should be a radiologist, cardiologist or
vascular surgeon is still unresolved.
One strong surgical viewpoint was
presented in 1983 by Pfeiffer16 who
stated, “ Vascular surgeons should per
form PTA ’s and offer it as a standard
alternative to the patient’s treatment regi
men. The surgeons’ clinical and surgical
background makes him the person best
suited to use this form of treatment. Vas
cular radiologists, although experts at
angiography, have little training or clini
cal experience in the diagnosis, treatment
and follow-up care of patients with vas
cular disease. For them to select therapeu
tic options and perform therapeutic oper
ations is an inappropriate use of their
talents.”
A solution to the problem is an efficient
working relationship between surgeon,
radiologist and the referring doctor, so
that all may be involved in the decision
making process and that the indications
for percutaneous transluminal angio
plasty are based on widely accepted
criteria.
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Indications for Percutaneous
Transluminal Angioplasty

The indications for percutaneous trans
luminal angioplasty are being stan
dardized, just as were the indications for
reconstructive arterial surgery, by careful
reporting of the early and longer term
results of the procedure. However,
decision-making is difficult because there
are no randomized prospective studies
comparing transluminal dilatation and
vascular reconstructive surgery. The indi
cations for percutaneous transluminal
angioplasty of peripheral, renal and coro
nary arteries are becoming more uniform
and more acceptable to clinicians. Other
arteries have been treated by this method
although in smaller numbers. They
include the vertebral, subclavian, pulmo
nary, mesenteric and infrapopliteal arter
ies, coarctation of the aorta and graft
stenoses. The number is insufficient to
arrive at any valuable conclusions.
The suggested indications for per
cutaneous transluminal angioplasty com
prise three groups as follows:
• Indications for surgery are valid but
the patient (a) refuses an operation, (b)
is a poor surgical risk or (c) has
unfavourable run-off making reconstruc
tion difficult.
• Mild symptoms interfere with life
style but are not severe enough to war
rant arterial surgery. It should be stressed
that the lesion must be shown by clinical
examination, noninvasive studies and
pressure gradients to be hemodynamically
important and not just a chance anatom
ical angiographic finding.
• The patient has combined lesions.
One lesion is treated by percutaneous
transluminal angioplasty and the other by
reconstructive surgery.

is indicated for renal artery disease in
patients with proven renovascular hyper
tension and possibly those with failing
renal function due to renal artery steno
sis, who have fibromuscular hyperplasia,
non-ostial arteriosclerotic lesions, reste
nosis after previous percutaneous trans
luminal angioplasty, or in whom recon
structive surgery has failed. However, the
method is contraindicated in patients with
ostial or bifurcation lesions and renal
arteries containing fresh mural thrombus.
Coronary Artery Disease
The classic indications for percutane
ous transluminal coronary angioplasty
have been disabling angina in patients
who may require operation for stenosis
in a single coronary artery — usually in
the left anterior descending but also in
other arteries and coronary artery bypass
grafts. With increasing experience and
better results the technique is now indi
cated in less severe angina, if the stenosis
is in a single vessel and in patients with
two stenoses in one artery or a single ste
nosis in each of two arteries.
Conclusions

Percutaneous transluminal angioplasty
has evolved from an uncertain beginning
to an accepted method of treating selected
arterial lesions. Indications for the proce
dure are becoming standardized and the
results more predictable. More experience
and improved techniques will probably
result in greater use of this relatively sim
ple method of treatment. All physicians

involved in the care of patients with
arterial lesions should become ex
perienced in this technique to provide
optimal patient selection and results.
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SESAP IV Question

Peripheral Arterial Disease
The indications for transluminal
angioplasty in peripheral arteries are as
follows: stenosis of the iliac artery; ste
nosis or thrombosis of the superficial
femoral artery less than 5 cm long —
longer segments can be dilated but the
results are not as good; stenosis of graft
anastomoses; stenoses of popliteal arter
ies, at times aided by intra-arterial strep
tokinase to lyse distal thrombus.
The contraindications to this technique
in peripheral arteries are multiple sequen
tial lesions in the common and external
iliac arteries, lesions in the common
femoral artery and lesions adjacent to the
origins of the deep femoral, internal iliac
and possibly the origins of the common
iliac arteries.
Renal Artery Disease

121. A man with severe pelvic trauma has blood dripping from the ure
thral meatus. The prostate is elevated on rectal examination. The next step
to assess the extent of urologic injury should be
(A)
(B)
(C)
(D)
(E)

insertion of a Foley catheter
cystogram
retrograde urethrogram
intravenous pyelogram (IVP)
arteriogram

For the incomplete statement above select the best completion of the five
given. For the critique of Item 121 see page 106.
(Reproduced by permission from SESAP IV Syllabus; Surgical Education
and Self-Assessment Program No. 4. For enrolment in the Surgical Educa
tion and Self-Assessment Program No. 4, please apply to the American
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)

Percutaneous transluminal angioplasty
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Cardiac Mortality and Morbidity
After Vascular Surgery
To determ ine the clinical, hem odynam ic
and p athological features th a t co n trib u te
to m ajor cardiac co m plications a fte r vas
cular surgery, six pa tie nts w ith early
p o stop e ra tive cardiogenic shock (group
1) w ere analysed retro sp e ctively and
com pared to nine patients w ith o u t co m 
p lica tio n s (group 2) w h o w ere carefully
analysed p rospectively. Four group 1
p a tie n ts had elective repair o f an
abdom inal a o rtic aneurysm , one had
repair o f a false iliac artery aneurysm
and one had a fe m oropopliteal g ra ft
inserted. Four group 2 patients had elec
tiv e repair o f an abdom inal aortic
aneurysm and five had aortobifem oral
re c o n stru c tio n . The Goldman m u ltifa c 
to ria l index w as sim ilar in both groups
and in dicated an expected death rate of
2 % and a m o rb id ity rate o f 5% . in group
1, th e earliest sign o f cardiovascular
com prom ise was an elevated pulm onary
w ed g e pressure during operation.
P ostoperatively, electrocardiographic evi
dence o f m yocardial ischem ia was
p resent in all six patients and preceded
cardiogenic shock. A u to p sy o f the fo u r
p a tie nts w h o died dem onstrated trip le 
vessel disease in all b u t recent occlusion
in o n ly one patient. There was evidence
o f exte nsive subendocardial in fa rctio n in
all fo u r. A n g io g rap h y o f th e tw o su r
v iv o rs in group 1 also dem onstrated
triple-ve sse l disease.
The a uthors conclude th a t by using
o rd in a ry clinical m ethods it is d iffic u lt to
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id e n tify p a tie nts like ly to have major
co m p lica tio n s postop e ra tive ly. Elevated
p u lm o n a ry w edge pressures or elec
tro ca rd io g ra p h ic evidence o f m yocardial
ischem ia m ay be early w a rn in g signs o f
im p en d in g cardiac ca ta stro p h e and
should be trea te d aggressively. The
un d erlyin g pa tho p h ysio lo g y appears to
be p e rioperative stress in a se ttin g o f
severe triple-vessel coronary artery
disease.

Dans le b u t de determ iner quels sont les
fa c te u rs cliniques, hem odynam iques et
patho lo g iq u e s qui c o n trib u e n t aux c o m 
p lica tio n s cardiaques de la chirurgie vasculaire, on a analyse retro sp e ctivem e n t
six p a tie nts qui o n t subi un choc cardiogene dans la periode postoperatoire precoce (le groupe 1) e t on les a com pares
a n e u f p a tie nts (le groupe 2) qui n 'o n t
pas eu de co m p licatio n s e t qui ont ete
analyses soigneusem ent, de facon p ro s
p e ctive . Q uatre pa tie nts du groupe 1
ava ie n t subi une reparation non urgente
d 'u n anevrism e de I'aorte abdom inale, un
a va it eu une reparation d 'u n fa u x ane
vrism e de I'artd re iliaque e t un avait eu
une g re ffe fe m oro-poplitee. Q uatre
p a tie n ts du groupe 2 avaient eu une
reparation non urgente d 'u n anevrism e
de I'a o rte abdom inale et les cinq autres
a va ie n t subi une re co n stru ctio n aortobifem orale. L 'in de x m u ltifa c to rie l de
G oldm an e ta it sim ilaire pour les deux
groupes e t in d iq u a it un ta u x apprehende
de deces de
e t un ta u x de m orbidite
de 5 % . Dans le groupe 1, le signe le
plus precoce d 'a tte in te cardiovasculaire a
ete une au g m e n ta tio n de la pression
capillaire pulm onaire durant I'operation.
En postop e ra toire , des signes electrocard io g raphiques d'ischem ie m yocardique
e ta ie n t presents chez les six patients e t
ceci a precede I'apparition du choc cardiogene. Pour les quatre p a tie nts qui
so n t decedes, I'au to p sie a re v ile une
stdnose de tro is vaisseaux m ais I'o cclu sion e ta it recente dans un seul cas. On a
c o n sta te dans les quatre cas un in fa rc tu s
sous-endocardique etendu. L'angiographie des deux survivants du groupe 1 a

2%

aussi d e m o n tr6 une trip le o cclu sio n co ro narienne.
Les a uteurs co n clu e n t qu a I’ aide des
m e th o d e s cliniques co n ve n tio n n e lle s, il
e st d iffic ile d ’ id e n tifie r les p a tie n ts qui
s o n t su sce p tibles de pre se n te r des c o m 
p lic a tio n s postop e ra toire s. Une e le va tio n
de la pression capillaire p u lm o n a ire ou
des m a n ife sta tio n s e le c tro ca rd io g ra p h iques d 'isch e m ie m yoca rd iq u e p e u ve n t
etre des signes a va n t-co u re u rs precoces
d 'u n e ca ta stro p h e cardiaque im m in e n te
e t d o iv e n t etre traite s a g re ssive m e n t. La
p h ysio p a th o lo g ie sou s-ja ce n te sem ble
e tre un stress p eroperatoire dans un
tableau d 'o cclu sio n co ro n a rie n ne trip le .

Patients requiring vascular surgery are a
high-risk group for several reasons —
their advanced age, the presence of gener
alized atherosclerosis, especially of the
coronary arteries, and the nature of sur
gery with infrarenal aortic cross
clamping. The operative death rate for all
types of vascular surgery averages 5%.
The 3% to 5% risk in elective infrarenal
aortic aneurysm surgery is the same as in
any major abdominal operation1 and has
been reported at less than 2%.2 The
majority of these deaths are due to com
plications of atherosclerosis in coronary
or cerebral vessels.
Over 1 year, we saw six patients (group
1) who suffered cardiogenic shock early
after vascular surgery. Four died and two
survived. Coronary anatomy was defined
in all six patients and their postoperative
courses were reviewed retrospectively
to determine common factors that might
be responsible. Subsequently we studied
nine patients (group 2) who underwent
abdominal aortic surgery on the same sur
gical service, and recorded pertinent
historic, electrocardiographic and
hemodynamic data. These patients had
no complications and served as a control
for group 1.

Patients and Method
From Feb. 1, 1984 to Jan. 31, 1985, six
men, ranging in age from 60 to 73 years
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(mean 68 years), underwent reconstruc
tive vascular surgery. Four had elective
repair of an abdominal aortic aneurysm,
one had repair of false iliac artery
aneurysm and one had a femoropopliteal
bypass graft inserted. Five of the six
patients had historical evidence of coro
nary artery disease (previous myocardial
infarction or angina), and the sixth had
dyspnea on exertion. All were heavy
smokers, averaging 50 pack-years.
Preoperatively, chronic obstructive lung
disease was evident in two, one patient
was diabetic (taking oral hypoglycemic
agents) and two had mild renal dysfunc
tion. Electrocardiograms were abnormal
in four: conduction disturbance (right
bundle branch block or left anterior
hemiblock) in three, ST-T anomalies in
two and left ventricular hypertrophy with
strain pattern in one. Two patients had
normal electrocardiograms. The Gold
man multifactorial index3 for these
patients ranged from 3 to 11 (average
5.6). This placed all the patients into class
II cardiac risk with an expected death rate
of 2°7o and morbidity rate of 5%. All
underwent hemodynamic monitoring
with a thermodilution no. 7 French
Swan-Ganz catheter, four during opera
tion and two immediately postoperatively. The perioperative hemodynamic
studies, postoperative electrocardiograms
and clinical courses were reviewed.
Subsequently, nine patients (eight men,
one woman) were studied prospectively
for comparison. They ranged in age from
57 to 86 years (mean 71 years) and also
underwent major vascular surgery. Four
had elective repair of an abdominal aor
tic aneurysm and five had aortobifemoral
reconstruction. Four patients had no
symptoms of coronary artery disease; the
other five had a history of angina or
myocardial infarction. AH were heavy
smokers, four were being treated for
hypertension, five demonstrated chronic
obstructive lung disease, three had previ
ously suffered transient ischemic attacks
or mild strokes and one was diabetic.
Preoperatively the electrocardiograms in
this group were normal in four and
abnormal in five (evidence of previous
myocardial infarction in four, left ventric
ular strain pattern in two, atrial fibrilla
tion in one, right bundle branch block in
one and nonspecific ST-T anomalies in
one). The Goldman multifactorial index
ranged from 3 to 15 (average 6.8), plac
ing this group also into class II cardiac
risk. All patients underwent intraopera
tive and postoperative hemodynamic
monitoring with a Swan-Ganz catheter.
Hemodynamic values of cardiac index
and pulmonary capillary wedge pressure
(PCWP) were obtained at three specific
stages during surgery (before, during and
after aortic cross-clamping), and again
three times postoperatively (days 0, 1 and
94

Fig. la

Fig. lb

FIG. 1—Intraoperative and postoperative hemodynamics in group 1 patients with cardio
genic shock. White rectangles represent mean values for PCWP (a) and cardiac output (b)
intraoperatively before aortic cross-clamping (PC), during cross-clamping (CC), after cross
clamping (POC) and postoperatively on days 0, 1 and 2. Blacked out areas encompass mean
± 1 standard deviation for control population (group 2).

Fig. 2a

Fig. 2b
FIG. 2—(a) Preoperative and (b) postoperative electrocardiograms of group 1 patient who
died. Preoperatively only nonspecific T-wave changes can be seen, but postoperatively there
is 3 mm of ST-segment depression in leads V5 and V6. R-wave voltage is also markedly decreased
in anterior precordial leads.
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2). Electrocardiograms were obtained on
days 0, 1, 2 and 7.
Results
At varying times postoperatively, cardi
ogenic shock developed in all six group
1 patients. It was defined by hypotension
(blood pressure less than 80 mm Hg),
oliguria and pulmonary edema. In four
of them a low cardiac output syndrome
developed within 48 hours of operation.
In the other two shock developed on days
6 and 16, respectively. The four deaths
occurred within 1 to 48 hours after the
episode of shock. The two survivors
required multiple inotropic agents for
several days.
The nine patients in group 2 had no
complications and were ready for dis
charge by day 12 after operation. The
hemodynamic values from this group
served as a control for comparison with
those of group 1 patients (Fig. 1). In
group 2, the PCWP decreased slightly
during cross-clamping and increased sub
stantially in the immediate postoperative
period (day 0). All group 1 patients had
values exceeding one standard deviation
(SD) above the mean at some point
intraoperatively or postoperatively. In
many it exceeded two SDs (Fig. la) and
generally remained elevated postopera
tively.

The cardiac index in group 2 patients
also decreased with cross-clamping but
then recovered and increased sharply after
operation. The intraoperative values of
cardiac index in group 1 patients did not
differ greatly from those of group 2, but
postoperatively they failed to increase
normally and were lower than those of
group 2 patients (Fig. lb).
Electrocardiograms done postopera
tively, hours before the episode of cardi
ogenic shock, invariably showed severe
myocardial ischemia (Fig. 2) (1 to 4 mm
of ST depression in precordial leads). The
length of time between the abnormal elec
trocardiograms and the episodes of shock
varied from 2 to 24 hours, the majority
being closer to 24 hours. The electrocardi
ographic findings are summarized in
Table I.
Autopsies were performed on the four
who died, and coronary angiography and
left ventriculography were carried out on
the two survivors (Table I). Three of the
four who died had severe triple-vessel
atherosclerosis without recent occlusion.
Examination of the left ventricles showed
extensive subendocardial infarction with
occasional focal areas of transmural
infarction. Angiography of the two sur
vivors showed a normal ventricle in one
and a globally hypokinetic ventricle in the
other. Both patients showed the same
severe atherosclerosis involving major

arteries or branches of all three coronary
artery systems (Fig. 3).
The following two reports are typical,
first of the four patients who died and
second of the two survivors in group 1.

FIG. 3—Coronary angiogram in surviving
patient from group 1. Right coronary artery
(top panel) is occluded. Left anterior descend
ing artery has proximal stenosis of 70% (white
arrow), and distal left circumflex artery (black
arrow) is occluded.
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Case Reports

Case 1
A 69-year-old man, who was a 55 pack-year
smoker, was admitted with gangrene of his left
foot. Past history included diabetes mellitus
and a transient attack of ischemia 13 months
earlier. He denied suffering from angina and
his preoperative electrocardiogram appeared
normal. Left femoropopliteal grafting was
uncomplicated apart from an episode of ven
tricular trigeminy and transient mild bronchospasm just after induction of anesthesia.
Immediately after the operation he became
acutely dyspneic, hypoxic (partial pressure of
oxygen 70 mm Hg while receiving 70% oxy
gen), hypercarbic (partial pressure of carbon
dioxide 60 mm Hg) and required reintubation.
He then became hypotensive, and tachycardia
and pulmonary edema developed. A pulmo
nary artery catheter was inserted. After dopa
mine was administered, the PCWP was 16 mm
Hg. A few hours later an electrocardiogram
showed 4 mm ST depression in lateral precor
dial leads and a reduction of 75% of the Rwave amplitude (maximal decreases in leads I
and AVL). After this acute episode, his con
dition improved temporarily and dopamine
was discontinued on day 2. On postoperative
day 3 he extubated himself and within hours
severe pulmonary edema developed with sinus
tachycardia (heart rate 130 beats/min), a high
PCW P (22 mm Hg) and a cardiac index of 3.5
L/m in • rr r2. Over the next 48 hours his con
dition deteriorated and he required increasing
amounts of inotropic agents (epinephrine,
dopamine, dobutamine and amrinone) because
of falling cardiac output. An electrocardiogram
obtained the day before his death showed
widespread ST-segment depression with a fur
ther reduction in R-wave amplitude. He finally
succumbed on postoperative day 6 with a triad
of hypotension, pulmonary edema and anuria.
Autopsy revealed extensive subendocardial
infarction in posterior, lateral, septal and
anterior walls with focal extension in the sep
tal wall. Serial sections of his coronary arter
ies showed 90% stenosis of the right coronary
artery, 50% stenosis of the circumflex artery,
60% stenosis of the left anterior descending
coronary artery and 90% stenosis of the first
diagonal branch.

Case 2
A 67-year-old man who was a 100 pack-year
smoker was admitted for surgery on an aortic
aneurysm because serial computed tomograms
had demonstrated a recent increase in
anterior-posterior diameter to 6.8 cm. His
medical history included dyspnea on walking
one block (no angina) and palpitations, which
were treated with Inderal. The preoperative
electrocardiogram showed left anterior hemiblock and nonspecific ST-segment anomalies
with T-wave inversion in leads V3 to V6. The
operation was technically uncomplicated, but
hemodynamically myocardial function was
depressed intraoperatively: the cardiac index
ranged from 1.55 to 1.65 L/min • m"2, the
PCW P was 19 mm Hg and systemic vascular
resistance ranged from 1760 to 2400 dyn s
c m '5. Within 1 hour of operation, the
patient had profound pulmonary edema with
hypoxia and severe bronchospasm. Hypoten
sion (systolic blood pressure 60 mm Hg)
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responded initially to inotropic agents (calcium
gluconate and dopamine) but recurred in
association with elevated filling pressures
(PCWP 31 mm Hg, central venous pressure 34
mm Hg). Low cardiac output (cardiac index
1.03 L/m in *m"2) persisted for 6 hours, but
with the administration of multiple drugs
(dopamine, calcium gluconate, epinephrine,
nitroglycerin, Inderal, aminophylline, sodium
bicarbonate, morphine, digoxin and Pavulon)
his condition improved. Electrocardiograms
obtained during this period showed ischemic
changes in the anterolateral precordial leads
and a generalized 60% to 70% reduction of Rwave amplitude. He required inotropic agents
for 4 days and was extubated on day 5. Sub
sequently, he made a smooth recovery. Cardiac
catheterization carried out just before he was
discharged on day 25 demonstrated a normal
left ventricle with a left ventricular end-diastolic
pressure of 8 mm Hg and also triple-vessel dis
ease: 70% stenosis of the right coronary artery,
80% stenosis of first marginal artery and 70%
stenosis of the left anterior descending coro
nary artery.

Discussion

We believe that the cardiogenic shock
suffered by our six patients was caused
by severe triple coronary artery atheros
clerosis in a setting of major cardiovas
cular stress (aortic cross-clamping, fluid
loading and hypotension). Myocardial
ischemia from triple-vessel disease either
intraoperatively or postoperatively leads
to extensive subendocardial myocardial
infarction with progressive cardiac dila
tation and the clinical features of
hypotension, pulmonary edema and
oliguria that proved lethal in four cases
and almost so in two. Transmural infarc
tion with the development of new Q
waves occurred in two of the patients, one
of them being the only patient to show
evidence of a recent coronary occlusion
at autopsy.
Preoperative assessment of these
patients (history, physical examination,
electrocardiography and Goldman clas
sification) failed to identify high-risk
persons. The Goldman classification was
comparable (class II) in the group of
patients with cardiogenic shock and
in the control group and, in both, in
dicated a possible death rate of 2%,
which is relatively low. Our previous
efforts to identify patients at risk
for cardiovascular complications, using
routine clinical assessment, showed
four factors that predicted cardiac com
plications.4 The New York Heart Associ
ation classification in group 1 patients
identified one patient as being in class III
and none in class IV, the highest risk
categories. The second factor (STsegment depression greater than 1 mm on
the preoperative electrocardiogram) was
present in two patients of each group. The
third factor (electrocardiographic evi
dence of previous myocardial infarction)
was not present in any of the group 1

patients. The fourth factor was age. The
mean age of 68 years in group 1 represents
a 17% risk of cardiac complication in our
experience. The mean age of patients in
the control group was 71 years which
represents a slightly greater risk (21%).
Hence, clinical identification of
patients who must undergo major vascu
lar surgery and may have catastrophic
cardiac complications is quite difficult
and underscores the need for a combina
tion of noninvasive and invasive cardiac
assessment preoperatively.
Early signs of myocardial dysfunction
are an inordinately high (more than 18
mm Hg) PCWP intraoperatively (Fig. la)
and severe myocardial ischemia as
observed on postoperative electrocardio
grams. Both preceded the development of
cardiogenic shock by at least 24 hours.
The PCWP measured in four group 1
patients exceeded 18 mm Hg at some
point intraoperatively. Several studies5-8
have attempted to determine an optimal
filling pressure intraoperatively and sug
gested keeping the PCWP above 10 mm
Hg, to avoid the decrease in PCWP and
cardiac output that is observed during
cross-clamping in patients who do not
have cardiac disease. Patients with
cardiac disease often show an increase in
PCWP during cross-clamping. So long as
this increase is small and the pressure is
less than 18 mm Hg, cross-clamping
would appear to be well tolerated.
The electrocardiographic findings of
myocardial ischemia observed in this
study need to be emphasized.
We have shown that ST-segment
depression on the preoperative elec
trocardiogram predicts cardiac complica
tions, also that postoperative ST-segment
depression precedes catastrophic cardiac
complications, so this change must be
noted early in the postoperative period
and treated aggressively.
In contrast, cardiac output intraoper
atively did not predict complications.
However, our study indicates that an
increase in cardiac output should be anti
cipated postoperatively. This finding is
not new; Bush and colleagues9 reported
perioperative hemodynamic values, up to
48 hours postoperatively, in 22 high-risk
patients who underwent abdominal aor
tic aneurysm surgery. Although 21
patients showed evidence of pre-existing
cardiovascular disease (e.g., myocardial
infarction and arrhythmia) there were no
deaths and no major cardiovascular com
plications. The cardiac index (pre-, intraand postoperatively) parallels our
experience in the control patients (Fig.
lb). The mechanism explaining this rise
in cardiac index after operation is
unknown, but several factors are proba
bly responsible; for example fluid load
ing during cross-clamping to prevent
generalized stress-induced release of
catecholamines.10 Failure to observe an
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increase in cardiac output postoperatively
should be a cause for concern.
We recommend continued close moni
toring of the PCWP and cardiac index
both intraoperatively (before, during and
after cross-clamping) and postoperatively,
until the patient is stable. Optimal filling
pressures intraoperatively, from this
study, would be a PCWP of less than 18
mm Hg. Daily cardiac output determina
tions and electrocardiography for 72
hours after operation constitute ideal
monitoring and may identify patients in
imminent cardiovascular danger. For
patients whose cardiac index is suboptimal, aggressive drug therapy with
inotropic agents and reduction of after
load may offset episodes of myocardial
ischemia that may cause clinically down
ward spirals and subsequent death.
Conclusions
Conclusions can be made in four areas:
clinical, electrocardiographic, hemo
dynamic and pathologic. From this study,
it is evident that clinical markers for
cardiovascular disease are variable and
often fail to predict postoperative prob
lems. The Goldman multifactorial index
of cardiac risk was not of value in our
study. Electrocardiographic evidence of

myocardial ischemia may be a sign of
impending acute cardiac failure and we
recommend that it be treated aggressively
with intravenous administration of
nitrates. High-risk patients may be iden
tified (a) in the operating room during
cross-clamping by a PCWP greater than
18 mm Hg, and (b) in the early postoper
ative period by lack of the normal exag
gerated response in cardiac output dur
ing the first 48 hours. Severe triple-vessel
disease, not necessarily associated with
acute coronary artery occlusion, appears
to be responsible for the episodes of clin
ical shock and attempts should be made
preoperatively to identify patients with
coronary artery disease. Damage to the
myocardium is subendocardial rather
than transmural, as in typical myocardial
infarctions. Perioperative death in these
high-risk patients can be reduced by pay
ing close attention to intra- and postoper
ative hemodynamic measurements, opti
mizing filling pressures and cardiac
function, and identifying and treating
myocardial ischemia early.
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PIPRACIL
Parental Antibiotic for Intravenous and Intramuscular Use
INDICATIONS AND CLINICAL USES: Treatment of serious infections caused by susceptible strains of the
designated organisms in the conditions listed below. Intra abdominal Infections including hepatobiliary and
surgical infections caused by Escherichia coli, Pseudomonas aeruginosa, enterococci. Clostridium sp., anaerobic
cocci, and Bacteroides sp., including B. fragilis. Urinary Tract Infections (complicated and uncomplicated)
caused by Escherichia coli, Klebsiella sp., Pseudomonas aeruginosa, Proteus mirabilis and enterococci. Also
uncomplicated urethritis caused by Neisseria gonorrhoeae. Gynecological Infections including endometritis and
pelvic inflammatory disease caused by Bacteroides sp., including B. fragilis, anaerobic cocci, Neisseria
gonorrhoeae, and enterococci (Streptococcus faecalis). Septicemia caused by Escherichia coli, Klebsiella sp.,
Serratia sp., Proteus mirabilis, S. pneumoniae, enterococci, Pseudomonas aeruginosa, Bacteroides sp., and
anaerobic cocci. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella sp., Enterobacter sp.,
Pseudomonas aeruginosa, Serratia sp., Haemophilus influenzae, Bacteroides species and anaerobic cocci
Although improvement has been noted in patients w ith cystic fibrosis, lasting bacterial eradication may not be
achieved. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella sp., Serratia sp.,
Acmetobacter sp., Enterobacter sp., Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis,
Bacteroides sp., including B. fragilis, anaerobic cocci and enterococci Bone and Joint Infections caused by
Pseudomonas aeruginosa, enterococci, Bacteroides sp., and anaerobic cocci. PIPRACIL* is useful for the
treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms;
infections produced by organisms resistant to other penicillins, some aminoglycosides and cephalosporins; and
infections at various sites caused by streptococcus species including Group A beta-hemolytic Streptococcus and
Streptococcus pneumoniae.
PIPRACIL* may be administered as single drug therapy in some situations where normally tw o antibiotics might
be employed. In vitro synergism has been shown between Piperacillin and some aminoglycosides in some
bacterial strains. PIPRACIL* has been used clinically w ith aminoglycosides, especially in patients w ith impaired
host defences. Both drugs were used in full therapeutic doses. PIPRACIL'can be used safely in combination with
a penicillinase-resistant penicillin, e.g. oxacillin, in mixed infections when beta-lactamase-positive Staphyloccus
aureus is isolated along w ith piperacillin-susceptible organisms. It may be administered concomitantly w ith a
cephalosporin, provided that an additive or synergistic antibacterial action of the two antibiotics is ascertained
through in vitro tests. Based on in vitro data, cefoxitin should not be given w ith piperacillin when Pseudomonas
infections are suspected or confirmed.
Because PIPRACIL* is excreted not only renally, but also by the biliary route, it can be used in patients with
hepatobiliary infections, or severely restricted kidney function, and in patients who have had nephrotoxic
reactions to other drugs, w ith appropriate adjustment of dosage (See DOSAGE).
Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if
appropriate, once the results are known.
CONTRAINDICATIONS: A history of allergic reactions to any of the penicillins and/or cephalosporins.
WARNINGS: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in
patients receiving therapy w ith penicillins. These reactions are more apt to occur in persons w ith a history of
sensitivity to multiple allergens.
Cross-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy
w ith PIPRACIL* careful inquiry should be made concerning previous hypersensitivity reactions to penicillins,
cephalosporins and other allergens.
If an allergic reaction occurs, the antibiotic should be discontinued. SERIOUS ANAPHYLACTOID REACTIONS
REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS
AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS NECESSARY.
PRECAUTIONS: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics
including piperacillin. These reactions have sometimes been associated w ith abnormalities of coagulation tests
such as clotting time, platelet aggregation and prothrombin time and are more likely to occur in patients with
renal failure.
If bleeding manifestations or significant leukopenia occur, PIPRACIL* should be discontinued and appropriate
therapy instituted.
The possibility of the emergence of resistant organisms and the development of superinfections should be kept in
mind, particularly during prolonged treatment. As w ith other penicillins, patients may experience neuromuscular
excitability or convulsions if higher than recommended doses are given intravenously.
Dosage adjustment should be made in renal insufficiency.
PIPRACIL* is a monosodium compound containing 1.98 milliequivalents (45.5 mg) of Na + per gram based on
vial content which includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85
mEq/g (42.55 mg). Periodic electrolyte determinations should be made in patients w ith low potassium reserves
and the possibility of hypokalemia should be kept in mind w ith patients who have potentially low potassium
reserves, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during
prolonged-treatment in patients w ith impaired cardiac function.
Prior to treatment, patients w ith gonorrhea should also be evaluated for syphilis. Specimens for darkfield
examination should be obtained from patients w ith any suspected primary lesions, and serologic tests should be
performed. In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a
minimum of 4 months.
The use of penicillins (ampicillin, amoxicillin) has been associated w ith morbilli form rashes in some cases of
infectious mononucleosis. PIPRACIL* should be used w ith caution in the treatment of patients w ith infectious
mononucleosis.
Drug Interactions: The mixing of PIPRACIL* w ith an aminoglycoside in vitro can result in substantial inactivation
of the aminoglycosides.
Usage During Pregnancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined
Because animal reproduction studies are not always predictive of human response, this drug should be used
during pregnancy only if clearly needed. It has been found to cross the placenta in rats. Caution should be
exercised when PIPRACIL* is administered to nursing mothers. It is excreted in low concentrations in milk.
Pediatric Use: Dosages for children under the age of 12 have not been established.
ADVERSE REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been
local in nature, following intravenous or intramuscular injection. The following adverse reactions may occur:
Local Reactions-ln clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or
induration at the injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis
and hematomas. Hypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less
frequent findings: Pruritus, vesicular eruptions, positive Coombs tests Gastrointestinal-Diarrhea and loose
stools were noted in 2.8% of patients. Less frequent reactions: vomiting, nausea, bloody diarrhea.
Hepatic-Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis.
Renal-Elevations of creatinine or BUN. Central Nervous System-Headache, dizziness, fatigue. Hemic and
Lymphatic-Reversible leukopenia, thrombocytopenia and/or eosinophilia, bleeding and decreases in prothrombin
time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in patients receiving prolonged
therapy at high dosages or in association w ith drugs known to cause this reaction. Serum Electrolytes-lndividuali
w ith liver disease or individuals receiving cytotoxic therapy or diuretics, were reported rarely to demonstrate a
decrease in serum potassium concentrations w ith high doses of PIPRACIL*. Musculo-Skeletal-Rarely, prolonged
muscle relaxation. Other-Superinfection, including candidiasis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular adminstration of 6 to 8 g
daily of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for
maintenance therapy after clinical and bacteriologic improvement has been obtained w ith intravenous piperacillin
sodium treatment. Administration should not exceed 2 g per injection at any one site. This route has been used
primarily in the treatment of patients w ith uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular
injection. The preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also
may be given in the mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and
then only w ith caution to avoid radial nerve injury. Intramuscular injection should not be made into the lower or
mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted w ith 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein
irritation. The reconstituted and diluted solution may be administered by interm ittent or continuous drip.

Intermittent infusion should be administered over a period of about 30 minutes. During intermittent infusion it is
desirable to discontinue the primary intravenous solution. Any unused portion must be discarded. For continuous
infusion the solution may be administered over a longer period of time
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for injection, or if required Bacteriostatic
Water for Injection, Lidocame HC1 0.5 or 1% (without epinephrinel-For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required, Bacteriostatic Water
for Injection. Either parabens or benzyl alcohol. Lidocaine HC1 is contraindicated in patients with a known history
of hypersensitivity to local anesthetics of the amide type.
RECONSTITUTION TABLE
Volume of Diluent
to be added

Approximate Available
Volume

Approximate Average
Concentration

Vials 2 g
3g
4g

4.0 mL
6.0 mL
7.8 mL

5.0 mL
7.5 mL
10.0 mL

1 g/2.5 mL
1 g/2.5 mL
1 g/2.5 mL

Infusion Bottles
3g
4g

15 mL
20 mL

17 mL
23 mL

Product Size

The prepared solution may be further diluted to the desired volume w ith any of the solutions for intravenous
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing any
of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Solutions:
Intravenous Admixtures:
5% Dextrose in Water IDsWI.
Normal Saline I + KCL 40 mEq.)
0.9% Sodium Chloride (Normal Saline) (NS).
5% Dextrose/Water ID'.WI I + KCL 40 mEql.
Dextrose 5% and 0.9% Sodium Chloride IDsNS)
5% Dextrose/Normal Saline (D‘-NS) ( + KCL 40 mEql.
Lactated Ringer's Injection, U.S.P.
Ringer's Injection, U.S.P. I + KCL 40 mEq).
Dextran 6% in 0.9% Sodium Chloride
Lactated Ringer's Injection, U.S.P. I + KCL 40 mEq).
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted with
recommended diluents and further diluted w ith the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarity! through 24 hours at room tern
perature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recommends
discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated If used as a
multi-dose container, the vials must be reconstituted only w ith the bacteriostatic diluents noted above
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous
administration w ith solutions containing sodium bicarbonate.
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently w ith aminoglycosides, it is recommended that both drugs be used in full
therapeutic doses, but administered separately. PIPRACIL* should not be mixed with an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation to the aminoglycoside.
DOSAGE FORMS: PIPRACIL’ (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of
piperacillin sodium equivalent to 2, 3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g/vial-3879-48 3 g/vial-3882 49 4 g/vial-3880-50.
Available in 100 mL size infusion ("piggyback") bottles, containing sterile, freeze-dried piperacillin sodium powder
equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles.
Product Numbers: 3 g/bottles-3882-41 4 g/bottles-3880-42.
Pipercillin Sensitivity Discs impregnated w ith 100 /ig of piperacillin are also available.
Storage: PIPRACIL'vials and infusion bottles should be stored at controlled room temperatures of 15 30°C
(59-86°F).
Pipercillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.
DOSAGE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously
by injection or infusion. Dosage and route of administration should be determined by the severity of the infection
and condition of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a
20 to 30 minute infusion administered intravenously. The maximum daily dose usually administered to adults is
24 g/day, although higher doses have been used.
DOSAGE
Type of Infection

Usual Total Daily Dosage

Frequency of Administration

Serious infections such as septicemia, nosocomial
pneumonia, intra-abdominal infections, aerobic
and anaerobic gynecologic infections, and skin
soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most
community-acquired pneumonia.
Uncomplicated gonococcal urethritis.

12-18 g I V.
(200-300 mg/kq)

Every 4 to 6 hours

8-16 g I.V. (125-200 mq/kq) Every 6 to 8 hours
6-8 Q 1 M. or I.V.
Every 6 to 12 hours
(100-125 mg/kg)
2 g I.M .*
Single dose

*0ne gram of probenecid given orally 1/2 hour prior to injection.
Dosage in Renal Impairment
Creatinine Clearance
mL/min.

Urinary Tract Infection
(uncomplicated)

Urinary Tract Infection
(complicated)

Serious Systemic
Infection

12 g/day 4 g every 8 hrs.

>40

No dosage adjustment necessary

20-40

No dosage adjustment necessary

9 g/day 3 g every 8 hrs.

<20

6 g/day 3 g every 12 hrs.

6 g/day 3 g every 12 hrs. 8 g/day 4 g every 12 hrs.

Patients on
Hemodialysis*

‘ Hemodialysis removes 30-50% of piperacillin in 4 hours;
1 g additional dose should be administered following
each dialysis period.

6 g/day 2 g every 8 hrs.

For patients w ith renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* w ill provide
additional guidance for adjusting dosage.
Infants and Children-Dosages in infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which
it is from 3 to 10 days; the duration should be guided by the patient's clinical and bacteriological progress. For
most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes
asymptomatic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10
days to reduce the risk of rheumatic fever of glomerulonephritis.
OBSTETRICS-GYNECOLOGY
1 Gilstrap LC III et al. Piperacillin versus clindamycin plus gentamicin for pelvic infections. Obster Gynecol
64(61:742-766, Dec. 1984.
2. Tally FP et al. Nationwide study of the susceptibility of the Bacteroides fra g ilis group in the United States.
A ntim icrob Agents Chem other 28151:675-677, Nov. 1985.
SURGERY
1. Wittmann DH. A clinical evaluation of piperacillin in intra-abdominal infections. C linical Therapeutics
6(A):35-44,1984.
2. Tally FP et al. Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.
A ntim icrob Agents Chem other 28(51:675-677, Nov. 1985.

‘ PIPRACIL is a registered trade mark of Lederle Piperacillin, Inc.
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Sensitivity of the Hemoccult II Slide Test
in Detecting Colonic Neoplasms
It is common clinical practice to test
stools for occult blood and to rely heav
ily upon the result in deciding whether to
investigate further. Because the accuracy
of such testing has been questioned, a
study was conducted to estimate the
sensitivity of the Hemoccult II slide test
in detecting colonic carcinoma and
polyps. Patients with lesions demon
strated on barium enema roentgenogra
phy had their stools examined for occult
blood. One to 2 weeks before
colonoscopy, stool specimens were col
lected for 3 consecutive days according
to the manufacturer's instructions. The
sensitivity of occult blood testing was
38% for patients with benign polyps and
64% for patients with polypoid carci
nomas. Thus, the authors conclude that
the Hemoccult II test is not reliable as a
diagnostic tool and that a negative test
result does not exclude the presence of
a colonic neoplasm in any patient.
II est courant sur le plan clinique de
depister le sang occulte dans les selles
et de se fier beaucoup au resultat pour
determiner s'il y a lieu de poursuivre plus
amples recherches. Etant donne que la
precision de ce genre de depistage a ete
I'objet de questions, une etude a ete
menee pour evaluer la sensibilite du test
sur lame, I'Hemocculte II, dans la detec
tion du carcinome et des polypes du
colon. Les patients dont les lesions ont
ete demontrees grace au lavement baryte
se sont fait examiner les selles pour
determiner si elles contenaient du sang
occulte. Durant une periode d'une a 2
semaines avant la colonoscopie, des
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echantillons de selles ont ete preieves
pendant 3 jours consecutifs selon les
directives specifiees par le fabricant. La
sensibilite de ce depistage du sang
occulte dans les selles etait de 38%
chez les patients souffrant de polypes
benins et de 64% chez des patients
souffrant de carcinomes polypoides. La
reaction de I'Hemocculte II de la
presente etude ne s'est pas reveiee etre
un test fiable de diagnostic. Par conse
quent, un resultat negatif n'eiimine pas
la possibiiite d'un neoplasme colique.

Colorectal carcinoma is the second com
monest internal malignant lesion in North
American people.1 Survival of patients
with this disease is better when it is
detected and treated early. Over the past
30 years the death rate from colorectal
carcinoma has not improved appreciably
despite the introduction of new surgical
techniques and various chemotherapeu
tic protocols.2 Among methods available
to screen for malignant lesions of the
large intestine, barium enema roentgenog
raphy and colonoscopy are not practical.
The use of blood tests such as the one to
measure the carcinoembryonic antigen
level has not yet proven of value. Fecal
occult blood testing and rigid sig
moidoscopy have been actively promoted
in screening for large-bowel neoplasms.
In the past it was suggested3 that routine
rectal examination and expert rigid rec
tal sigmoidoscopy would be able to detect
two thirds of all colorectal neoplasms.
However, it has been shown4 recently
that the distribution of carcinoma of the
large bowel has changed from the rectum
and left colon to the right colon. This
diminishes the value o f rigid sig
moidoscopy as the only screening method
for detecting colorectal carcinoma.
Testing stool samples for occult blood
in the manner proposed by Greegor5 is
currently advocated as a means of screen
ing populations for colorectal carcinoma.
Initial reports of randomized prospective
trials using the Hemoccult slide test have

indicated a high specificity with a false
positive rate of only 0.5% to 2.1% for
neoplasms of the colon and rectum .6
However, it will take 5 to 10 years before
the sensitivity of stool occult blood test
ing can be obtained, as the false-negative
results only surface after several years of
follow-up.7 For a screening test to be
useful both the sensitivity and specificity
must be high. A screening test with a low
sensitivity will give many false-negative
results with many affected persons being
missed. There is a growing consensus that
the majority o f colorectal carcinomas
begin as adenomas.8 This would suggest
that the secondary prevention of colorec
tal carcinoma might be possible by early
detection and removal of the precursor
lesions. To estimate the sensitivity of the
Hemoccult II slide test (SmithKline Diag
nostics, Sunnyvale, Calif.) in detecting
colonic carcinomas and polyps, patients
with known lesions of the colon were
tested before colonoscopy.

Methods
All patients with colonic lesions
demonstrated by barium enema examina
tion were entered into the trial. Those
with lesions within 15 cm of the anal verge
were excluded. Since Hemoccult testing
is meant to screen asymptomatic persons,
individuals with anemia were excluded.
Patients with a coagulopathy, those on
anticoagulants and those taking salicy
lates were also excluded. Those with a
previous history of rectal bleeding were
included provided the above criteria were
met and there was no evidence of blood
on proctosigmoidoscopy carried out
before the occult blood testing. One to 2
weeks before colonoscopy the patients
were given the Hemoccult II slides and
were told to follow the dietary instruc
tions outlined by the manufacturer. The
stool specimens were collected for 3 con
secutive days. Two samples were obtained
from different portions of the same stool,
each being smeared on a separate window
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of the slide. The subjects were asked to
return the cards as soon as possible after
obtaining the samples. The slides were not
rehydrated before testing. All results were
read by one of the two technicians who
process all occult blood tests for the
hospital and its outpatient clinics. They
were not aware of the nature of the study.
In all, 72 patients completed the slides.
They ranged in age from 40 to 79 years
(mean 60.3 ± 11.6 years). Of the 72, 61
had benign polyps and 11 carcinomas.
Results
In 38 patients with one or more benign
polyps, the Hemoccult II test gave a nega
tive result, for a sensitivity of 38%; in
other words, this test failed to detect
blood in 62% of cases. Sensitivity with
respect to size is shown in Table I. Of the
11 patients with polypoid carcinomas, 4
had test results that were negative for
occult blood, a sensitivity of 64% (i.e.,
blood was not detected in 36%). Table II
illustrates the sensitivity for benign and
malignant lesions.
Discussion
The use of occult blood testing of stool
to detect and prevent colorectal carci
noma has been advocated by the Ameri
can Cancer Society9 and the Canadian
Task Force on the Periodic Health
Examination.10 The question remains
whether current tests available for detect
ing occult blood in the stool are the ideal
screening methods for detecting colorec
tal neoplasms
Several issues regarding the use of
occult blood testing have not been
resolved. These include age of onset of
screening, patient compliance, diet while
stools are being collected, time limit of
slide storage, necessity for rehydration,
sensitivity, effect on the natural history
(i.e., morbidity, mortality) of colonic
cancer and cost-effectiveness.
Current, ongoing, prospective studies
of Hemoccult testing have reported a rate
of slide positivity of 1% to 3.7% and a
false-positive rate of 0.5% to 2.1% .6'n

Pathologic type
Benign
Malignant
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These results suggest a relatively high
specificity, defined as the percentage of
patients without disease who have a nega
tive test. The validity of the screening test
also depends on a low false-negative rate
or a high sensitivity. Sensitivity can be
defined as the percentage of patients with
disease who have a positive test.
The relatively low sensitivity of Hemoc
cult II for carcinomas (64%) and polyps
(38%) in our series is similar to that
reported by others (Table III6-12' 18). In
assessing the sensitivity of Hemoccult II
for patients with colorectal carcinoma,
Van Maercke and colleagues12 found
30.2% of patients to be Hemoccult nega
tive. In a preliminary report of a large,
ongoing, mass screening study, the false
negative rate of the Hemoccult II test was
76% for adenomas in the rectosigmoid.6
In another study using Hemoccult alone,
58% of adenomas were not detected.13
Hagihara and colleagues14 suggested that
the results of the stool Hemoccult test to
detect neoplastic polyps were size-related.
Of 20 polyps ranging in size from 0.5 to
1.0 cm, negative results were obtained for
19. Even for the 32 polyps measuring 1
cm or greater, 19 (60%) tested negative.

in studies by Macrae and col
leagues,15-19 the sensitivity could be
Table III—Studies of Hemoccult Sensitivity
False-negative, %
Series________________ Polyps
Carcinoma
Schewe and
associates, 197913
58
36
—
Winawer, 19806
76
Gnauck, 198016
40
13
Griffith and
—
associates, 198117
18
Van Maercke and
—
associates, 198212
30
Hagihara and
95*
—
associates, 198214
601
Macrae and
—
associates, 198215
31
Crowley and
associates, 198318
77
48
Present series
62
36
* < 1 cm.
t > 1 cm.

Table II—Polyp Type Versus Sensitivity of
Hemoccult II Test
No. of
patients
61
11

No. positive
(sensitivity, %)
23 (38)
7(64)

improved by rehydrating the slides before
testing. Their previous work had sug
gested that rehydration resulted in an
unacceptable rise in the false-positive rate.
They suggested that this problem could
be prevented if the patients followed a
strict red-meat-free diet and avoided
vegetables with a high peroxidase activity.
The issue of rehydration was not
addressed in our study and is still con
troversial.
These slide tests are meant for asymp
tomatic individuals on a regular basis.
When using the Hemoccult test the
patient must complete all six slides. Anal
ysis of daily individual smears indicated
that only 41% of neoplastic lesions would
have been detected if only one smear per
day was examined instead of the two
smears required.6 A recent report20 on
the use of HemoQuant, a new technique
for detecting occult blood in stool, shows
considerable promise and may prove to
be a more sensitive method, but clinical
confirmation is still necessary. Hemo
Quant is not yet available commercially.
The current evidence of a low sensitiv
ity or high false-negative rate of Hemoc
cult II slide testing suggests that this
approach alone is not reliable in screen
ing patients for colorectal carcinoma. Evi
dence from our personal experience and
from the literature suggests that some cli
nicians have been erroneously using
Hemoccult testing to replace rectosigmoidoscopy.21 Anyone using this test
must recognize that it is only as good as
our results show. Individuals at increased
risk of colonic carcinoma, such as those
with a strong family history of cancer of
the large bowel or a previous personal his
tory of colonic cancer or adenomatous
polyps, should be investigated more
aggressively by rectosigmoidoscopy, bar
ium enem a roentgenography or
colonoscopy, or all three.
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We thank Judy Pollack for typing the
manuscript.

•^
References
1. SlLVERBERG E: Cancer statistics, 1984. CA 1984; 34:
7-23
2. D evesa SS, Silverman DT: Cancer incidence and mor
tality trends in the United States: 1935-74. J Natl Cancer
Inst 1978; 60: 545-571
3. WELCH CE, GIDDINGS WP: Carcinoma of colon and
rectum; observations on Massachusetts General Hospi
tal cases, 1937-1948. N Engl J Med 1951; 244: 859-867
4. Mam azza J, GORDON PH: The changing distribution
o f large intestinal cancer. Dis Colon Rectum 1982; 25:
558-562
5. GREEGOR DH: Occult blood testing for detection of
asymptomatic colon cancer. Cancer 1971; 28: 131-134
6. W inawer SJ, A ndrews M, F lehinger B, et al:
Progress report on controlled trial of fecal occult blood
testing for detection of colorectal neoplasia. Cancer 1980;
45: 2959-2964
7. W inawer SJ: Introduction to position papers from the
Third International Symposium on Colorectal Cancer.
CA 1984; 34: 130-133
8. MORSON BC: Genesis of colorectal cancer. Clin Gas
troenterol 1976; 5: 505-525
9. Cancer of the colon and rectum. In EDDY D: Guidelines
for the cancer-related checkup: recommendations and

VOLUME 29, NO. 2, M ARC H 1986 / THE CANADIAN JOURNAL OF SURGERY

r '
*

4

-

* ♦

10.

11.

12.

13.

14.

15.
16.

17.

18.

rationale. ACS report on the cancer-related health
checkup. CA 1980; 30: 208-215
Canadian Task Force on the Periodic Health Examina
tion: The Periodic Health Examination. Can Med Assoc
J 1979; 121: 1193-1254
G ilbertsen VA, Mc H ugh R, SCHUMAN L, et al: The
earlier detection of colorectal cancers: a preliminary
report of the results of the Occult Blood Study. Cancer
1980; 45: 2899-2901
Van Maercke Y, Van M oer E, P elckmans P, et al:
Hemoccult test, its diagnostic value (abstr). Gastroen
terology 1982; 82: 1203
SCHEWE S, F eifel G, H eldwein W, et all: Sensitivitat
des Haemoccult-Tests bei kolorectalen tumoren. Dtsch
Med Wochenschr 1979; 104: 253-256
HAGIHARA PF, Ram M, Sachatello CR, et al: Detec
tion of neoplastic polyps of the large bowel with stool
Hemoccult test. Presented at the annual meeting of the
American Society of Colon and Rectal Surgeons, San
Francisco, May 1982
Macrae FA, St J o h n DJB, C aligiore P, et al:
Optimal dietary conditions for hemoccult testing. Gas
troenterology 1982; 82(5 pt 1): 899-903
GNAUCK R: World Health Organization criteria for
screening. In WlNAWER SJ, SCHOTTENFELD D, SHER
LOCK P (eds): Colorectal Cancer: Prevention, Epidemi
ology, and Screening, Raven, New York, 1980: 175-180
G riffith CDM, T urn er DJ, Saunders JH: False
negative results of Hemoccult test in colorectal cancer.
Br Med J [Clin Res) 1981; 283: 472
C rowley ML, F reem an LD, Mottet MD, et al: Sen
sitivity of guaiac-impregnated cards for the detection of
colorectal neoplasia. J Clin Gastroenterol 1983; 5:
i -> 7-110

19. M acrae FA, St J oh n DJB: Relationship between pat
terns of bleeding and Hemoccult sensitivity in patients
with colorectal cancers or adenomas. Gastroenterology
1982; 82(5 pt 1): 891-898
20. AHLQUIST DA, McGlLL DB, SCHWARTZ S, et al: Fecal
blood levels in health and disease. A study using HemoQuant. N Engl J M ed 1985; 12: 1422-1428
21. CUMMINGS KM, J aen CR, FUNCH DP: Family physi
cians’ beliefs about screening for colorectal cancer using
the stool guaiac slide test. Public Health Rep 1984; 99:
307-312

BACTRIM™ ROCHE®
(trimethoprim plus sulfamethoxazole)
Therapeutic Classification
Antibacterial agent
Indications
The following infections when caused by susceptible micro
organisms:
• upper and lower respiratory tract (particularly chronic bron
chitis and including acute and chronic otitis media)
• urinary tract: acute, recurrent and chronic
• genital tract: uncomplicated gonococcal urethritis
• gastrointestinal tract
• skin and soft tissue
'B actrim ' for Infusion is indicated in serious systemic infec
tions (e.g. meningitis, septicemia) caused by susceptible
organisms and in Pneumocystis carinii pneumonitis, when
oral administration is impractical.
Not indicated in infections due to Pseudomonas, Mycoplasma
or viruses.
Contraindications
Known hypersensitivity to trimethoprim or sulfonamides:
marked renal impairment where serum determinations can
not be performed; marked liver damage; blood dyscrasias.
During pregnancy or lactation, and in infants under two
months old.
Warnings
Fatalities have occurred rarely with sulfonamides due to
severe reactions, e.g. Stevens-Johnson syndrome, toxic
epidermal necrolysis, fulminant hepatic necrosis, agranulo
cytosis, aplastic anemia and other blood dyscrasias.
Precautions
Appraise benefit against risk in patients with liver damage,
renal damage, urinary obstruction, blood dyscrasias, aller
gies, or bronchial asthma. Beware of kernicterus in neonates.
Reduce dosage and determine serum concentrations in
patients with renal impairment. Do not use if creatinine clear
ance is below 15 m L/m in . Monitor blood counts during long
term therapy and in patients disposed to folate deficiency,
including those on anticonvulsant therapy. Folinic acid may
reverse signs of folate deficiency.
Consider possible superinfection with a non-sensitive
organism.
Drug Interactions: Antagonists: PABA and its derivatives.
Potentiators: urinary acidifiers, oral anticoagulants, sulfo

NOTICES
P o s tg ra d u a te C o u rs e
in G e n e ra l S u rg e ry
The Paul A. Ebert Postgraduate Course
in General Surgery will be held Apr.
17-19, 1986, at the Hyatt on Union
Square, San Francisco, Calif. This pro
gram is presented by the Department of
Surgery and the Howard C. Naffziger
Surgical Society of the University of Cali
fornia School o f Medicine in San Fran
cisco and is sponsored by Extended
Programs in Medical Education.
Clinically oriented, the program offers
general surgeons an intensive overview of
problems encountered in daily practice.
The emphasis is on venous thromboem
bolism, burns, acute pancreatitis, biliary
tumours, portal hypertension, esophageal
disease and colorectal cancer.
Advance registration is recommended.
Tuition includes lectures and syllabus.
The fee is $250.00 or $135.00 for nonUCSF interns, residents and fellows, who
submit a letter o f verification from train
ing program with application.
For further information on the scien
tific program please call (415) 476-4251;

nylurea hypoglycemics, phenylbutazone, oxyphenbutazone,
indomethacin, sulfinpyrazone and salicylates.
Adverse Reactions
Hematological: primarily, neutropenia and throm bo
cytopenia; less frequently, leukopenia, aplastic or hemolytic
anemia, purpura, agranulocytosis, and bone marrow depres
sion. Occur particularly in the elderly and are mostly asymp
tomatic and reversible on withdrawal.
Most frequent: nausea, vomiting, gastric intolerance, rash.
Less frequent: diarrhea, constipation, flatulence, anorexia,
pyrosis, gastritis, gastroenteritis, urticaria, headache, and
elevated alkaline phosphatase and serum transaminase.
Occasional: erythema, edema, pruritis, toxicoderma, photo
sensitivity, glossitis, stomatitis, dyspepsia, dry mouth,
dysuria, oliguria, anuria, hematuria, urgency, dyspnea, trem our, vertigo, tiredness, jaundice, vision troubles, drug fever,
alopecia, epistaxis, black tongue, elevated BUN, NPN, serum
creatinine or urinary protein and anaphylactoid reactions.
Rare: goiter, diuresis and hypoglycemia have occurred with
sulfonamides.
Dosage and Administration
INTRAVENOUS
Parenteral therapy is indicated if patient cannot take oral
medication or if high serum concentrations are required
rapidly.
PARENTERAL TREATMENT SHOULD BE TERMINATED AND
ORAL TREATMENT INSTITUTED AS SOON AS POSSIBLE.
CAUTION - 'BACTRIM' FOR INFUSION MUST BE DILUTED IN
STERILE D5W, RINGER'S OR NaCI 0.9% SOLUTION PRIOR
TO ADMINISTRATION. DIRECT INTRAVENOUS INJECTION
NOT RECOMMENDED. DO NOT MIX WITH OTHER DRUGS OR
SOLUTIONS. For method of dilution and infusion administra
tion, see Package Insert.
Pneumocystis carinii pneumonitis:
Children and adults: 5 mg trim ethoprim/kg + 20 mg
sulfamethoxazole/kg q.i.d. until oral therapy can be
instituted.

Serious systemic infections:
Adults: 160 to 240 mg trimethoprim + 800to 1200 mg sulfa
methoxazole (10-15m l 'Bactrim' for Infusion)every 6 , 8 o r 12
hours, depending on severity of infection.
Children: 5 to 10 mg trim ethoprim /kg/day + 25 to 50 mg
sulfamethoxazole/kg/day in 2-4 equally divided doses.

to register by phone or inquire about
registration call (415) 476-5808, or write:
Extended Programs in Medical Educa
tion, Registration Office, Room 575-U,
University o f California, San Francisco,
CA 94143-0764.

N e u r o v a s c u la r S u rg e ry
The 3rd annual meeting o f the Neurovas
cular Society o f North America and the
Society for Neurovascular Surgery will be
held in Chicago, 111., Apr. 17-19, 1986.
General sessions will strive to identify
problems affecting the heart, blood ves
sels and brain, pathologic mechanisms,
and methods of diagnosis and manage
ment. Special sessions will address in
detail such topics as vertebral artery sur
gery, ultrasonography, headaches, nerve
repair and anticoagulation. The meeting
will be open to all diagnostic, medical and
surgical specialties.
For further information write the
Executive Director, Neurovascular Soci
ety o f North America/Society for Neu
rovascular Surgery, PO Box 679, Oak
Park, IL 60302; or call (312) 482-3950.

PATIENTS WITH IMPAIRED RENAL FUNCTION
Not recommended if creatinine clearance ( C y less than
15 m l/m in . At CICr 15-30 m l/m in : 1 /2 usual regimen. At CICr
above 30 m l/m in : usual regimen.
Supply
Adult tablets: 80 mg trim ethoprim and 400 mg sulfa
methoxazole. Bottles of 100 and 500. Unit dose: boxes of 100.
DS tablets: 160 mg trimethoprim and 800 mg sulfamethox
azole. Bottles of 100 and 250. Pediatric tablets: 20 mg
trim ethoprim and 100 mg sulfamethoxazole. Bottles of 100.
Suspension: Cherry-flavoured, 40 mg trim ethoprim and
200 mg sulfamethoxazole, per 5 m l. Bottles of 20, 100 and
400 m l. Solution for Infusion: Each m l contains 80 mg
sulfamethoxazole and 16 mg trim ethoprim, for infusion with
D5W. Ringer’s or NaCI 0.9% solution. Packs of 10 x 5 ml
vials, single 30 m l vials and 10 x 5 ml ampoules.
Product Monograph available on request.
References
1. Sattler FR, Remington JS. Another look at trim ethoprim sulfamethoxazole: its role in parenteral therapy. Eur J Clin
Microbiol 1984;3:174-76.
2. Ferguson LJ, Imrie CW. A comparative study of intra
venous co-trimoxazole and cephalothin in patients with
intra-abdominal sepsis. Pharmatherapeutica 1978;2:
91-96.
3. Marandian MH, et al. Interet de I'administration intraveineuse de trimethoprime-sulfantethoxazole dans les septicbmies a bacilles Gram-negatif chez I'enfant. Rev Pediat
1979;15:519-22.
4 . Nelson JD, et al. Oral or intravenous trim ethoprim sulfamethoxazole therapy fo r shigellosis. Rev Infect Dis
1982;4: 546-50.
5. Leverve X,et al. Interet de I'association sulfamethoxazoletrirrtethoprime dans le traitement des infections sSveres en
reanimation. Med Actuel 1982;9:162-63.
6. Murisasco M, Saingra S. Utilisation du sulfamethoxazoletrim ethoprime en nephrologie. Med Intern 1975;10:
306-08.
™ Trade Mark of Hoffmann-La Roche Limited
, ■/'ab 1
® Reg. Trade Mark
© Copyright 1985 Hoffmann-La Roche Limited
5012
,
-v
Etobicoke, Ontario

< ROCHE)
\

V O L U M E 2 9 , N O . 2, M A R C H 1 9 8 6 / THE CANADIAN JOURNAL OF SURGERY

A

M9C5J4
Original Research in m edicine and chemistry

101

P i e r r e L e g e n d r e , m d ; J o h n V. F o w l e s , m b , b s (l o n d ), f r c s c ; C l a u d e G o d i n , m d , f r c s c

Chondromalacia of the Fabella: a Case Report
A 46-year-old man suffered from chon
dromalacia of the fabella after minor
trauma to the back of the knee. The con
dition was misdiagnosed initially as fasci
itis, tendinitis, a Baker's cyst and a her
niated lumbar intervertebral disc.
Pathognomonic signs were pain behind
the lateral femoral condyle on palpation
and compression of the fabella and also
on passive extension of the knee. Con
servative management was unsuccess
ful. Excision of the fabella gave quick
and lasting relief.
Un diagnostic de chondromalacie fabellaire a ete pose chez un homme de 46
ans ayant recu un trauma mineur a I'arriere de son genou. Cette pathologie fut
initialement confondue avec une fasciite,
une tendinite, un kyste de Baker et une
hernie discale lombaire. Les signes
pathognomoniques etaient une douleur a
I'arriere du condyle femoral externe a la
palpation et compression de la fabella,
de meme qu'a I'extension passive du
genou. Le traitement conservateur fut
sans succes; par contre I'exerese de la
fabella soulagea rapidement et de facon
permanente les symptomes de notre
patient.

HG. 1—Lateral and anteroposterior roentgenograms show normal-looking fabella (arrows)
lying behind and articulating with lateral femoral condyle.

Chondromalacia o f the fabella is uncom
mon. Fewer than 30 cases have been
described in the French and English liter
ature.1-9 Because o f its rarity, the condi
tion is easily misdiagnosed, and it can be
quite disabling. This paper describes the
management of such a case.

Case Report
The patient, a 46-year-old man, banged the
back of his right knee on a desk edge when
From the Orthopedic Service, Department
o f Surgery, Hotel-Dieu de Montreal,
Montreal, PQ
Accepted fo r publication Sept. 6, 1985
Reprint requests to: Dr. John V. Fowles,
Ste. 209, 3875 rue St-Urbain, Montreal, PQ
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FIG. 2—Section of fabellar articular cartilage shows structural disorganization and fibril
lar degeneration. Cartilage-bone junction is seen at upper right (hematoxylin and eosin, origi
nal magnification x 5).
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jumping down from it to the floor. For the next
12 months he had pain over the back of the
lateral femoral condyle, radiating up and down
the back of the limb. During that time he was
investigated and treated for a number of con
ditions — plantar fasciitis with a bone spur,
tendinitis, lumbar degenerative disc disease and
a Baker’s cyst seen on an arthrogram — all to
no avail. When a myelogram for herniated disc
and an arteriogram for arterial insufficiency
were suggested, the patient demurred and was
referred to the Hotel-Dieu Hospital.
On examination, both compression of a pal
pable fabella against the femoral condyle and
passive extension of the knee reproduced the
patient’s symptoms. Otherwise the findings on
examination of the knee and of the neurologic
and vascular examinations were normal.
Roentgenograms showed a fabella of normal
appearance behind the lateral femoral condyle
(Fig. 1).
The fabella was removed through a posterior
longitudinal incision, identifying and retract
ing the common peroneal nerve, which lay
directly over it, and splitting the fibres of the
gastrocnemius tendon which was later resu
tured. The articular surface of the fabella was
yellowish and roughened, but the femoral con
dylar cartilage appeared normal. Microscopic
examination of the fabella showed fibrillar
degenerative changes of the articular cartilage
with fibrosis and mucilaginous cystic degener
ation of adjacent synovia (Fig. 2).
The patient returned to work 2 weeks after
the operation and was pain free when seen 1
year later.

Discussion
The fabella is a fibrocartilaginous or
ossified sesamoid bone most commonly
situated in the lateral head of the gastroc
nemius muscle, and rarely in the medial
head. The anterior surface is usually
covered with hyaline cartilage and artic
ulates with the posterior aspect of the
femoral condyle.6 In the coronal plane
the fabella is oval with average dimen
sions of 4 mm x 8 mm, but in the sagit
tal plane it is semicircular with the flat,
articular surface anteriorly.10 Ossifica
tion, when it occurs, is endochondral and
starts between 12 and 15 years of age. An
ossified fabella, visible on roentgeno
grams, is present in 9% to 29% of peo
ple and occurs in both knees in more than
two thirds of these.5,6
A painful fabella has been reported in
both adolescents and adults. Many cases
were initially misdiagnosed as a knee
sprain, Baker’s cyst, torn lateral meniscus
or sciatica.1-3,11 The diagnosis was likely
missed because the condition is rare and
the examining physician did not palpate
the fabella. A number of patients had
already been treated for months or years
by physiotherapy, casts, braces and local
intra-articular cortisone injections. One
patient had a lateral meniscectomy. Con
servative treatment seldom gave lasting
relief of pain.1-3,5-8,11
The typical clinical presentation is one
of intermittent posterolateral knee pain

accentuated by knee extension and also
by compression directly over the palpa
ble fabella.7 The syndrome may occur
with an ossified fabella, a cartilaginous
model or a thickened area of tendinous
fibres in the gastrocnemius.7 The differ
ential diagnosis of the painful fabellar
syndrome includes fabellar fracture,
osteoarthritis and chondromalacia. The
common peroneal nerve may be com
pressed or irritated by the fabella, which
lies immediately underneath or adjacent
to the nerve.2,6 In this instance, the sym
ptoms may include hyper- or hypoesthesia and muscle weakness in the distribu
tion of the nerve.
The pathologic changes of the fabellar
articular cartilage are often similar to
those o f chondrom alacia of the
patella,1-3,5-8 and Goldenberg and Wild3
coined the term “ chondromalacia fabellae” . Goldenberg2,3 found localized or
generalized degenerative changes with
fibrillation and pitting in the fabella of
four patients.2,3
Some authors2,3,5 have noted degener
ative changes in the contiguous lateral
femoral condyle with chondromalacia
fabellae. Goldenberg2 recommended
excision of this cartilage in conjunction
with fabellectomy. We doubt the wisdom
of removing cartilage from the back of
the femoral condyle, especially as this
area of the bone is non-weight bearing.
Patients reported in the literature had per
manent relief of symptoms after fabellec
tomy alone,1,5-8,11 as did our patient. The
fabella should be excised as soon as the
diagnosis is m ade, thus avoiding
prolonged and relatively ineffective
treatment.
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Posterior Sternoclavicular Dislocations
Tw elve cases of posterior sternoclavicu
lar dislocation were seen over 15 years
at the Victoria General Hospital and the
Izaak Walton Killam Hospital for Children
in Halifax, IMS. Tw o patients
required open reduction of the disloca
tion but the rest were treated by closed
reduction. One of the former group
required threaded K wires for stability,
but all other dislocations were deemed
stable after reduction and application of
a figure-of-eight bandage and an arm
sling. There were no failures of reduction
and no recurrent dislocations; the
authors have been successful even in
late closed reduction (up to 5 days) and
therefore recommend it highly as the
primary treatment. Open reduction is
much more difficult and hazardous.
En 15 ans, 12 cas de dislocations sternoclaviculaires ont ete vus au Victoria
General Hospital et au Izaak Walton Kil
lam Hospital for Children de Halifax,
Nouvelle Ecosse. Deux patients ont
necessity une reduction ouverte alors
que les autres etaient traites par reduc
tion fermee. Dans le premier groupe, un
patient a eu besoin de fil K pour assurer
la stability, alors que toutes les autres
dislocations ont paru stables apres
reduction, bande en huit et immobilisa
tion du bras dans une echarpe. II n'y eut
ni echec ni recidive. Les auteurs ont
reussi meme dans les cas de reduction
tardive (jusqu'd 5 jours) et recommandent fortement cette approche comme
traitement primaire. Une reduction
ouverte est beaucoup plus difficile et
risquee.
F rom the Department o f Orthopedics, Dalhousie University, Halifax, NS
*Fellow, St. Michael’s Hospital, Toronto,
Ont.

fAssociate Professor, Department o f
Orthopedics, Victoria General Hospital,
H alifax
XChief o f Orthopedics, Izaak Walton K il
lam Hospital f o r Children, Halifax
A ccepted f o r publication July 22, 1985
R eprint requests to: Dr. Ross K. Leighton,
1971 Rosebank Ave., Halifax, NS
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Fig. lb
FIG. 1— (a) Anteroposterior view of chest showing normal mediastinum, (b) Coned view
of sternoclavicular joint shows posterior dislocation of left sternoclavicular joint.
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Dislocation of the sternoclavicular joint
is uncommon, accounting for less than
3% of shoulder girdle injuries and less
than 1% of all dislocations.1 Posterior
dislocations of the joint are even rarer.
Gazak and Davidson2 found fewer than
100 cases in the literature since Sir Astley Cooper first described a case in 1824.
The literature documents the difficulty
radiologically in dem onstrating the
posterior dislocation of the sternoclavic
ular joint.3 Selesnick and colleagues4
suggested computed tomography as a
definitive diagnostic test.
In this paper we review our experience
with 12 posterior dislocations of the ster
noclavicular joint between 1969 and 1984.

tation and confirmed by oblique roent
genograms, with or without tomography.
The dislocations were reduced in the oper
ating room. There was one failure of
closed reduction secondary to buttonhol
ing through the posterior capsule. This
required open reduction and soft-tissue
repair but no internal fixation. One other
dislocation was judged to be unstable and
was treated with threaded K wires.2 All
the other dislocations were reduced by
closed manipulation and held with a
figure-of-eight bandage and a sling. One
of these cases is presented in detail, to
illustrate some of the interesting points.

Patients and Methods

A 16-year-old boy was seen at the Izaak Wal
ton Killam Hospital for Children with an injury
to the posterolateral aspect of the left shoul
der, sustained when he was checked into the
boards while playing hockey. He had shoul
der pain and his neck was flexed laterally to
the left. The left arm was flexed and he sup
ported it with the opposite arm. He felt a lump
in his throat and had slight dysphagia but no
dyspnea or stridor.
There was an obvious depression at the left
sternoclavicular joint. The outer edge o f ster
num was palpable with definite swelling cen
trally around the sternal notch. There was no
evidence of vascular damage.
Chest films and sternoclavicular oblique
views demonstrated normal lung parenchyma
and a normal mediastinum (Fig. la) with
posterior dislocation of the left sternoclavicu
lar joint (Fig. lb).
Under general anesthesia a sand bag was first
placed between his scapulae. The area o f the
clavicle was prepared and draped in the usual
fashion. Traction was applied to the left arm
and a towel clip used to grasp the medial end
of the clavicle as anteriorly as possible to avoid
vascular injury. The end of the clavicle was
then pulled forward. Traction was released and
the reduction checked for stability.
A large hematoma now became apparent

Twelve patients with posterior ster
noclavicular dislocations were treated at
the Victoria General Hospital or the Izaak
Walton Killam Hospital in Halifax dur
ing the study period. In all patients the
diagnosis was made clinically on presen-
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FIG. 2—Anteroposterior view of chest
showing asymmetric widening of mediastinum.

Case Report

FIG. 3—Anteroposterior view of chest with normal mediastinum after only 12 hours in
intensive care unit.

over the sternoclavicular joint, with extension
laterally. A roentgenogram showed a widened
mediastinum (Fig. 2). However, all pulses
remained strong and there was no evidence of
active bleeding. The patient was placed in the
intensive care unit, supervised by cardiovascu
lar and orthopedic surgical staff, with monitor
ing by radial arterial line, electrocardiogram
and serial chest films. Twelve hours later the
chest film appeared normal (Fig. 3).
A figure-of-eight strap plus a sling were
applied, and the patient was discharged home
24 hours later. He wore the restraints for 4
weeks.

Results
All patients were treated similarly after
reduction of the dislocation. The two
patients who had open reductions were
immobilized for 8 weeks versus 4 to 6
weeks for those treated by the closed
method. The threaded K wires were
removed at 8 weeks. One migrated out
and one migrated in, making its removal
difficult. There were no failures of reduc
tion and no recurrent dislocations.
Discussion
To our knowledge, this series of
posterior sternoclavicular dislocation is
the largest in the literature to date. Some
authors differentiate between a true dis
location and a Salter-Harris type I epi
physeal injury.1 In our opinion this is
unnecessary as in the acute stage, both are
treated in the same fashion. The period
of immobilization for a true dislocation
in an older patient is increased (6 weeks
versus 4 weeks).
The most common injury reported is
a blow to the posterolateral aspect of the
shoulder.5 Another is a direct forceful
blow to the chest.2 The clinical
manifestations may range from shoulder
pain to hoarseness, dyspnea, dysphagia
with or without numbness, or weakness
of the upper extremity. The injury may
also cause a pneum othorax, pneu
momediastinum or a tear in a major
vessel.6
Although none of our patients had a
widened mediastinum on initial examina
tion, we agree with W orm an and
Leagus7 that arteriography should be
done in these cases to rule out serious
underlying vascular injury. Most authors
agree that open reduction is indicated
only when closed reduction is unsuccess
ful or instability persists.6,8
We recommend early closed reduction
under general anesthesia. This prevents
such long-term problems as thoracic out
let syndrom e.9 We have perform ed
closed reduction successfully as late as 5
days after dislocation with no increase in
complications. During manipulation we
have not heard an audible click upon
reduction, as suggested by some.3,10 The
stability of the reduction m ust be
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checked, before the patient leaves the
operating room, by pushing posteriorly
with the towel clip in the clavicle. We do
not advocate internal fixation as the com
plications can be serious.11 This series
and others support the conclusion that
once reduction is o btained it is
stable.10-11
References
1. Rowe CR, Marble HC: Sternoclavicular dislocations.
In C ave EF (ed): Fractures and Other Injuries, Year Bk
Med, Chicago, 1958
2. G a z a k S, D a v id s o n SJ: Posterior sternoclavicular dis
locations: two case reports. J Trauma 1984; 24: 80-82
3. HENIG CF: Retrosternal dislocation of the clavicle; early
recognition, x-ray diagnosis, and management. J Bone
Joint Surg [Am] 1968; 50: 830
4. SELESNICK FH, J ablon M, F rank C, et al: Retroster
nal dislocation of the clavicle. Report of four cases. J
Bone Joint Surg [Am] 1984; 66: 287-291
5. PATERSON DC: Retrosternal dislocation of the clavicle.
J Bone Joint Surg [Br] 1961; 43: 90-94
6. POST M (ed): The Shoulder: Surgical and Nonsurgical
Management, Lea& Febiger, Philadelphia, 1978: 488-500
7. WORMAN LW, LEAGUS C: Intrathoracic injury follow
ing retrosternal dislocation of the clavicle. J Trauma 1967;
7: 416-423
8. SlMURDA MA: Retrosternal dislocation of the clavicle:
a report of four cases and a method of repair. Can J Surg
1968; 11: 487-490
9. GANGAHAR DM, FLOGAITES T: Retrosternal dislocation
of the clavicle producing thoracic outlet syndrome. J
Trauma 1978; 18: 369-372
10. P eacock HK, Brandon JR, J ones OL jr : Retroster
nal dislocation of the clavicle. South Med J 1970; 63:
1324-1328
11. NETTLES JL, Linscheid RL: Sternoclavicular disloca
tions. J Trauma 1968; 8: 158-164

SESAP IV Critique
ITEM 121

Blood dripping from the urethral meatus of a patient who has had severe
pelvic trauma is a classic sign of disruption of the prostatic urethra.
In this type of injury the prostatic urethra is torn off the pelvic
diaphragm. Insertion of a Foley cathether contaminates the urethra and
serves no purpose. A cystogram is done if a retrograde urethrogram
shows that the urethra is intact and no extravasation is noted.
Intravenous pyelograms should be done after the urethrogram and
cystogram, because the dye from the intravenous pyelogram would
obscure extravasation. An arteriogram would not be useful to evaluate
this injury.
C
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Nontraumatic Spontaneous Rupture
of the Urinary Bladder
Rupture of the urinary bladder without a
history of recent trauma or instrumenta
tion is rare; it is usually associated with
bladder disease or outlet obstruction.
The patient is usually seen as an emer
gency case and has an atypical clinical
picture. The four patients in this report
were initially seen and treated by a
general surgeon; in only two was the
diagnosis established preoperatively and
confirmed by retrograde cystography.
Awareness on the part of the consulting
surgeon that bladder rupture is possible
in a predisposed patient may lead to a
correct preoperative diagnosis. In this
series, early operation — removing urine
from the peritoneal cavity or retropubic
space, closing the rupture and securing
good vesical drainage — resulted in
resumption of vesical function in all four
patients and there were no deaths.

En I'absence d'antecedents de traumatisme recent ou d'exploration a I'aide
d'instruments, une rupture de la vessie
est rare; ceci survient habituellement en
presence d'une maladie de la vessie ou
d'une obstruction de I'orifice de sortie.
Le patient est habituellement vu en
urgence alors qu'il presente un tableau
Clinique atypique. Dans cet article, les
quatre patients ont ete vus et traites par
un chirurgien general; dans seulement
deux cas, le diagnostic avait ete etabli
en preoperatoire et confirme par cystographie retrograde. Si le chirurgien soupconne la possibilite d’une rupture de la
vessie chez un patient predispose, on
peut anticiper un diagnostic preoperatoire
exact. Dans la presente serie, une opera
tion pr£coce, comprenant evacuation de
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I'urine de la cavite peritoneale et de
I’espace retropubien, fermeture de la
lesion et poste d'un bon drain vesical, a
reinstaure la fonction vesicate chez les
quatre patients. II n’y eut aucun deces.

Spontaneous rupture o f the urinary blad
der is the extravasation o f urine into the
intra- or extraperitoneal spaces without
evidence o f recent trauma. Usually, a
predisposing bladder lesion or urinary
retention can be found,1 but it has been
claimed that rupture of a normal bladder
can also occur.2
Because o f the low frequency and atyp
ical presentation o f this event, diagnosis
and treatment are usually delayed, lead
ing to an increased death rate and
prolonged hospitalization. Because o f the
urgent nature o f the condition such
patients are commonly seen and treated
initially by a general surgeon. The usual
presentation is that of an acute abdomen.
At operation the patient’s abdomen is
often explored extensively, the surgeon
seeking a perforated viscus, mainly a duo
denal ulcer, as a first possibility.
Although uncommon, the condition is
not rare, so we thought we should alert
the general surgeon who is the one most
likely to encounter it.
We present four patients treated in our
department for nontraumatic perforation
o f the urinary bladder. All were initially
seen by the general surgeon. The diagno
sis was made preoperatively in only two
cases, one o f which involved an
extraperitoneal rupture. In all patients the
rupture was closed, and eventually blad
der function was restored. There were no
deaths and no complications involving the
urinary system.

Case Reports
Case I
A 76-year-old white woman, known to have
a well-differentiated lymphocytic lymphoma
for which she was taking cyclosphosphamide,
was admitted to the emergency department,
complaining of chest pain, dyspnea and cough.
Her blood pressure was 140/80 mm Hg and

pulse rate 100 beats/min. Her lungs were clear
and heart sounds normal. The abdomen was
soft and not tender. Chest films and elec
trocardiogram were normal. Measurement of
blood gases revealed hypoxemia and respira
tory alkalosis. Lung scanning confirmed the
presumed diagnosis of multiple pulmonary
emboli to the left lung. Treatment with hepa
rin led to relief of symptoms and evidence of
improvement on lung scanning. Ten days after
admission, she experienced sudden suprapubic
pain and was unable to pass urine. In an other
wise soft abdomen there was bulging of the
suprapubic area with marked tenderness. A
Foley catheter inserted into the urinary blad
der drained 25 mL of clear urine, changing to
macroscopic hematuria. A retrograde cystogram showed an anterior perforation of the
bladder with extravasation of contrast material
into the retropubic space. Cystoscopy under
anesthesia confirmed the perforation and
showed normal bladder mucosa.
At laparotomy, the area of perforation was
trimmed and closed around a suprapubic
catheter. A urethral catheter was inserted. Her
postoperative course was uncomplicated. The
suprapubic catheter was removed after 2 weeks,
the urethral catheter a few days later. Bladder
function returned to normal. Histologic exami
nation of the specimen from the edge of the
perforation revealed changes in the mucosa and
submucosa typical of those seen after long-term
use of cyclophosphamide.

Case 2
A 75-year-old white man was admitted to
the neurology department after an acute
cerebrovascular accident. During the first week
he was treated with heparin, leading to some
improvement in his neurologic deficit. On day
10 he complained of diffuse abdominal pain
and nausea. His abdomen was distended with
guarding, generalized and rebound tenderness
and no audible bowel sounds. A condom
catheter attached to his penis was twisted, but
there was urine in the bedside bag. His leuko
cyte count was 12.0 x 109/L , and the urea
nitrogen level was 12 mmol/L urea. Abdomi
nal roentgenography showed moderately
dilated loops of small bowel, but there was no
evidence of free air under the diaphragm. The
diagnosis was perforated duodenal ulcer.
At laparotomy, the peritoneal cavity was
found to contain 2 L of yellowish fluid. The
gastrointestinal tract was intact. There was an
anterior intraperitoneal perforation of the uri
nary bladder. The perforation was trimmed
and the bladder closed around a suprapubic
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catheter that was brought out extraperitoneally.
A urethral catheter was inserted. The patient
had no complications postoperatively related
to the urinary system.

postoperatively. She was discharged home 60
days after admission with an indwelling ure
thral catheter in place.

Case 4

Case 3
A 72-year-old white woman had been treated
for squamous cell carcinoma of the esophagus
3 years before admission. She received radio
therapy only. Subsequently she suffered from
irradiation myelitis and a neurogenic bladder
for which she had required an indwelling Foley
catheter for the last 2 years. Her presenting
complaint was diffuse abdominal pain and
vomiting that had begun 24 hours earlier. She
was in a state of shock, with a blood pressure
of 60/40 mm Hg and a pulse rate of 134
beats/m in. Her abdomen was tender and
edematous. The Foley catheter was occluded.
Insertion of a new catheter drained a small
amount o f cloudy urine. After resuscitation
with fluid replacement, antibiotics and dopa
mine, the abdomen was found to be more
tender with diffuse guarding and rebound
tenderness. Both inguinal regions were red and
swollen. A retrograde cystogram confirmed the
presumptive diagnosis of rupture of the urinary
bladder.
At operation, the abdominal cavity was
found to contain a large amount of urine. A
hole in the dome of the bladder was identified
and closed after a suprapubic catheter had been
inserted through a separate incision. A urethral
catheter was also inserted. Pulmonary compli
cations and sepsis developed following the
operation, but the patient eventually recovered.
The suprapubic catheter was removed 4 weeks

A 30-year-old schizophrenic man was
brought to the emergency room for evaluation
of abdominal pain and fever. He was known
to have suffered from renal stones and had
passed several small stones spontaneously.
Three weeks before admission he complained
of difficulty in urinating and an associated
burning sensation. For 3 days he had had a
fever (body temperature to 39°C), and subse
quently he stopped voiding. On the day of
admission he complained of diffuse abdomi
nal pain without nausea or vomiting. On
examination the patient was somnolent, his
blood pressure was 130/80 mm Hg, pulse rate
140 beats/min and rectal temperature 39°C.
The abdomen was slightly distended, with no
audible bowel sounds. There was guarding with
diffuse and rebound tenderness. A Foley
catheter was inserted with some difficulty as
there seemed to be partial obstruction at the
level of the posterior urethra. The catheter
drained 300 mL of dark yellow urine. The
nasogastric aspirate contained a small amount
of “ coffee ground” material. No free air was
seen under the diaphragm in the chest film. The
diagnosis was an acute abdomen, probably due
to a perforated duodenal ulcer.
The peritoneal cavity contained 3 L of dark
yellowish fluid. The gastrointestinal tract was
intact. There was a 2-cm longitudinal tear in
the inflamed and friable anterior wall of the
urinary bladder. At this stage the existence of

an obstructing stone was suspected, and indeed
a small stone measuring 1 cm in diameter was
extracted from the posterior urethra. The rup
ture was closed and the bladder drained with
a urethral whistle-tip catheter for 2 weeks.
There were no complications, and the patient
was released 3 weeks later with normal blad
der function.

Discussion
Spontaneous rupture of the urinary
bladder is rare. The prevalence was
reported to be around 1:126 000 admis
sions to a London hospital1 and was
found to be 1:100 000 admissions to our
hospital. Most of the patients reported
had a predisposing factor that could inter
fere with the normal bladder function and
cause perforation.1'3
An outlet obstruction causing an over
distended bladder may lead to rupture.
Various neurologic disorders and organic
urethral obstructions have been reported,
such as tabes dorsalis, urethral stricture
and an enlarged prostate. Recent alcohol
intake, which increases output and
decreases mental awareness, may lead to
rupture following minor trauma to an
overdistended bladder.4 Obstruction of
an indwelling catheter as in our case 3,
or by a urethral stone as in case 4, can
also be responsible.
Lesions of the bladder such as tuber
culosis, prolonged cystitis and carcinoma
1
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may account for the nontraumatic rup
ture. In our first case, prolonged
cyclosphosphamide treatment concomi
tant with typical histologic changes in the
bladder could have led to the rupture. To
the best of our knowledge this is the first
description of such an event. No associ
ation could be made between the continu
ous treatment with heparin received by
two of our patients and the vesical rup
ture. There were no vascular abnormali
ties or hematomas in the areas of perfo
ration. Rupture in an otherwise normal
bladder has been reported and designated
idiopathic.2 It is our impression that the
term “ spontaneous rupture of the blad
der” should be used to describe all non
traumatic ruptures, bearing in mind the
possibility of underlying disease and its
contribution to the mechanism leading to
rupture. Such a predisposing factor can
be detected in a few of the cases reported
as idiopathic rupture.2
The rupture is usually intraperitoneal,
since the pelvic attachments of the blad
der allow its expansion into the peritoneal
cavity where it eventually tears at its thin
nest part.2 The patient usually has gener
alized peritonitis, with an elevated blood
urea nitrogen level due to the absorption
of urine from the peritoneal cavity.5 An
extraperitoneal rupture can occur if the
disease is in the extraperitoneal part of the
bladder wall, as in our case 1. In such a

case the patient may complain of sharp
suprapubic pain and be unable to pass
urine. The suprapubic area is tender and
may be swollen and edematous. This sit
uation will develop within the first 24
hours following rupture and draw atten
tion to specific diagnostic procedures and
a correct preoperative diagnosis.
Insertion of a catheter and the finding
of urine in the bladder does not exclude
the possibility of rupture. From the
presenting signs and symptoms the
general surgeon will usually suspect an
acute abdomen. Awareness of the possi
bility of rupture in all patients suffering
from urinary tract disease is essential if
the correct diagnosis is to be made and
extensive and time-consuming explorative
surgery avoided. When the condition is
suspected, retrograde cystography should
be done to confirm the diagnosis.
Although not infallible, it is the only relia
ble method of making the diagnosis
preoperatively. Cystoscopy done before
operation can exclude other bladder con
ditions that may interfere with the surgi
cal procedure. We recommend it be done
in the operating room immediately before
exploration, as the entrance of irrigating
fluid may exacerbate the intraperitoneal
infection.
Operative treatment includes removing
urine from the peritoneal cavity or retro
pubic space, closing the rupture, secur
SORTIE
EXIT
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ing good vesical drainage and draining the
retropubic space. We recommend the use
of both suprapubic and urethral catheters
to minimize the possibility o f urine
leakage.
The death rate in nontreated patients
has been reported to be 80%.6 After the
introduction of surgical repair there was
a gradual improvement in survival, reach
ing 50% in the early 1960s1'3 and even
higher in the last decade.2 It should be
noted that all our patients survived oper
ation and eventually regained their previ
ous vesical function. This can be
explained by the relatively early diagno
sis, prompt surgical repair and intensive
postoperative care.
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Aneurysmal Bone Cyst: a Review of 26 Cases
Twenty-six cases of aneurysmal bone
cyst are reviewed to determine the fre
quency, preferred treatment and progno
sis. Some observations are made as to
the existence of aneurysmal bone cyst
as a primary entity or a secondary
manifestation of a more serious underly
ing condition. The difficulty of differen
tiating an aneurysmal bone cyst from a
giant cell tumour of bone is
acknowledged and certain similarities to
unicameral bone cyst are noted, with
reference to some intriguing hypotheses
put forward in the literature.

Vingt-six cas de kystes osteoides anevrismaux ont ete passes en revue afin
d'en determiner la frequence, le traitement de premier choix et le pronostic.
Certaines observations font 6tat de
kystes osteoides an£vrismaux en tant
qu'entit6 primitive, ou en font mention
comme manifestation secondaire d'une
maladie sous-jacente plus s£rieuse. On
reconnait la difficult^ de diffgrencier le
kyste osteoide anevrismal de la tumeur
osseuse 6 cellules g6antes; on note egalement certaines similarit6s avec le kyste
osteoide uniloculaire, a I'origine de cer
taines hypotheses fascinantes avanc6es
dans la presse m6dicale

Aneurysmal bone cyst is a benign, local
ized lesion of bone formed of fibrous tis
sue honeycombed by vascular spaces. It
has a predilection for the shafts of long
bones and vertebrae, it bulges and erodes
the cortex but is limited peripherally by
a thin shell of reactive new bone.
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Although the lesion was encountered
earlier (when it was known variously as
aneurysmal giant cell tumour, benign
bone aneurysm or ossifying subperiosteal
hematoma), it was not until 1942 that it
was recognized as an entity by Jaffe and
Lichtenstein1 and as recently as 1950
became incorporated into the orthopedic
terminology with the publication of
separate papers by Jaffe2 and by
Lichtenstein.3
From the beginning its pathogenesis
has been an enigma. Thompson4 noted
that trauma was associated in 61% of
cases in the literature, but most5 believe
that injury simply calls attention to the
lesion. Most of the controversy centres
around whether it is a primary entity,
produced by a local alteration of vascu
lar hemodynamics,3,6 or whether it is a
secondary manifestation in a pre-existing
lesion, altered by hemorrhage or cystic
degeneration.2 Lichtenstein6 in 1953
denied that aneurysmal bone cyst was
secondary to hemorrhagic alteration of a
pre-existing lesion: in a 1957 report, he7
steadfastly maintained it was the product
of “ some persistent local alteration of
hemodynamics leading to increased
venous pressure and the subsequent
development (in ramifying bayou-like
fashion) of a dilated and engorged vas
cular bed within the transformed bone
area” . Jaffe,2 on the other hand, first
mentioned in 1950 that aneurysmal bone
cyst might be a “ hemorrhagic blow-out
of a pre-existing benign lesion” . This
hypothesis has continued through the
literature and Enneking8 in his recent
textbook accepts both hypotheses,
describing primary aneurysmal bone cyst
(an entity in itself) and secondary
aneurysmal bone cyst (a secondary vas
cular manifestation of some primary con
dition such as non-ossifying fibroma,9
giant cell tum our10 or even osteogenic
sarcoma10).
Whatever its pathogenesis, aneurysmal
bone cyst remains an entity. Dahlin11
referred to the Mayo Clinic experience of
134 cases; Schajowicz12 illustrated its
gross and microscopic appearance and
Enneking8 has described his experience
of 80 cases in a chapter of his book deal

ing with lesions of uncertain origin aris
ing in bone.
To reach some definitive conclusions
on the frequency, treatment and progno
sis of aneurysmal bone cyst, we in the
Department of Orthopedics at the Univer
sity of British Columbia have reviewed
the experience of these lesions entered in
the university’s bone tumour registry.
Materials and Methods

From 1956 to 1984 inclusive, 26 cases
of aneurysmal bone cyst were registered
in the University of British Columbia
Bone Tum our Registry. We have
reviewed the case records, radiologic
appearance, operative observations and
microscopic appearance of these cysts.
We also made some observations on its
pathogenesis, particularly the “ hemor
rhagic blow-out” hypothesis of Jaffe, in
relation to giant cell tumour and certain
malignant lesions, and on similarities to
unicameral bone cyst. During the same
29-year period, 62 cases of unicameral
bone cyst and 44 cases of giant cell
tumour of bone were documented in the
bone tumour registry.
Observations

Frequency
Age (Table I) ranged from 2 to 50 years
with 12 cases occurring in the first decade
and 22 of the 26 cases in the first three
decades of life. Dahlin’s much larger ser
ies of patients11 showed a similar age dis
tribution with 78% of patients being
younger than 20 years.
In our series 14 of the 26 patients were
m ale, which is unusual. D ahlin11

Table 1-Age Distribution of 26 Patients
With Aneurysmal Bone Cyst
No. of
patients
Age, yr
12
0-10
6
11-20
4
21-30
2
31-40
2
41-50
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reported the more usual female prepon
derance of almost 1.5 to 1.
Sites involved in this series are shown
in Table II. Notable is the wide distribu
tion with five cases involving the vertebral
column and seven the knee. The same
observations were made in the larger
Mayo Clinic series.11
Treatment
All patients were treated surgically.
Thirty-nine procedures were carried out
in the 26 patients — 1 procedure in 17
patients, 2 in 7, 3 in 1 and 5 in 1 other
patient. Biopsy was done as a separate
procedure in only eight patients.
The commonest operation was curet
tage and bone grafting (21 procedures).
Autogenous bone was used in 14,
homologous bank bone in 5 and Boplant*
in 2. Nine lesions were curetted but not
grafted. In four instances the procedure
could be described as total excision, in
three as subtotal resection. Radiotherapy
was added to surgical treatment in three
cases (in one patient with a sacral lesion,
in the patient operated upon five times
and in one who eventually underwent
amputation because of complications of
local treatment). Carbolic cautery accom
panied curettage in two early cases and
arterial embolization preceded surgery in
one recent case.
Outcome
One 50-year-old woman died. She had
a sacral aneurysmal bone cyst treated first
by decompression laminectomy followed
by radiotherapy and, within 2 months, an
attempt at local excision. Death occurred
6 months later in the presence of con
tinued cauda equina deficiency, local
infection and septicemia. A second

patient required hindquarter amputation
to control her disease in the proximal
femur and complications of its treatment
(local recurrence, dislocation of a custom
total hip replacement and draining infec
tion). She was alive and well 9.5 years
later.
Of the 24 remaining patients, 15 were
followed up for 2 years or more after
treatment, 5 for 6 months to 2 years and
4 for less than 6 months.
Of the 15 patients followed up for more
than 2 years, 3 were treated by intralesional curettage alone for cysts involving
the 12th dorsal vertebra, the 4th lumbar
vertebra and the femoral condyle. Treat
ment was successful in all, with no local
recurrence at 10 years, 7 years and 4 years
respectively. In three patients total exci
sion was possible (two proximal fibulas
and one small lesion in the medial femoral
condyle). All were free of their disease
2.75 years, 5.5 years and 2.08 years later,
respectively. One patient treated by sub
total resection of the distal fibula was
fully functional, with a small residual
cyst, at 6.5 years.
The remaining 8 patients in this group
of 15 were treated initially by curettage
and bone grafting. All results were con
sidered satisfactory even though one
patient required five surgical procedures
over 14 months, underwent radiotherapy
and was left with quiescent chronic
osteomyelitis. One patient required resec
tion arthrodesis of the knee as a second
and successful procedure, and another
required a second operation described as
subtotal resection of his olecranon lesion.
Two patients, although fully functional,
had radiologic evidence of cysts 2.5 years

T a b le I I — B o n e In v o lv e d in 2 6 C a s e s o f
A n e u ry s m a l B one C y s t
N o . of
B o n e in v o lv e d

p a t ie n t s

V e r te b r a e

5

D is t a l f e m u r

4

D is t a l tib ia

3

P r o x im a l tib ia

3

T a rs u s

3

P r o x im a l fib u la

2

D is t a l fib u la

1
1
1
1

P r o x im a l h u m e ru s
P r o x im a l u ln a
P r o x im a l f e m u r
C la v ic le

1

P e lv is

1

‘ Commercially prepared heterogenous corti
cal bone obtained from calves, subjected to
extraction by a detergent, a fat solvent and
prolonged washing, sterilization by betapropiolactone, freeze-drying and sterile pack
aging under vacuum for storage at room tem
perature.

FIG. 1—Case 1. Radiologic appearance of
left hip in May 1982, after two surgical proce
dures. Local recurrence of tumour is evident
in enlarged osteolytic greater trochanter.

after operation. It is interesting that of
these eight patients who had bone graft
ing, the initial procedure used autogenous
bone in six, and three grafts failed, neces
sitating a second procedure. One initial
bone-bank graft failed and in another the
source of the bone graft could not be
determined.

Discussion
The recent literature on aneurysmal
bone cyst has emphasized its possible
pathogenesis and its appearance secon
dary to other disease entities. The two
most discussed theories of origin overlap
in that they both involve vascular abnor
m ality or alte ra tio n o f vascular
hemodynamics, and both have a bearing
on discussions of whether aneurysmal
bone cyst is a primary lesion or a secon
dary manifestation of previously existing
disease.
Aneurysmal Bone Cyst
as a Primary Entity
Lichtenstein3 suggested that aneurys
mal bone cyst resulted from a local alter
ation of vascular hemodynamics, and his
theory suggested to some13 that aneurys
mal bone cyst was simply a secondary
manifestation of a pre-existing lesion,
altered by hemorrhage or cystic de
generation. D onaldson14 nevertheless
remained convinced that aneurysmal
bone cyst has “ distinct clinical patholog
ical and roentgenographic characteris
tics” and is not produced by secondary
pathologic changes in a primary lesion.
The opposing view is put forth by
Biesecker and colleagues9 who believe
that a primary lesion of bone initiates an
osseous arteriovenous malformation and
the altered hemodynamic forces produce
a secondary reactive lesion recognized as
aneurysmal bone cyst. They documented
this sequence of events in 21 of 66 cases;
all were benign and 2 followed curettage
of other lesions (unicameral bone cyst and
giant cell reparative granuloma).
Levy and colleagues10 favoured the
“ secondary” hypothesis even more
strongly, reporting 57 such lesions in 54
patients, including 12 osteogenic sarco
mas. Even so, both groups9’10 acknowl
edged that aneurysmal bone cyst may also
be present as a de novo lesion.
Clough and Price15 probably come
closer to reality by accepting aneurysmal
bone cyst as a definite recognizable des
tructive vascular lesion of bone, proba
bly not truly neoplastic but rather the
result of overgrowth of juxtaepiphyseal
tissue with vascular change. It is proba
bly better thought of as an aberration of
enchondral bone growth and remodelling
(as may be the case in unicameral bone
cyst16), but Clough and Price accepted
that this histologic appearance secondary
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to another lesion is theoretically possible.
This less-rigid view is accepted in
Enneking’s8 recent text.
Experience convinced us that there is
a hard core of bone lesions that fit
Lichtenstein’s3 original description and
cannot be called anything else but
aneurysmal bone cyst. We believe that
lesions that at first glance may appear to
be aneurysmal bone cysts but later prove
not to be so are really examples of misdi
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with a nail-plate — was carried out in October
1981. Again, aneurysmal bone cyst was the
diagnosis. However, his pain persisted, he
required crutches for walking and there
appeared to be radiologic progression of the
tumour. When 1 first saw him in May 1982,
the radiologic appearance was as shown in Fig.
1. It was consistent with, but not diagnostic
of, aneurysmal bone cyst. Review of the patho
logical material from his first two surgical
procedures (Fig. 2) revealed that radiologic and
surgical enthusiasm for this diagnosis proba
bly led the pathologist to misinterpret large
areas of hemorrhage as representing aneurys
mal bone cyst and not to recognize that the
intervening lesional tissue was not formed by
benign spindle cells with a few giant cells but
rather by malignant cells, a variety of chondroblasts that Unni and colleagues17 have
named clear cell chondrosarcoma. The patient
underwent a limb salvaging wide local excision
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Case 1.—A 27-year-old man complained of
pain, stiffness and weakness of his left hip in
1977. His symptoms increased, and on the basis
o f a radiologic diagnosis of aneurysmal bone
cyst the highly vascular lesion was curetted and
bone grafted in May 1980. One year later a
minor injury resulted in increasing pain of the
left hip. A second operation — curettage,
autogenous iliac bone grafting and fixation
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Fig. 3b

FIG. 2—Case 1. (a) Appearance of lesion under low power. Bands o f tissue containing
spindle cells and giant cells surrounding vascular spaces could be interpreted as aneurysmal bone
cyst (hematoxylin and eosin, original magnification x 30). (b) High-power appearance reveals
large round clear cells with pleomorphic nuclei and occasional mitotic figure properly inter
preted as clear cell chondrosarcoma (hematoxylin and eosin, original magnification x 500).

FIG. 3—Case 2. (a) Oblique and (b) lateral
radiographs of distal femoral tumour showing
large lytic lesion with permeative pattern, cor
tical destruction and (in lateral projection) large
anterior soft-tissue mass.
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with reconstruction by custom total hip
replacement and was alive and free of tumour
3 years later.

Aneurysmal Bone Cyst and
Giant Cell Tumour o f Bone
Our experience with aneurysmal bone
cyst and with giant cell tumour o f bone18
has led us to appreciate the difficulty in
distinguishing the two lesions in certain
instances and that any series o f each may

include examples of the other. Two o f our
cases illustrate this point.
Case 2.—A 20-year-old woman complained
of pain and swelling at her right knee for 4
months. Pain gradually increased in severity
so that she required crutches for walking.
Roentgenograms (Fig. 3) show the epiphyseal
and metaphyseal location of a lytic lesion, cor
tical destruction and a large soft-tissue mass
not characteristically outlined by a thin shell
of reactive bone. Following an open-biopsy

diagnosis of aneurysmal bone cyst she was
treated by subtotal resection and curettage with
autogenous iliac and tibial bone grafting (Fig.
4). Five months later (Fig. 5) there was clini
cal and radiologic evidence of continued
activity of the lesion with destruction of the
bone graft, requiring further treatm ent by
resection arthrodesis of the knee. Enneking8
commented on this aggressive behaviour as fol
lows: “ When poorly contained aggressive
expanding aneurysmal bone cysts are curetted
and packed with bone graft, recurrence may

FIG. 4—Case 2. Postoperative lateral film
with lesional tisue excised and resulting defect
replaced with autogenous bone graft.

Fig. 6b
FIG. 5—Case 2. Five months after opera
tion. Oblique roentgenogram shows aggressive
advance of tumour with destruction of bone
graft.

FIG. 6—Case 2. (a) Low-power appearance with folded membrane-like areas enclosing
loculated vascular spaces was initially interpreted as aneurysmal bone cyst (hematoxylin and
eosin, original magnification x 30). (b) Review o f available tissue following second resection
aknowledged similarities to giant cell tumour by adding qualification “ with giant cell reaction”
(hematoxylin and eosin, original magnification X 125).
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be quite explosive.” This patient remained well
and free from local recurrence 3.5 years after
the second surgical procedure.
The biopsy and residual tissue from the first
surgical procedure were described as aneurys
mal bone cyst on the basis of vascularity, loculated spaces and folded membrane-like areas
(Fig. 6) but a later review, together with tissue
from the second resection, acknowledged
similarities to giant cell tumour by adding the
qualification “ with giant cell reaction” .
Case 3.—In 1969, a 42-year-old woman
suffered a severe injury to her right ilium and
acetabulum, treated by open reduction. By
1978 she had a painful right hip with posttraumatic arthritis, and late in 1980 roentgeno
grams revealed a large, lytic, expansile lesion
of the right ischium (Fig. 7). After investiga
tion by computed tomography and radio
nuclide scanning, the lesion was biopsied. From
the radiologic appearance, the great vascular
ity described at operation and the histologic
features (Fig. 8), the lesion was diagnosed as
an aneurysmal bone cyst. Successful emboli
zation was carried out in preparation for defini
tive surgical treatment. In March 1981 the
lesion was treated by subtotal excision, curet
tage and left iliac bone grafting. Rapid ossifi
cation occurred obliterating the lesion which
remained healed 4 years later (Fig. 9).
However, examination of the excised specimen
in this patient led to a change in diagnosis to
giant cell tumour of bone because there were
large cellular masses with numerous giant cells,
and the aneurysmal vascular spaces were con
sidered secondary (Fig. 10).

It is acknowledged that in these two
cases it may not be possible to diagnose
the aneurysmal bone cyst definitively as
a primary or secondary manifestation. In
the informed opinion of the pathologist,
the first was a primary aneurysmal bone
cyst and the second a giant cell tumour
with secondary aneurysmal appearances.
Even so, the initial radiologic appearance
and the subsequent behaviour of the
tum our led to labelling the first case as
giant cell tumour, and the prompt
response to treatment in the second case
(case 3) seemed to favour a diagnosis of
primary aneurysmal bone cyst rather than
giant cell tumour.

a hematogenous manifestation, the other
lymphogenous. Radiologic follow-up of
residual cysts of both types also suggests
such a relationship.
In regard to this similarity, Edling20
proposed an intriguing hypothesis,
describing aneurysm al bone cyst,
unicameral bone cyst and giant cell
tumour as dysfibroplastic processes, the
result of developmental errors at the
epiphyseal plate, the type of lesion
produced by this dysfibroplasia depend
ing on the site in bone and the blood sup
ply. Hence, the disturbance occurring

centrally in the diaphysis produces
unicameral bone cyst, eccentrically or
subperiosteally produces aneurysmal
bone cyst, and in the epiphysis itself
produces a giant cell tumour.
Conclusions
Based on the observations made in the
analysis of 26 examples of aneurysmal
bone cyst, a number of relevant com
ments can be made.
No specific statement can be made as
to the role of radiotherapy (three cases)

FIG. 7—Case 3. Initial appearance of right hip region showing severe post-traumatic arthritis
of right hip and expanded lytic lesion of right ischium.

Aneurysmal Bone Cyst and Unicameral
Bone Cyst
Without wishing to confuse the issue,
we have been impressed, as have
o th ers,19,20 by the striking similarity
between unicameral bone cyst and persist
ing aneurysmal bone cysts, particularly
those persisting after treatment by curet
tage and bone grafting. No longer is the
lesion a “ bloody sponge” but rather there
is a dearth of soft tissue, with the ex
pected incomplete bone septa resulting
from the ineffective bone graft and the
presence only of a heavily stained serous
fluid rather than gross blood. One
wonders whether these two lesions might
have similar pathogeneses, the one being
114

FIG. 8—Case 3. Histologic features of spindle cell stroma enclosing vascular areas, together
with radiologic and gross appearances at operation, led to diagnosis of aneurysmal bone cyst
(hematoxylin and eosin, original magnification x 30).
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and arterial embolization (one case) in the
definitive or adjunctive treatment of
aneurysmal bone cyst.
The cyst presents a serious problem as
evidenced by the one death and the one
hindquarter amputation.
Biopsy as a preliminary diagnostic
procedure was thought necessary in 8 of
26 cases. Rush or frozen section at the
time of surgery was not used consistently.
The surgeon usually relied for operative
management on the radiologic appear
ance strongly suggesting a diagnosis of
aneurysmal bone cyst and the gross

appearance at operation being consistent
with that diagnosis.
Intralesional excision (curettage), with
or without bone grafting, can cure the
patient with one operation. (This was true
for 6 of 11 patients or 8 of 11 in our ser
ies if the 2 fully functional patients with
residual disease are included. A second
curettage with bone grafting cured 2 more
patients — that is, 10 of 11 — when fol
lowed up for more than 2 years. These
results are comparable to those of
Enneking8 who quoted a 70% success
rate with a first operation and recom-

mended a repeat procedure for failures.)
Wide local excision, when applicable,
is certain to cure the patient of aneurys
mal bone cyst, as it did in three of our
patients in which it was a primary proce
dure and two patients in which it was a
secondary procedure.
Aneurysmal bone cyst is an entity in
itself and not simply a hemorrhagic or
degenerative product of some underlying
lesion. Superficial exam ination o f
histopathologic material may lead to mis
diagnosis of the tissue as certain malig
nant tumours and other benign lesions.
An awareness of the ability of a number
of pathologic entities to mimic the
appearance o f aneurysmal bone cyst is
essential so that diligent examination of
general tissue samplings will ensure that
an accurate histopathological diagnosis is
made.
The gross appearance of aneurysmal
bone cyst at second operations and in
radiologic follow-up of residual disease
suggests similarities to unicameral bone
cyst and the possibility of a common
pathogenetic mechanism. Others have
made this observation16 and Edling20 has
proposed an intriguing explanation of this
possible relationship.
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Tetracycline Instillation for
Recurrent Cystic Thyroid Nodules
first successful treatment of recurrent
pure thyroid cysts with tetracycline instil
lation. Since then, there has been one
other report of one patient by Ryan and
associates.7
We describe our experience with 10
patients, 5 with pure cystic and 5 with
mixed cystic-solid thyroid nodules, who
were treated with tetracycline instillation
when repeated aspirations failed to
resolve the recurrent cysts.

Ten patients, 5 with recurrent pure cys
tic and 5 with recurrent mixed cysticsolid thyroid nodules, were studied.
When repeated needle aspirations failed
to decrease reaccumulation of fluid,
tetracycline was injected directly into the
cysts. As a result, all the pure cysts
resolved completely, and four of the five
mixed cystic-solid nodules diminished in
size and fluid did not reaccumulate.
Follow-up ranged from 12 to 20 months
(mean 15 months). The procedure was
generally well tolerated. It is concluded
that instillation of tetracycline into both
recurrent pure cystic and mixed cysticsolid thyroid lesions is a simple, safe and
effective treatment.

Quand la ponction a I'aiguille n'a pu
reduire ('accumulation de liquide, de la
tetracycline a ete injectee directement
dans le kyste. On a alors constate une
resorption complete des kystes purs, et
quatre des cinq nodules mixtes ont diminu6 de volume, ne montrant plus d'accumulation de liquide. Les examens de sur
veillance se sont repartis sur de 12 h 20
mois (15 mois en moyenne). Generalement, ('intervention a ete bien toleree.
On conclut que I'instillation de tetracy
cline dans les cas de nodules thyroidiens
kystiques recidivants purs ou mixtes, est
une technique de traitement simple, sure
et efficace.

Cette etude porte sur 10 patients; 5 porteurs de nodules kystiques thyroidiens
recidivants purs, 5 de nodules mixtes
recidivants, a la fois solides et kystiques.

Single, hypofunctioning thyroid nodules
are common and approximately 15% are
cystic.1 Although most are effectively
treated by a single aspiration,2 about
30% will recur.3 Even when careful aspi
ration cytology has eliminated the likeli
hood of thyroid cancer, the patient is
often concerned because of local discom
fort, dysphagia or cosmetic implications.
Levo-thyroxine therapy does not gener
ally prevent cystic fluid recurrence and
surgical removal has its risks.
Prompted by successful treatment of
recurrent pleural effusions with
intrapleural instillation of tetracycline,4
Georgitis and associates5 6 reported the
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Patients

The 10 patients had single cold thyroid
nodules on iodine 131 scanning; one also
had a small goitre. All were clinically and
chemically euthyroid. All had undergone
fine-needle aspiration of their nodules for
cytologic examination, and to determine
whether the nodule was a pure cyst or a
cystic-solid lesion. Complete regression
of the nodule after needle aspiration, as
judged by palpation, was considered to
indicate a pure cyst and persistence of a
palpable nodule a mixed cystic-solid
lesion. On this basis, two separate
categories were established: pure cyst (five
cases) and mixed cystic-solid (five cases).
One patient with a pure cyst received
sodium L-thyroxine until the tetracycline
instilled. All patients with mixed lesions
received sodium L-thyroxine therapy
throughout the study. Each patient had
complete evacuation of the cystic fluid
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from two to six times before instillation
of tetracycline. None of the aspirates were
grossly hemorrhagic.
Method

With the patient supine on an examin
ing table, the neck was extended to a 30°
angle and the thyroid nodule located by
palpation. No local anesthetic was used
and aspiration was performed using a
10-mL syringe in a Cameco holder (Pre
cision Dynamics Corp., Burbank, Calif.)
with a 21- or 23-gauge needle. The fluid
was removed completely, and then 1 to
2 mL of the aspirate was reinjected to
maintain cyst distension. With the needle
in place, the syringe was removed and
replaced by one containing 100 mg of
tetracycline hydrochloride in 1 mL of
0.9% saline. This solution was instilled
into the cyst cavity and left for 2 to 3
minutes. All fluid was then aspirated, the
needle removed and pressure applied for
several minutes with a sterile gauze pad.
The aspirate was inspected and sent for
cytologic examination. After the proce
dure, patients were re-examined for
residual thyroid nodules. They were asked
to report immediately any adverse effects
from the procedure and were given a
follow-up appointment.
Results

A summary of patient data is set out
in Table I. Most patients tolerated the
procedure well. One woman had intense
local pain which resulted from extrava
sation of the tetracycline, but it subsided
within a few minutes. For several hours
she had a dull ache, which was eased by
warm compresses.

All patients with pure cysts had com
plete resolution of their cysts following
tetracycline instillation. In the second
category, four of the five patients had
reduction in size of their mixed cysticsolid nodules. Repeat aspiration in these
patients after 12 to 20 months showed no
recurrent fluid accumulation, except for
the one failure.
Discussion

In the past decade, fine-needle aspira
tion of thyroid nodules has become an
important diagnostic tool.8 It is the most
cost-effective way of determining whether
a nodule is solid or cystic, benign or
malignant. Suppressive therapy with l thyroxine did not prevent recurrences in
any of our patients, and repeated needle
aspirations did not lead to a lessening of
fluid accumulation. Having done a num
ber of needle aspirations, all of which
failed to show malignant cells, we under
took to instil tetracycline as a sclerosing
agent. Both Treece and colleagues6 and
Ryan’s group7 reported that this tech
nique is effective in patients with recur
rent pure cystic thyroid nodules.
In Treece’s series of purely cystic
thyroid nodules, tetracycline instillation
led to complete resolution in seven and
a partial response in two of their nine
cases. In Ryan’s report of a single patient,
it is unclear whether the lesion was a pure
cyst or mixed cystic-solid nodule.
However, there was a decrease in nodule
size from 2 cm to less than 0.5 cm with
treatment.
Crile and Hawk8 first described the
use of sodium tetradecyl sulfate as a
sclerosing agent to treat thyroid cysts.
Sykes9 used this agent in 75 patients, but

the results were given for only 7 of them.
O f these seven, the cysts apparently
resolved in six, although the exact follow
up was not reported. In the seventh
patient, the cyst recurred within 4 weeks,
so the patient underwent operation. We
preferred tetracycline because of its avail
ability and lesser toxicity.10
During a 12- to 18-month follow-up
period, none of the pure cysts in our
patients have recurred since tetracycline
instillation, even though there were
numerous recurrences before this treat
ment (Table I, Fig. 1).
Four of our five patients with mixed
cystic-solid thyroid nodules had good
shrinkage of the nodule after tetracycline
was given. Of even greater importance is
that repeated aspirations up to 20 months
later failed to show any reaccumulation
o f fluid. Our one failure was probably
due to extravasation of the tetracycline
resulting in inadequate dosage.
Conclusions

Tetracycline instillation appears to be
a simple, safe and effective treatment for
recurrent cystic thyroid nodules, of both
the pure and mixed type. Careful cyto
logic examination of the fluid aspirate
and solid component, if present, should
always be done first to rule out the
presence of a malignant lesion. If tests
indicate a benign lesion after at least two
fine-needle aspirations, tetracycline instil
lation is a useful approach.
We thank Dr. Arthur Rizzo for doing the
tetracycline instillation in case 5 and Lyne
Maurice for valuable technical assistance.
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White Clot Syndrome:
a Rare Complication of Heparin Therapy
A case of white clot syndrome in a
6 1 -year-old man is reported. The patient
suffered simultaneous aortic and vena
caval thromboses while receiving heparin
therapy for pulmonary embolism. Throm
bocytopenia was noted. Thrombectomies
successfully relieved the thromboses.
Apart from heparin, no factors predispos
ing to aortic thrombosis were evident,
and the patient remained well in the suc
ceeding 7 years since. A brief review of the
literature on the white clot syndrome
suggests that the entity remains poorly
defined, regarding both the mechanism
of heparin-induced thrombocytopenia and
its relation to thrombosis.

On signale un cas de syndrome thrombotique leucocytaire chez un homme de
61 ans. Ce patient a souffert de throm
boses simultanees de I’aorte et de la
veine cave alors qu'il recevait de I'heparine pour une embolie pulmonaire. Une
thrombocytopenie a ete observee. Les
thromboses ont ete gueries par thrombectomie. A part I'heparine, aucun facteur predisposant a une thrombose aortique n'a ete notee, et le patient demeure
en bonne sante 7 ans apres cet incident.
Une breve revue de la litterature sur ce
sujet indique que cette entite reste mal
definie, aussi bien en ce qui concerne le
mecanisme par lequel I'heparine provoque une thrombocytopenie qu'en son
rapport avec la thrombose.

The term white clot syndrome describes
spontaneous major arterial thrombosis in
a patient receiving heparin therapy.1 It
may involve an immune reaction to hepa
rin, resulting in excessive platelet aggre
gation and thrombosis.2 Regardless of
the etiology and pathogenesis, it is very
rare, having been recognized only once
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during the past 20 years on the vascular
surgical service at the Health Sciences
Centre, Winnipeg. A major international
symposium on heparin in 1974 made no
mention o f heparin-induced throm
bocytopenia and throm bosis.3 We
describe a case and discuss the related
literature.

Case Report
A 61-year-old white man sustained a frac
ture of the lateral condyle of the right tibia,
with ligamentous injury. He was admitted to
a rural hospital where open reduction was per
formed and a cylinder cast applied. He was dis
charged home 39 days after admission, but was
readmitted a month later because of shortness
of breath and right-sided chest pain. Because
perfusion to the right upper lobe appeared
decreased on the lung scan, continuous,
intravenously administered heparin was given
for 10 days. Shortly after heparin was discon
tinued the right leg began to swell. Venogra
phy showed absence of contrast in the deep
venous system of that limb. He was transferred
to the Health Sciences Centre for further treat
ment. There were no allergies, bleeding dis
orders or thromboembolic diseases in his own
history, family history or a review of systems.
The patient was in no apparent distress but
had a grossly swollen right lower limb from
groin to foot. The dorsum of the foot was
warm, erythematous and mildly tender. There
was moderate tenderness on the medial aspect
of the right thigh, but none in the calf. Hepa
rin therapy was resumed with an intravenous
bolus of 10 000 units, followed by continuous
intravenous infusion at 1000 units/h.
For the next 5 days, heparin therapy was con
tinued at a rate ranging from 500 to 1500
units/h, depending upon Lee-White clotting
times that were kept between 30 and 60
minutes. There was then evidence of lower limb
arterial ischemia, with pain, pallor and cold
ness in the right foot, weakened femoral pulses,
absent distal pulses and a loud abdominal
bruit. Transaxillary aortography demonstrated
a localized filling defect at the bifurcation of
the abdominal aorta (Fig. 1). At this time, the
platelet count was 50.0 x 109/L , the
hemoglobin was 113 g/L and the clotting time
30 minutes.
Operative exploration carried out the next
day confirmed the presence of fresh thrombus
in an otherwise normal distal abdominal aorta
(Fig. 2). Mobile thrombus was identified in the
inferior vena cava also. The latter was ligated
distal to the renal veins, and thrombectomies

FIG. 1—Pear-shaped radiolucency is seen at
bifurcation of abdominal aorta. Apart from
tortuosity, lower abdominal aorta and iliac
arteries appear normal.

FIG. 2—Upper limit of pale thrombotic
material (white clot) can be seen through ver
tical aortotomy just above bifurcation.
Grossly, aortic wall is normal.
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of both vena cava and aorta were done through
vertical incisions (Fig. 3).
Postoperatively, arterial perfusion to both
lower limbs was excellent, despite minor skin
necrosis on the right toes, presumably the result
of peripheral embolization. Heparin therapy
was resumed on postoperative day 1. Two days
later the platelet count was 94.0 x 109/L .
Anticoagulant therapy was continued orally
starting on day 11. The patient was returned
to the rural hospital in good condition 8 days
later. This man has had no further peripheral
vascular disease and was in good health 7 years
after operation.

In 1962, Gollub and Ulin4 reported an
immediate drop in platelet count of up to
33% in healthy persons associated with
the administration of heparin. This could
be an aggregation phenomenon, but it is
not necessarily associated with throm
boembolic disease. The white clot syn
drome, on the other hand, is said to occur
after either several days of heparin ther
apy or repeated therapy, suggesting an
immune reaction, perhaps mediated by an

Fig. 3a

Fig. 3b

Fig. 3c

Fig. 3d

FIG. 3—(a) Pale thrombus (white clot) removed from aorta, (b) Pale thrombus with
propagated red clot removed from inferior vena cava, (c) Photomicrograph of aortic thrombus,
suggesting platelet aggregation (hematoxylin and eosin, original magnification x 100).
(d) Photomicrograph of fibrin clot in inferior vena cava (hematoxylin and eosin, original mag
nification x 64).

immunoglobulin G fraction forming a
complex between heparin, IgG and plate
lets.511 On the basis of in-vitro tests of
heparin-induced platelet aggregation,
clinical reports of the white clot
syndrome1,2 have included patients with
venous thromboembolic disease. Whether
these patients should be included is
debatable, since platelet aggregation does
not necessarily imply throm bosis.
Moreover, since venous thromboembolic
disease is quite common, the findings may
be disease-related rather than heparinrelated in this circumstance. If patients
with only venous thrombosis are exclu
ded the white clot syndrome becomes a
rarer phenomenon with perhaps more
clinical validity.
A discussion of the white clot syndrome
raises two important clinical questions:
First, should heparin be stopped in the
thrombocytopenic patient? On the basis
of their experience, Kapsch and Silver2
believe it is dangerous to continue hepa
rin therapy in the presence of throm
bocytopenia. In contrast, King and
Kelton11 have observed a return to nor
mal platelet count with continued hepa
rin administration. Second, do heparin
requirements increase in the white clot
syndrome (as monitored by partial throm
boplastin time)? Theoretically, heparin
would be bound in the platelet thrombus,
and thus be rendered inactive. The oppo
site has, in fact, been observed.1 There
may be several reasons for variations in
heparin anticoagulant activity, given the
complexity both of the heparin molecule
and of its interactions with the coagula
tion mechanisms in the blood stream.
Further monitoring of patients receiving
heparin will be necessary to answer these
questions.
The most striking feature of our case
was the pale aortic thrombus, observed
while the patient was fully heparinized
and thrombocytopenic and in the absence
of any obvious arteriosclerotic disease.
Kapsch and Silver2 reported 7 patients
who underwent distal aortic thromboembolectomies, among 31 with throm
bocytopenia receiving heparin therapy.
However, they did not indicate whether
these phenomena were recurrent, embolic
or associated with arteriosclerosis. If the
arterial occlusion is recurrent or embolic,
or if it occurs in the presence of arterios
clerosis, then the circumstantial evidence
incriminating heparin is less acceptable.
Weismann and Tobin12 reported on 10
patients who suffered arterial throm
boembolism while taking heparin; in 4 of
them the original disease was venous,
which perhaps implies a relative absence
of underlying arteriosclerosis. Unfor
tunately, they did not perform platelet
counts, so that any inference of a plateletheparin interaction in their patients is
impossible. Towne and colleagues1
described acute arterial occlusions in four
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patients out of seven who received hepa
rin for a variety of reasons and subse
quently suffered thromboembolic disease.
In only one patient did arterial occlusion
probably arise in the absence o f underly
ing arterial disease. Thus, our case seems
to be one o f the few bona fide examples
o f this syndrome, if in fact it exists. Con
tinued clinical diligence when using hepa
rin is necessary to distinguish the true
nature o f the white clot syndrome.
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Chronic Ileal Obstruction in Adults Due
to Peri-ileal Vitelline Vascular Remnants
Two young adults had distal ileal
obstruction at sites where a fold of
mesentery extended from its posterior
leaf to the antimesenteric border of the
bowel. No Meckel's diverticulum or
mesoumbilical band was present in either
case. Clinical, gross and microscopic
findings suggested that the mesenteric
fold represented a remnant of vitelline
vessel that persisted in the peri-ileal por
tion of its course. Chronic ileal obstruc
tion was apparently due to disordered
peristalsis caused by the fold tethering
the adjoining posterior bowel wall. In one
patient, a chronic ulcer at the site of
obstruction was interpreted as being an
additional complication of the congenital
lesion.
Deux jeunes adultes ont presente une
obstruction de la partie distale de I'ileon
en un point 0C1 un pli du mesentfere
s'etendait a partir de son feuillet posterieur jusqu'au bord externe de I'intestin.
On n'a constate dans les deux cas ni
diverticule de Meckel, ni bandelette
meso-ombilicale. Le tableau clinique, de
meme que les r6sultats des examens
macro et microscopiques indiquent que
ce pli mdsenterique reprdsentait un ves
tige de vaisseau viteliin dont la partie
p£ri-il6ale avait persiste. L'obstruction
ileale chronique etait apparemment due a
un probl&me du pdristaltisme cause par
I'attachement de ce pli h la paroi intestinale posterieure adjacente. Chez un de
ces patients, un ulc&re chronique au
point d'obstruction a 6t§ interprets
comme etant une complication suppISmentaire de la ISsion congenitale.

Obstruction of the distal ileum is a com
mon complication of a Meckel’s divertic
ulum, a persistent omphalomesenteric
duct or a persistent vitelline vessel that
joins the ileum to the umbilicus.1'4 We
describe two adults in whom a vitelline
vascular remnant, persisting only in its
peri-ileal segment, appeared to be the
cause of recurrent obstruction that
required surgical treatment. To our
knowledge only one similar case, in an
8-month-old infant, has been described
previously.5

Case Reports
Case 1
A 20-year-old man complained o f acute,
crampy, central abdominal pain, similar to that
o f previous episodes occurring over several
years. He had had an umbilical hernia repaired
in Germany when he was 8 years old, but no
record was available. His mother had had
bowel malrotation repaired in her infancy.
Abdominal films showed dilated loops of
sm all bowel in terp re ted as ileus. A t
laparotomy, the site of obstruction was found
60 cm proximal to the ileocecal valve. There,
a tongue of mesentery containing a central
blood vessel extended from the posterior leaf
o f the mesentery to the antimesenteric border
o f the ileum (Fig. la). Proximally, the ileum

measured 4 cm in diameter and distally, 2 cm.
A 10-cm segment of ileum was resected and an
end-to-end anastomosis done. Recovery was
uncomplicated.

Case 2
A 30-year-old woman presented with acute,
crampy, central abdominal pain, similar to
attacks that had occurred for several years.
Abdominal films showed distended loops of
small bowel, consistent with a localized ileus
or partial obstruction. A barium enema
relieved the pain temporarily, so a resolved vol
vulus of the ileum was suspected. At operation,
a dilated ileum narrowed abruptly 35 cm prox
imal to the ileocecal valve, where a fold of
mesenteric fat encroached on the posterior ileal
serosa to reach its antimesenteric border. A
26-cm segment of ileum was resected with endto-end anastomosis. The bowel circumference
proximally was 10 cm and distally, 5 cm.
The woman had a pectus excavatum and
broad, short thumbs but did not have a recog
nizable syndrome of congenital malformation.

Pathological Findings
Grossly, the two resected segments of
ileum were similar. A fold of fat covered
a segment of the serosal surface, extend
ing from the posterior leaf of the mesen
tery to the antimesenteric border of the
bowel (Fig. la). Opened lengthwise, the
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FIG. 1—Case 1. (a) Gross view o f resected ileum. Fold of mesenteric fat crossing posterior
serosal surface demarcates distended proximal bowel on left from ileum of normal diameter
on right, (b) Microscopic view shows hypertrophied muscularis propria in proximal bowel (arrow
heads), above level of tethering mesenteric fold attached to serosa (arrow), compared with nor
mal muscle thickness below this level (hematoxylin and eosin, original magnification x 7).
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bowel from case 2 showed a mucosal ulcer
(2 cm in diameter) on the anterior wall of
the ileum opposite the mesenteric fold
posteriorly (Fig. 2a). Microscopically, the
mesenteric extensions consisted of mature
fat, with a centrally placed vein in case
1 (Fig. lb).
In each case, the proximal bowel had
hypertrophied muscularis propria (Fig.
lb) but no deficiency in myenteric or sub
mucosal plexus ganglion cells. The ulcer
in case 2 (Fig. 2b) had a floor of granu
lation tissue covering scar tissue in the
submucosa that did not extend into the
underlying muscle coats. A small focus
of pyloric glandular metaplasia was
present at the edge of the ulcer, but no
heterotopic epithelium was evident in
either case. Hypertrophied nerves were
prominent in Meissner’s plexus deep to
the ulcer in case 2 (Fig. 2b).
Discussion
While the yolk sac supplies nutrition to
the developing embryo, a network of
blood vessels connect its broad base in the
body stalk to the primitive paired dorsal
aortas and cardinal veins.1-3'5 As the
umbilical cord develops, vitelline vessels
are simplified into a pair of arteries and
a pair of veins that accompany the vitel
line (omphalomesenteric) duct. The lat
ter regresses by the 5th week and the ves
sels involute later.6-7 The right artery and
left vein persist longer than the con
tralateral vessels. The right (anterior)
vitelline artery contributes to the proximal
superior mesenteric artery and the left
(posterior) vitelline vein forms part of the
portal venous system.1-6 Vitelline vessels
distal to the ileum normally regress before
the 8th week of gestation but may persist
as vascular bands connecting to the
umbilicus.4-6-7 Bands containing vascular
remnants may pass either anterior or
posterior to the ileum to become continu
ous w ith the superior m esenteric

artery.4-7 Kleinhaus and colleagues7
observed that a persistent vitelline vascu
lar remnant may be distinguished from a
persistent vitelline duct because the lat
ter ends at its attachm ent to the
antimesenteric border of the ileum but the
former continues across the serosa of the
ileum on one or other side to enter the
mesentery.
Mesodiverticular vessels are obvious in
newborn infants because the mesentery
and mesodiverticulum have not become
adipose at this age (Fig. 3). Some
Meckel’s diverticula are so short at birth
(Fig. 3) that they could disappear during
postnatal growth or by incorporation into
a distended segment of ileum. We liken
the mesenteric folds in our two patients
to a mesodiverticulum of an incorporated
or “ flat” diverticulum.
Seagram and colleagues5 described an
infant with ileum dilated proximal to a
“ bound-down” mesodiverticular band
that ran from the mesentery to the apex
of the cystically dilated bowel, in which
heterotopic epithelia were identified
microscopically.4 Their Fig. 2 depicted
an obstructive lesion of the ileum that
resembled the one we describe (Figs, la
and 2a) except the band crossed the

FIG. 3—Short, wide Meckel’s diverticulum
(asterisk) is seen on antimesenteric border of
ileum of newborn infant. Vascular supply of
diverticulum is from vessel running in free edge
of mesodiverticulum (arrowheads). Islands of
adipose tissue are visible in attached mesentery
but have not yet appeared in mesodiverticulum.

anterior ileum rather than the posterior
aspect as in our two cases.
No-one appears to have reported ileal
obstruction in adults occurring at the
“ apex o f the bowel” (midpoint of the
primitive midgut) in the absence of a
Meckel’s diverticulum or a mesoumbilical band. This site is well known for intus
susception in infancy, presumably due to
reverse or disordered peristalsis. We could
find no evidence o f segmental aganglionosis at the site of ileal narrowing in our
cases and believe that the hypertrophied
submucosal nerves in case 2 resulted from
the chronic ulcer, akin to the neural
hypertrophy seen in Crohn’s disease.
Both patients presented with cramping
abdominal pain that had recurred over a
number of years, and the degree of hyper
trophy o f ileal muscle wall proximal to
the mesenteric fold (Fig. lb) in each case
correlates well with this history. Disor
dered peristalsis, owing to part of the
bowel wall being tethered to the mesen
tery by the vascular remnant, may explain
long-standing functional obstruction in
the two cases. Because of the hyper
trophy, we do not believe that simple exci
sion of the mesenteric fold would have
treated the obstruction adequately in
either patient.
We also believe that the ulcer present
in case 2 (Fig. 2) was the result and not
the cause of obstruction because the mus
cularis propria deep to it showed no scar
ring and no heterotopic gastric mucosa
was evident. Therefore, we suggest that
a peri-ileal vitelline vascular remnant
could be a cause of so-called solitary ulcer
in the ileum. We recommend that sur
geons and pathologists examining such an
ulcer look for evidence of a congenital
vascular remnant at the same level, par
ticularly in young adults. Such evidence
could easily be overlooked if the ulcer was
associated with marked scarring and local
peritonitis.
Photographs were by Lois Lines. We thank
Dr. M.D. Silver for a critical review of the
manuscript.
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FIG. 2—Case 2. (a) Gross view of ileal segment shows ulcer (arrow) at junction of dilated
proximal (left) and normal-diameter bowel, (b) Ulcer has floor of granulation tissue (above)
and scar that extends to true muscle coat (below); hypertrophied nerves of submucosal plexus
are prominent (arrowheads, central one overlying lymphoid patch) but ganglion cells are present
in normal numbers (hematoxylin and eosin, original magnification x 82).
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B. fragilis, the most prevalent anaerobe in intra-abdominal infections,
was responsible for up to 60% of mortalities in patients with B. fragilis
bacteremia when inappropriate treatment was given1. And recent
North American studies show23 B. fragilis is becoming resistant to
newer antibiotics such as clindamycin or cefoxitin.
A verag e re s is tan c e
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No proven resistance to metronidazole
Flagyl 500 Inj. (metronidazole) remains unaffected by B. fragilis
resistance23. Flagyl 500 Inj. is active, regardless of bacterial concentra
tion or growth stage4-5. It has an excellent record of safety, and it is
compatible with most antibiotics6 used for aerobic coverage in intra
abdominal and pelvic surgery.
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a selective anaerobicide
Therapeutic Classification

Antibacterial-Antiprotozoal
Actions
Flagyl (metronidazole) is bactericidal against
anaerobic bacteria, it exerts trichomonacidal
activity and is also active against Giardia
lamblia and Entamoeba histolytica. Its exact
mechanism of action has not been entirely
determined as yet. It has been proposed that
an intermediate in the reduction of metronidazole,
produced only in anaerobic bacteria and
protozoa is bound to deoxyribonucleic acid
and proteins, and inhibits subsequent nucleic
acid synthesis.

INDICATIONS AND CLINICAL USES
Bacterial infections
The treatment of serious anaerobic abdominal
infections due to susceptible anaerobic bacteria,
such as Bacteroides fragilis (and other species
of Bacteroides), Clostridium, Fusobacterium,
Peptococcus, and Peptostreptococcus species.
Culture and susceptibility studies should be
performed to determine the causative organisms
and their susceptibility to metronidazole.
Based on clinical judgment and anticipated
bacteriological findings, therapy may be
started while awaiting the results of these
tests.
In mixed aerobic and anaerobic infections,
consideration should be given to the con
comitant administration of an antibiotic
appropriate for the treatment of the aerobic
component of the infection. (See Warnings).
Flagyl (metronidazole) has also been used in
the treatment of a small number of cases of
brain or lung infections (some with abscesses)
caused by anaerobic bacteria.

CONTRAINDICATIONS
Flagyl (metronidazole) is contraindicated in
patients with a prior history of hypersensitivity
to metronidazole or other nitroimidazole
derivatives.
Flagyl should not be administered to patients
with active neurological disorders or a history
of blood dyscrasia, hypothyroidism and
hypoadrenalism.

Warnings
Flagyl (metronidazole) has no direct activity
against aerobic or facultative anaerobic bacteria.
In patients with mixed aerobic-anaerobic
infections appropriate concomitant antibiotics
active against the aerobic component should
be considered.
Known or previously unrecognized moniliasis
may present more prominent symptoms after
treatment with Flagyl.
Studies in rats and mice have provided some
evidence that metronidazole may cause tumors
in these species when administered orally for
a long period at high doses. The relevance of
these findings in humans is not known.
Severe neurological disturbances (i.e. convulsive
seizures and peripheral neuropathy) have
been reported in patients treated with Flagyl
(administered orally or intravenously). These
have been observed very infrequently.

Precautions
Patients taking Flagyl (metronidazole) should
be warned against consuming alcohol, because
of a possible disulfiram-like reaction. For the
same reason, patients receiving Flagyl should
not be administered disulfiram concomitantly.
Transient eosinophilia and leukopenia have
been observed during treatment with Flagyl.
Regular total and differential leukocyte counts
are advised if administration for more than

10 days or a second course of therapy is
considered to be necessary.
Metronidazole crosses the placental barrier.
Although Flagyl has been given to pregnant
women without apparent complication, it is
advisable that oral administration be avoided
in pregnant patients and Flagyl be withheld
during the first trimester of pregnancy. In
serious anaerobic infections, if the adminis
tration of Flagyl to pregnant patients is
considered to be necessary, its use requires
that the potential benefits be weighed against
the possible risks to the fetus.
Metronidazole is secreted in breast milk in con
centrations similar to those found in plasma.
Intravenous or oral administration of Flagyl
should be avoided in the nursing mother.
Metronidazole has been reported to potentiate
the anticoagulant effect of warfarin resulting
in a prolongation of prothrombin time. This
possible drug interaction should be con
sidered when Flagyl is prescribed for patients
on this type of anticoagulant therapy.
Clinical experience in children is very limited.
The monitoring of this group of patients is
particularly important. The safety and effec
tiveness of intravenous Flagyl in children has
not been established.
A rare case of reversible but profound
neurological deterioration has been reported
following a single oral dose of Flagyl; it is
therefore advisable that a patient taking
Flagyl for the first time not be left unattended
for a period of two hours. The appearance of
abnormal neurologic signs demands prompt
discontinuation of Flagyl therapy and, when
severe, immediate medical attention. Gastric
lavage may be considered if no more than
two or three hours have elapsed since
administration of the drug.
Treatment with Flagyl should be discontinued
if ataxia or any other symptom of CNS
involvement occurs.
Patients with severe hepatic disease metabolize
metronidazole slowly with resultant
accumulation of metronidazole and its
metabolites in the plasma. Accordingly, for
such patients, doses of Flagyl below those
usually recommended should be
administered and with caution. The
determination of serum glutamic oxaloacetic
transaminase (SGOT) by the Technicon SMA
12/60 system in blood samples from patients
receiving Flagyl may give abnormally low
values. This abnormality is artifactual and
caused by the absorption of metronidazole at
the wavelength where the enzymatic reaction
is monitored spectrophotometrically.

Adverse reactions
Gastrointestinal: diarrhea, nausea, vomiting,
anorexia, epigastric distress, dyspepsia,
constipation.
Mouth: furred tongue, dry mouth, unpleasant
metallic taste.
Hematopoietic: transient eosinophilia or
leukopenia.
Dermatologic: rash and pruritus.
Cardiovascular: palpitation and chest pain.
Central Nervous System: convulsive
seizures, peripheral neuropathy, transient
ataxia, dizziness, drowsiness, confusion,
insomnia and headache.
Peripheral neuropathies have been reported
in a few patients on moderately high to
high-dose prolonged oral treatment with
metronidazole. It would appear that the
occurrence is not directly related to the daily
dosage and that an important predisposing
factor is the continuation of oral and/or I.V.
medication for several weeks or months.

Profound neurological deterioration, within 2
hours after Flagyl administration has been
reported. The occurrence is not directly
related to the dosage level.
Metabolic: An antithyroid effect has been
reported by some investigators but three
different clinical studies failed to confirm this.
Local Reactions: Thrombophlebitis has
occurred with I.V. administration.
Other: Proliferation of Candida albicans in
the vagina, vaginal dryness and burning;
dysuria; occasional flushing and headaches,
especially with concomitant ingestion of
alcohol; altered taste of alcoholic beverages.
Darkening of the urine has been reported.
This is probably due to a metabolite of
metronidazole and seems to have no clinical
significance.

SYMPTOMS AND TREATMENT OF
OVERDOSAGE
Symptoms
Massive ingestion may produce vomiting and
slight disorientation.

Treatment
There is no specific antidote. Early gastric
lavage may remove a large amount of the
drug; otherwise, symptomatic treatment.

DOSAGE AND ADMINISTRATION
Treatment of anaerobic infections
Treatment should be initiated by the I.V.
route. Oral medication may be substituted
when it is feasible and/or practical. Duration
of therapy depends upon clinical and
bacteriological assessment. Treatment for
seven days should be satisfactory for most
patients. However in cases where infection
sites cannot be drained or which are liable to
endogenous recontamination by anaerobic
pathogens, a longer treatment may be
required.

I.V. Administration
100 mL (500 mg) by intravenous infusion
every 8 hours. The injection should be
infused intravenously at the rate of 5 mL per
minute.
Flagyl Injection is compatible in a volume
ratio of 1:5 with normal saline, dextrosesaline, dextrose 5 per cent w/v or potassium
chloride injections (20 mmol and 40 mmol).
These admixtures will remain stable for a
period of 24 hours when kept in the dark or
in combined daylight and artificial light. Not
to be mixed with sodium lactate injection
5% w/v, or dextrose injection 10% w/v.

AVAILABILITY
Injection 0.5% w/v Viaflex' plastic bags of
100 mL (500 mg) for i.v. infusion.
'Tradem ark of Baxter Travenol Laboratories Inc.
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Effects of Cod-Liver Oil on Intimal Hyperplasia
in Vein Grafts Used for Arterial Bypass
Cod-liver oil rich in eicosapentaenoic
acid, an unsaturated fatty acid, has been
shown to inhibit platelet aggregation. To
determine the effect of this acid on veingraft intimal hyperplasia, 46 segments of
undistended external jugular vein were
interposed between the bilaterally
divided femoral arteries of 26 mongrel
dogs. The animals received a 2 %
cholesterol diet for 1 week before and 6
weeks after the operation. Eight control
animals received the diet alone, eight
received cod-liver oil containing 1.8 g of
eicosapentaenoic acid daily, for 1 week
before and 6 weeks after operation,
and seven animals received 1.8 g of
eicosapentaenoic acid daily for 6 weeks
after operation. Intimal thickness was
measured at 6 weeks with a Zeiss com
puterized interactive image analysing
system from multiple cross-sections of
vein graft; 3 9 5 ± 1 0 measurements were
made from each graft. The intima meas
ured 4 ± 0 .2 fitn (SEM) before implanta
tion and increased to 8 3 + 1 0 fim in the
controls. Eicosapentaenoic acid
administered before and after operation
reduced intimal hyperplasia to 24 + 2.5
/im (p <0.0011 and to 3 0 ± 5 jtm in
animals receiving eicosapentaenoic acid
after operation only ( p < 0.001). These
results indicate that the acid inhibits
intimal hyperplasia of canine vein grafts
but that it is more effective when
given before operation (p < 0 .0 1 ).
L'huile de foie de morue qui est riche en
acide eicosapentaenoique, un acide gras
From the *Division o f Thoracic and Cardi
ovascular Surgery, Department o f Surgery
and tDepartment o f Pathology, Dalhousie
University, Halifax, N S
Supported by a grant from the New
Brunswick Heart Foundation
Accepted f o r publication Nov. 1, 1985
Reprint requests to: Dr. R. W. Landymore,
Rm. 3065, R.C. Dickson Center, Victoria
General Hospital, Halifax, N S B3H 2Y9

insature, inhibe I'agregation plaquettaire.
Afin de constater I'effet de cet acide sur
I'hyperplasie de I'intima des greffes veineuses, on a interpose 46 segments de
veines jugulaires externes non distendues
entre les arteres femorales bilateralement
divisees de 26 chiens batards. Les animaux ont recu un regime alimentaire
contenant 2 % de cholesterol a partir
d'une semaine avant I'operation jusqu'a
la 6e semaine qui a suivie. Huit animaux
temoins ont regu la diete seule, huit ont
recu de l'huile de foie de morue renfermant 1.8 g d'acide eicosapentaenoique
quotidiennement pendant la meme
periode, et sept animaux ont recu une
dose quotidienne de 1.8 g d'acide eico
sapentaenoique apres I'operation seulement. L'epaisseur de I'intima a ete mesuree apres la 6e semaine a I'aide d'un
systeme Zeiss d'analyse interactive des
images par ordinateur sur des coupes
multiples des greffons veineux;
395 ± 1 0 analyses ont ete faites sur
chaque greffe. L'intima qui mesurait
4 ± 0.2 /tm (± ET) avant la greffe a
augmente a 83 ± 10 /im chez les
temoins.
L'acide eicosapentaenoique administre
avant et apres I'intervention a reduit
I'hyperplasie de I'intima a 24 ± 2.5 /*m
(p < 0.001) et, quand il a ete administre
apres I'operation seulement, a 30 ± 5
/*m (p < 0.001). Ces donnees indiquent
que l'acide eicosapentaenoique inhibe
I'hyperplasie de I’intima dans les greffons
de veines canines mais qu'il est plus efficace quand le traitement commence
avant I'operation.

Cod-liver oil is rich in the unsaturated
fatty acid eicosapentaenoic acid.12 Find
ings o f recent investigations3,4 indicate
that increased dietary intake o f eicosapen
taenoic acid results in decreased platelet
aggregation and total platelet counts. The
potential for eicosapentaenoic acid to
inhibit platelet aggregation prompted this
study to determine whether it could be
used to prevent platelet-mediated intimal

hyperplasia in autogenous vein grafts
used for arterial bypass.

Material
Twenty-three adult mongrel dogs,
weighing between 25 and 30 kg, were
divided into three groups. The animals
were fed a 2% cholesterol diet (IC N
Nutritional Biochemicals, Cleveland,
Ohio) that was started 1 week before
operation and continued for the duration
o f the study. Eight animals served as con
trols (group 1) and received the lipidsupplemented diet alone. Eight animals
also received cod-liver-oil capsules, con
taining 1.8 g o f eicosapentaenoic acid
daily for 1 week before and 6 weeks after
operation (group 2); a further seven
animals received the diet and 1.8 g o f
eicosapentaenoic acid daily but only after
the operation (group 3).

Operative Protocol
Preoperative sedation consisted o f 1
mL o f Innovar, containing fentanyl
citrate (0.4 m g/m L) and droperidol (20
mg/mL). Anesthesia was induced and
maintained with sodium pentobarbital (3
mg/kg) and the animals were ventilated
with a pressure-regulated ventilator.
The fem oral arteries were exposed
bilaterally and a segment o f autogenous
external jugular vein was harvested from
the neck, using sterile technique. A small
segment o f external jugular vein was
immediately fixed in formaldehyde for
later examination under the light micro
scope. A fte r the systemic administration
o f heparin (2 mg/kg), undistended 2.5-cm
segments o f external jugular vein were
interposed between bilaterally divided
femoral arteries. The anastomoses were
completed with running 6-0 Prolene,
using optical magnification. Hepariniza
tion was then reversed with protamine
sulfate and the incisions were closed.
The animals were anesthetized 6 weeks
later and the vein grafts were harvested
and fixed in formaldehyde.
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Analysis of Vein-Graft
Intimal Hyperplasia
Cross-sections of the autogenous vein
grafts were sampled at 2-mm intervals
along the entire length of each graft. The
cross-sections were stained with hematox
ylin and eosin and Masson stains. Intimal
thickness of each vein graft was measured
from multiple cross-sections using a Zeiss
computerized interactive image analysing
system. This system comprises a com
puter, a Zeiss microscope and a 12-inch
television screen. Slides are projected on
the screen and a mobile cursor, connected
to the computer, is used to measure
intimal thickness in micrometres. Meas
urements were made at 100-^m intervals
around the circumference of each crosssection. The resolution of the measuring
equipment was in the range of ± 0.52 tun.
Hematologic and Biochemical Analyses
Serum cholesterol and hemoglobin
levels, the hematocrit, total platelet count,
and prothrombin, partial thromboplastin
and bleeding times were all measured
before the 2% cholesterol diet was
started, while the animals were receiving
the lipid-supplement diet before operation
and at 2 and 4 weeks after autogenous
vein implantation.
Student’s /-test and the F distribution
were used for statistical comparisons.
Results are reported as the arithmetic
mean with corresponding standard error.
Results
Lipid supplementation caused a simi
lar weight gain in all three groups and
resulted in an overall increase in total
body weight of 3.5± 0.4 kg (p <0.01).
The baseline serum cholesterol level was
4.6 ± 0 .4 mm/L and the level increased
similarly in all groups: to 8.3 ± 0.4 mm/L
in group 1, 7.1+ 0.5 m m /L in group 2
and 6.6±0.5 m m /L in group 3 (p<0.01).
The hemoglobin and hematocrit values,
the bleeding, prothrombin and partial
thromboplastin times and the total plate
let count were unchanged throughout the
study.

difference in mean intimal thickness in
vein grafts harvested from the right and
left extremities. Measurements (395 ± 10
per graft) o f intimal thickness are
represented diagrammatically in Fig. 1.
Intimal thickness before implantation
measured 4 ± 0.2 ;tm; this increased to
83 ±10 fim at 6 weeks in group 1. In
group 2, there was a smaller increase in
intimal thickness (24± 2^m ) (p<0.001).
Similarly in group 3, the increase in
intimal thickness was smaller than in con
trol animals (30 ± 5 jim) (p < 0.001).
Although the administration of eicosapentaenoic acid resulted in a lesser
degree of vein-graft intimal hyperplasia
when given either before and after or only
after arterial bypass, there was less vari
ance in mean intimal thickness when codliver oil was administered both before and
after implantation (p<0.01, F distri
bution).
Vein-graft cross-sections are illustrated
in Fig. 2. The marked increase in thick
ness in control animals (Fig. 2A) is in con
trast to that in animals receiving eicosapentaenoic acid before and after (Fig. 2B)
or only after arterial reconstruction (Fig.
2C).

epidemiologic observations have been
made in other parts of the world. The
prevalence of atherosclerotic heart disease
is lower on the island of Okinawa and in
Japanese fishing villages where fish con
stitute a large part of the diet.7 Kromhout and colleagues8 have just concluded
a 20-year prospective study on heart dis
ease in the town of Zutphen in the Nether
lands. They observed an inverse relation
between dietary consumption of fish oil
and the 20-year death rate from coronary
artery disease.
High platelet counts and elevation of
serum lipid levels have been implicated in
the pathogenesis of atherosclerosis.9
Marine oils, rich in the unsaturated fatty
acid eicosapentaenoic acid, have been
shown to inhibit platelet aggregation and
reduce total platelet counts.3'4 Also,
increased dietary intake of eicosapen
taenoic acid reduces serum lipid levels in
normolipidemic subjects and in patients
with hyperlipidemias.10,11 The effects of
marine oil on platelet function and serum
lipid values may explain the lower fre
quency of coronary artery disease in
populations in which there is a high daily
intake of fish.

Discussion
Epidemiologic studies5'6 indicate that
Greenland Eskimos have a much lower
prevalence of atherosclerotic heart disease
than the non-Eskimo North American
population. Subsequent clinical investi
gations1’2 have shown that this finding is
related to the Eskimo diet that is rich in
marine oils containing the unsaturated
fatty acid, eicosapentaenoic acid. Similar

Intimal Thickness
Exam ination of vein-graft crosssections under the light microscope before
implantation demonstrated that the
intima was intact and had not been
damaged during harvesting. Statistical
comparison of individual cross-sections
of vein graft demonstrated that intimal
thickness as determined with a Zeiss com
puterized microscope did not vary signifi
cantly along the entire length of the graft
and that any one section was representa
tive o f the degree of intimal hyperplasia.
Furthermore, there was no statistical
130

FIG. 1—Intimal thickness measured in
micrometres with corresponding standard error
of mean (395 ±10 measurements per graft) for
three groups of dogs: group 1 (controls) that
received only lipid-supplemented diet, group
2 (EPA-B) animals that received eicosapen
taenoic acid before and after operation and
group 3 (EPA-A) that received eicosapen
taenoic acid after operation only.

FIG. 2—Vein-graft cross-sections. (A) Typi
cal appearance of intima in vein graft from
control dog, receiving lipid supplementation
only. Intimal thickening after implantation is
reduced when eicosapentaenoic acid is
administered (B) before or (C) after operation
(hematoxylin and eosin, original magnification
X 250).
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Experimental catheter abrasion of the
arterial intima causes fibromuscular
intimal hyperplasia and the formation of
an early atherosclerotic plaque in animals
receiving a lipid-supplemented diet. In
contrast, the intim al proliferative
response is reduced and early athero
sclerotic lesions fail to develop in animals
with platelet deficient serum.12 Similar
histologic features are present in vein
grafts used for arterial reconstruction.
Fibromuscular intimal hyperplasia is
present within 6 months and typical
atherosclerotic lesions have been observed
in vein grafts removed at autopsy many
years after operation.13-15 Metke and
colleagues16 have demonstrated that
antiplatelet drug regimens reduce intimal
hyperplasia in canine autologous vein
grafts and, more recently, Chesebro and
associates17 have shown that platelet
inhibition improves long-term patency in
vein grafts used for myocardial revas
cularization, thus establishing a link
between platelets and the development of
fibromuscular intimal hyperplasia.
The findings o f experimental studies
and clinical trials indicate that eicosapentaenoic acid inhibits platelet aggregation
by reducing the platelet membrane
production of proaggregatory prostaglan
din thromboxane A 2.18-20 Arachidonic
acid is the precursor for platelet
prostaglandin biosynthesis and is con
verted by platelet membranes to proag
gregatory thromboxane A 2. Eicosapentaenoic acid competes with arachidonic
acid for the enzyme cyclo-oxygenase and
is metabolized by platelet membranes to
a weakly aggregatory prostanoid throm
boxane A 3,21 whereas blood vessels
metabolize eicosapentaenoic acid to
prostacyclin I3.22 The effects of increased
dietary intake of eicosapentaenoic acid on
platelet aggregation and more recent
reports demonstrating the effectiveness of
antiplatelet drug regimens on the reduc
tion of intimal hyperplasia suggest that
eicosapentaenoic acid might be used to
prevent intimal hyperplasia in veins used
for arterial reconstruction.
We have shown previously23 that a
high cholesterol diet accelerates intimal
hyperplasia in canine autologous vein
grafts and we used the same model in this
study to determine the effects of
eicosapentaenoic acid on vein-graft
intimal hyperplasia. Our data show that
eicosapentaenoic acid reduces intimal
hyperplasia when given either before or
after operation, but the unsaturated fatty
acid is less effective when administered
following arterial bypass. This observa
tion is in keeping with those of previous
studies.24
Although this study is only prelimi
nary, it suggests that cod-liver oil reduces
canine vein-graft intimal hyperplasia and
that further studies are needed to deter

mine whether eicosapentaenoic acid may
be used to improve long-term graft
patency following arterial reconstruction.
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◄ PRESCRIBING INFORMATION ►
ANUSOL*-HC
ointment/suppositories
hemorrhoidal preparations
INDICATIONS: For the relief of the pain and dis
comfort following anorectal surgery of all types
and that which is associated with the acute phase
of common anorectal disorders. These include
hemorrhoids, internal and external (including
those accompanying pregancy) whether or not
complicated by thrombosis and prolapse; pruritis
ani; proctitis, cryptitis, fissures and incomplete
fistulas; and other congestive allergic or inflam
matory conditions.
CONTRAINDICATIONS: Should not be used in
patients with a sensitivity to any of the compo
nents. Not to be used in the presence of existing
tuberculous, fungal and viral lesions of the skin.
PRECAUTIONS: Until an adequate proctologic
examination is complete and a diagnosis made,
any preparation containing hydrocortisone
should not be used. In addition, specific measures
against infection, allergy and other causal factors
must not be neglected. Prolonged use could pro
duce systemic corticosteroid effects, although
none have been noted to date. As with all medica
tion that is applied locally, if idiosyncratic reactions
occur, medication should be discontinued. The
safe use of topical corticosteroids during preg
nancy has not been fully established. Therefore,
during pregnancy, they should not be used unne
cessarily on extended areas, in large amounts, or
for prolonged periods of time.
ADVERSE EFFECTS: Occasionally patients may
experience burning upon application, especially
if the anoderm is not intact. Local sensitivity reac
tions have been rare.
OVERDOSE: The chances of overdosage are very
rare, and no toxic reactions or side-effects have
been reported. In case of accidental ingestion,
perform gastric lavage followed by a purgative
dose of magnesium sulfate.
DOSAGE: OINTMENTS: Administer in the morn
ing and again at bedtime, and after each bowel
movement. Continue this treatment until the acute
phase of pain and discomfort passes and the
inflammation subsides.
SUPPOSITORIES: Insert 1suppository in the morn
ing and 1 suppository at bedtime and after each
bowel movement. Continue this treatment until
the acute phase of pain and discomfort passes
and the inflammation subsides.
SUPPLIED: Ointment: Available in 15 g and 30 g
tubes with a plastic applicator. Suppositories:
Available in boxes of 12 and 24 suppositories.
INGREDIENTS:
Zinc Sulfate
Monohydratef
Hydrocortisone
Acetate

Suppositories

Ointment

10 mg

0.5%

10 mg

0.5%

TUCKS*
A soothing, cooling, medicated wet dressing and
cleansing pad for hemorrhoids, feminine hygiene
and personal itching problems.
DIRECTIONS: Gently wipe and cleanse affected
area. For additional relief, apply Tucks for 15-30
minutes, 3 to 4 times daily.
Soft pads medicated with Hamamelis water 50%,
glycerin 10%, distilled water, q.s.
ANUSOL*-HC
*Reg. TM. of Warner-Lambert Canada Inc.
Parke-Davis Canada Inc. auth. user
TUCKS*
*Reg. TM. of Parke, Davis & Company,
Parke, Davis & Company, Ltd. Registered user

PARKE-DAVIS
Parke-Davis Canada In c. Scarborough. Ontario
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Dalacin C Phosphate S.S.

(clindam ycin phosphate)
Recommended Applications

Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by
causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections
where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and microaerophilic streptococci,
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when
the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in
patients previously found to be hypersensitive to this compound, the parent compound, clindamycin, or
clindamycin palmitate. Although cross-sensitization w ith Lincocin® (lincomycin hydrochloride) has
not been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have
demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn
(infants below 30 days of age), or in pregnant women.
turnings: Some cases of severe and persistent diarrhea have been reported during or after therapy with
Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary,
continued only w ith close observation. Significant diarrhea occurring up to several weeks post-therapy
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes may
respond to simple drug discontinuance. Moderate to severe cases, including those showing ulceration
or pseudomembrane formation, should be managed w ith fluid, electrolyte, and protein supplementa
tion as indicated. Corticoid retention enemas and systemic corticoids may be of help in persistent
cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes of colitis
should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually lensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 - 1 0 or more days, there was a rapid observed
disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
Is should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with
caution in atopic individuals.
Dalacin C Phosphate must be diluted for intravenous administration. (See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly
yeasts. Should superinfections occur, appropriate measures should be taker, as indicated by the
clinical situation.
As w ith all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy.
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic
liver function tests should be performed during prolonged therapy. Blood counts should also be
monitored during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients with impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not
effective means of removing the compound from the blood. Periodic serum levels should be determined
in patients w ith severe hepatic and renal insufficiency.
Adverse Reactions: Local.
(a) Intramuscular Injections: Of 404 patients treated w ith Dalacin C Phosphate (clindamycin phos
phate) intramuscularly (with a solution containing 150 m g/m L), six (1.5%) demonstrated local
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at the
injection site and tw o developed sterile abscesses.
(b) intravenous Infusions: Of 192 patients treated w ith Dalacin C Phosphate by intravenous infusion,
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and
one patient developed both superficial and deep thrombophlebitis. The majority of these cases
developed in conjunction with the use of indwelling I.V. catheters and it is difficult to know how much
the drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated w ith Dalacin C Phosphate (clindamycin
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as
follows:
Number o f Patients
R ash.................................................................................................................................................................. 7
U rtic a ria .......................................................................................................................................................... 1
Pruritus............................................................................................................................................................. 1
Fever, Leucocytosis .................................................................................................................................... 1
Nausea, w ith or without v o m itin g ............................................................................................................. 1
Diarrhea (See also under“Warnings” ) ....................................................................................................... 4
Hypotension ................................................................................................................................................... 1
Hypertension................................................................................................................................................... 1
Shortness of Breath ....................................................................................................
1
S up erinfection ".............................................................................................................................................. 4
Cardiac arrest” ........................................................................................................................................... 1
Bad and bitter taste inm o u th ...................................................................................................................... 5
" Superinfection is a complication of antibiotic therapy in general and is not necessarily a true
side effect of clindamycin phosphate.
■* Due to underlying myocarditis in this patient.

Clinical anil Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology, * *
urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and returned
to normal during therapy with Dalacin C Phosphate, while others were normal initially and became
abnormal during therapy. Overall evaluation of clinical laboratory values in these patients does n o t'
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal
systems. Transient elevations of serum transaminases have occurred in some patients, but other lived ' J
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and
there have not been clinical signs of drug-induced hepatic toxicity.
e—
Symptoms sod Trratmmt of Overdossgo: No cases of overdosage have been reported. No specific antidote
is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days have been •< 4
given without adverse effects,
DOSAGE AND ADMINISTRATION
,
Adults
Intramuscular Injection: 600 mg/day in 2 equal doses.

d * ‘

Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2 .3 or 4 equal doses. Intramuscular injections of more than
600 mg into a single site are not recommended.

~~

Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to I.V. *
administration to a dilution of 300 mg in 50 ml of diluent (6 m g/m l) or more, and infused in not less
than 10 minutes. Administration of more than 1200 mg in a single 1 hour infusion is not recommended * — ■
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, eactt 4 *
infused over 20 minutes or longer.
Severe infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused over *«
20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by continuous drip
or in 3 or 4 equal doses each infused over 20 minutes or longer may be given,
.. ,
Dilution and Infusion rites:
Dose
300 mg
600 mg
900 mg
1200 mg

Diluent
50 ml
100 ml
150 ml
200 ml

Time
10 min.
20 min.
30 min.
45 min.

*

<4

4

♦‘

Alternatively, drug may be administered in the form of a single rapid infusion of thefirst dose followed
by continuous I.V. infusion as follows:
+, 11
To maintain serum
Rapid
Maintenance
clindamycin levels
infusion rate
infusion rate
4
Above 4 mcg/ml
10 mg/min. for 30 min.
0.75 mg/min.
Above 5 mcg/ml
15 mg/min. for 30 min.
1.00 mg/min.
Above 6 mcg/ml
20 mg/min. for 30 min.
1.25 mg/min.
4
*
Children: (Over one month of age)
Intramuscular injection: 10 to 15 m g/kg/day in 2, 3 or 4 equal doses.
Moderately severe infections: 15 to 20 m g/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 m g/kg/day in 3 or 4 equal doses.
1
Intravenous Administration:
Moderately severe infections: 15 to 25 m g/kg/day by continuous drip or in 3 or 4 equal doses, each””* ’
infused over 20 minutes or longer. In severe infections, it is recommended that children be given no less
than 300 mg/day regardless of body weight. (Dilute Dalacin C Phosphate Sterile Solution in the same»
manner as for adults.)
Dilution and Compatibility:
4
4 ml (600 mg) Dalacin C Phosphate when diluted w ith 1000 ml of the following commonly used in
fusion solutions was found to be physically compatible and demonstrated no significant change in pH 4
or antimicrobial potency over a period of 24 hours:
Sodium chloride injection
Dextrose 5% in water
'
Dextrose 5% in saline
Dextrose 5% in Ringer’s Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
Dextrose 2%% in lactated Ringer’s Solution (Hartmann’s Solution)
. Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is
not recommended that Dalacin C Phosphate be mixed w ith any infusion solution containing B vitamins - >
Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution:
Clindamycin phosphate equivalent to clindamycin base 150 mg
Benzyl alcohol 5 mg
Disodium edetate 0.5 mg
Water for injection q.s.

j
^
'

When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a pH ^
range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.
NOTE: Do not store below 15°C.
Product Monograph available upon request. CE 1377.1C
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Right Hemothorax: an Unusual Presentation
of Ruptured infrarenal Abdominal Aortic Aneurysm
The authors describe what they believe
is the first reported case of rupture of an
infrarenal abdominal aortic aneurysm into
the right pleural cavity. A 75-year-old
woman presented simultaneously with
two common causes of severe abdomi
nal pain and hypotension: perforated
duodenal ulcer and ruptured abdominal
aortic aneurysm. The absence of an
infrarenal retroperitoneal hematoma
delayed the diagnosis of rupture of the
abdominal aortic aneurysm and the ter
minal event was exsanguination into the
right pleural cavity through an erosion in
the right hemidiaphragm.
Les auteurs ddcrivent ce qu'ils croient
etre le premier cas rapporte de rupture
d'un andvrisme sous-renal de I'aorte
abdominale dans la cavite pleurale droite.
Une femme de 75 ans a ete vue prdsentant simultan6ment deux causes frequentes de douleur abdominale intense et
d'hypotension: un ulcdre perform du duo
denum et une rupture d'un an6vrisme de
I'aorte abdominale. L'absence d'un
hematome retroperitoneal sous-renal a
retarde le diagnostic d'anevrisme rupture
et Tissue finale a ete I'exsanguination
dans la cavite pleurale droite £ travers
une erosion dans I'hemidiaphragme droit.

Infrarenal abdominal aortic aneurysms
usually rupture into the retroperitoneal
space, less commonly into the peritoneal
cavity and rarely into adjacent structures
such as the inferior vena cava, the left
renal vein and the gastrointestinal tract.
Massive left hemothorax has been found
at autopsy in three patients with ruptured
abdom inal aortic aneurysm s.1 This
report describes a case of secondary rup-
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ture o f an infrarenal abdominal aortic
aneurysm into the right pleural cavity.
Case Report
A 75-year-old woman was admitted for
investigation of persistent abdominal pain radi
ating to the back without associated gastroin
testinal or constitutional symptoms. She had
had the symptoms for 2 weeks. Her medical
history included hypertension but was other
wise non-contributory.
The only positive finding on physical exami
nation was tenderness on deep palpation of the
lower abdomen. The leukocyte count was 19.7
x 109/L . A chest film showed a left upper
lobe infiltrate; the abdom en appeared
normal. The urine contained pus that grew
Escherichia coli on culture. Urinary tract infec
tion and a lung infiltrate of unknown cause
were diagnosed. Ampicillin (1 g every 6 hours)
was given intravenously.
During the first hospital week, the patient’s
abdominal pain persisted and she experienced
anorexia and nausea. The hemoglobin value
remained at 13 g/L , but the leukocyte count
gradually increased to 21.6 x 109/L despite
ampicillin therapy. Ultrasonography of the
abdomen revealed a 4 x 5-cm abdominal aor
tic aneurysm surrounded by what was thought
to be intraperitoneal fluid or, less likely, fluid
leaking from the aneurysm.
Severe epigastric pain radiating to the back
and clinical shock developed, so emergency
laparotomy was done. A large perforated duo
denal ulcer with purulent peritoneal fluid was
found; an infrarenal abdominal aortic
aneurysm was noted, but there was no bloodstaining of the retroperitoneal tissues to sug
gest rupture. The ulcer was oversewn with an
omental patch.
Postoperatively, massive fluid administra
tion was required to maintain normal blood
pressure and urine output. A right pleural effu
sion developed and 6 days after operation 300
mL of sanguineous fluid with a hematocrit of
8% was removed at thoracentesis. Thrombotic
occlusion of the common iliac veins and the
infrarenal inferior vena cava was demonstrated
by venography. Systemic heparinization gave
transient improvement in her respiratory status.
Eight days after operation the hematocrit fell
from 34% to 29% and the patient became
hypotensive and hypoxemic. She was placed
on cardiopulmonary bypass with a presump
tive diagnosis o f pulmonary embolism. The
pulmonary artery was free of clot, but profuse
bleeding into the right pleural cavity was noted
from a defect in the posteromedial aspect of
the right hemidiaphragm. Laparotomy was

performed, but the patient died in the operat
ing room.
At autopsy, a rupture of the anterolateral
wall on the right side of an infrarenal abdomi
nal aortic aneurysm was found, with a defect
in the aorta measuring 4 x 5 cm and sur
rounded by blood clot (Fig. 1). There was no
free blood in the peritoneal cavity or in the
lesser sac, and the retroperitoneal tissues
inferior to the aneurysm were not blood
stained. A large collection of blood had tracked
superiorly from the point of aortic rupture,
from the superior pole of the right kidney to
the costal attachments of the right hemidi
aphragm and through a necrotic tear in this
structure into the right pleural cavity. Complete
thrombosis of the iliac veins and the inferior
vena cava was encountered up to the level of
the adjacent ruptured aneurysm, but the
suprarenal and thoracic inferior vena cava and
the pulmonary arteries were free of clot. Apart
from the previously patched duodenal ulcer
and small splenic and right renal infarcts, no
other abnormalities were noted.

Discussion
The natural history o f an abdominal
aortic aneurysm terminates in its rupture.
The size o f the aneurysm correlates well
with the risk o f rupture, small aneurysms
less than 5 cm in diameter carrying a low
risk.1 In 17% o f autopsy cases the
aneurysm has been found to rupture into
the peritoneal cavity and in 82% o f cases
into the retroperitoneum2 where the
blood dissects caudally to the pelvis,
producing a large hematoma that has
a tamponade effect on the ruptured
aneurysm. Other sites o f rupture of
infrarenal adominal aortic aneurysms

FIG. 1—Lower arrow marks site of aortic
rupture. Upper arrow shows erosion of right
hemidiaphragm allowing blood to enter right
pleural cavity.

VOLUME 29, NO. 2, MARCH 1986 / THE CANADIAN JOURNAL OF SURGERY

133

have been described, such as into the
inferior vena cava,34 the left renal vein,5
an anomalous renal vein6 and the gas
trointestinal tract7'8 where the duodenum
(especially the third part) is the organ
most commonly involved. Secondary rup
ture of an infrarenal abdominal aortic
aneurysm into the left pleural cavity was
found in three cases of a large autopsy
series,1 but to our knowledge no case of
rupture of an infrarenal aortic aneurysm
into the right pleural cavity has previously
been reported.
The coexistence of perforated peptic
ulcer and ruptured abdominal aortic
aneurysm in this elderly woman is
interesting and unusual. The proportion
of abdominal aortic aneurysms is higher
in men than in women by a ratio of
approximately 10 to l .9 Although the
rate of peptic ulcer disease in the general
population is estimated to be between 5%
and 15% ,10 this disease has been found
at autopsy in 22.6% of those with an
abdominal aortic aneurysm.11 In the lat
ter series, however, an important associ
ation between abdominal aortic aneurysm
and peptic ulcer was noted in men, but
not in women.
Although it is impossible to determine
the exact time of initial rupture of the
abdom inal aortic aneurysm in our
patient, retroperitoneal rupture was most

likely present at the time of admission but
remained clinically silent because of the
tamponade effect of the hematoma. Con
comitantly, the patient had an active pep
tic ulcer that was aggravated by the stress
of a ruptured aneurysm and perforated
intraperitoneally. Rupture of the abdomi
nal aortic aneurysm was missed at
laparotomy because the perianeurysmal
hematoma dissected superiorly rather
than inferiorly. Postoperatively, the
blood tracked into the pleural space
through a diaphragmatic defect, resulting
in an initial small right hemothorax which
was drained 2 days before the patient
died. A ssociated with this initial
hemothorax was thrombosis of the deep
pelvic veins and the inferior vena cava by
the expanding retroperitoneal aneurysm.
This angiographically demonstrated
thrombosis together with the persistent
severe hypoxemia led to the decision to
heparinize the patient systemically
because of presumed pulmonary embo
lism. Unfortunately, this transformed the
initial minimal bleeding into uncontroll
able hemorrhage into the right pleural
space, causing the patient’s death.
This case illustrates the fact that rup
tured abdominal aortic aneurysm may
occur simultaneously with other lifethreatening lesions, including perforated
peptic ulcer. Thus, when a patient with

a known abdominal aortic aneurysm
presents with abdominal pain and
hypotension, rupture must definitely be
ruled out even when the patient’s condi
tion can be explained by other abdomi
nal disease.
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Contribution of Immunohistochemistry to the
Diagnosis of Breast Cancer in Men
formly enlarged. A left breast biopsy was
performed under general anesthesia. The
breast tissue was fixed in buffered forma
lin and processed for light microscopy
and for immunohistochemistry to deter
mine the presence of prostate-specific
antigen. The immunohistochemical
method used was the PAP immunoperoxidase technique described previously.2
The primary antibody was obtained from
Primary carcinoma of the breast is rare Dako Corporation (Cedarlane Laborato
in men, compared with women, the ratio ries, Hornby, Ont.). Breast tissue from
being 1:100. Secondary carcinoma or five men with primary breast carcinoma
metastasis to the breast in both men and was stained simultaneously for the
women is also uncommon. It may arise presence of prostate-specific antigen. Two
from prostatic carcinoma, malignant cases of prostate carcinomas were used as
melanoma, lymphoma or renal cell can a positive control.
A portion of the breast tumour was
cer. In a patient with prostatic carcinoma
and a tumour mass in the breast, there is quickly frozen in liquid nitrogen and exa
often controversy as to whether the lat mined for the presence of estrogen and
ter is a true metastasis or a primary breast progesterone receptors as described previ
carcinoma induced by estrogen therapy.1 ously.3,4
Chez I'homme qui souffre d'un cancer
We report the case of a man with
avarice de la prostate et qui presente
undifferentiated metastatic carcinoma to Pathological Findings
une tumeur du sein, il est souvent diffi
the breast from a carcinoma of the
cile de distinguer une lesion mammaire
Microscopically, the biopsy material
prostate. The breast lesion was identified
from the breast lesion contained sheets,
primitive d'une lesion secondaire. Les
by immunohistochemistry.
nests and, in focal areas, “ Indian files”
auteurs decrivent le cas d'un homme de
72 ans chez qui on a constate un cancer
of a poorly differentiated tumour
Case Material
du sein mal differencie apres qu'il eut
infiltrate in a fibrous stroma (Fig. 1).
recu un traitement aux oestrogenes pour
A 72-year-old man presented with con Rare tumour nests showed poorly defined
un cancer prostatique dissemine. L'utilistipation 6 years before the present admis glands. The cells had a thin eosinophilic
sation d'une methode immunohistochimision. At that time, needle biopsy of the cytoplasm with indistinct borders. The
que mettant en oeuvre un syst&me
prostate showed a poorly differentiated nuclei were dark and uniformly stained.
peroxydase-anticorps antiperoxydase non
adenocarcinoma involving striated mus Most cells had one prominent eosinophilic
marque a demontre I'existence d'un anti
cle (stage D). The acid phosphatase level nucleolus.
gene prostatique specifique dans les cel
was 7.51 IU/L (normal 0 to 11.0 IU/L).
When the immunoperoxidase tech
lules tumorales, etablissant ainsi I'origine
He took ethinyl estradiol, 0.05 mg twice nique was used to demonstrate the
secondaire de la lesion. Cinq sujets
daily until 1 year before the present presence of prostate-specific antigen, the
admission and also underwent bilateral cytoplasm of many tumour cells was
orchiectomy and three separate trans strongly stained (Fig. 2), but the residual
urethral prostate resections. Six months breast ducts did not stain.
From the *Department of Pathology,
The tissue from the five control
t Department o f Surgery and \Departmenl earlier an intravenous pyelogram showed
bilateral hydronephrosis and hydroureter. primary breast cancers showed no stain
o f Medicine, Royal Victoria Hospital and
McGill University, Montreal, PQ
Skeletal roentgenograms showed blastic ing for prostate-specific antigen.
Estradiol and progesterone binding
lesions
in the right sacroiliac joint and left
Supported in part by the Royal Victoria
innominate bone.
were both negative in our case.
Hospital Research Institute
Physically the patient was an elderly
Accepted for publication Sept. 6, 1985
man who had bilateral gynecomastia and Discussion
a firm mass (approximately 2.0 cm in
Reprint requests to: Dr. Serge Jothy,
The presence of prostate-specific anti
diameter) in the upper, outer quadrant of
Department of Pathology, McGill Univer
the left breast with no skin retraction. On gen in many cells of this otherwise poorly
sity, 3775 University St., Montreal, PQ
H3A 2B4
rectal examination the prostate was uni differentiated male breast cancer led us
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In men with advanced carcinoma of the
prostate who have a breast tumour, it is
often difficult to distinguish a primary
from a secondary breast lesion. The
authors describe the case of a 72-yearold man who presented with a poorly
differentiated carcinoma in one breast
after receiving estrogen therapy for dis
seminated prostatic cancer. Application
of the unlabelled antibody peroxidaseantiperoxidase immunohistochemical
method demonstrated prostate-specific
antigen in the tumour cells, thus estab
lishing the secondary origin of the lesion.
Five controls — men with primary breast
cancer — when tested by the same
method did not have this marker. The
authors conclude that in this clinical con
text, prostate-specific antigen is a useful
marker of breast cancer in men.

temoins, des hommes souffrant d'un
cancer mammaire primitif, n'ont pas
montrS la presence de ce marqueur
lorsqu'ils ont ete soumis au meme test.
Les auteurs concluent que dans ce contexte clinique, I'antigdne prostatique spe
cifique est un marqueur utile pour le can
cer mammaire chez I'homme.

to conclude that it represented a metasta
sis of prostate carcinoma. The usefulness
and the specificity of prostate-specific
antigen in this context are supported by
the observation that the marker was
absent in all control cases of primary
breast carcinoma that we studied simul
taneously.
The sensitivity of prostate-specific anti
gen as a marker of prostate cancer was
documented as being 100% in a study of
primary and metastatic prostate carci

nomas with no positive staining in the
other tissues tested.s However, extremely
poor differentiation of prostatic carci
noma can occasionally lead to negative
results, as shown in a report6 describing
the absence of prostate-specific antigen
marker in cases of prostate carcinomas
with Gleason’s grades7 higher than 9.
The case described in this report illus
trates a common problem in the patho
logical diagnosis of a breast tumour in a
man known to have a prostate carcinoma.
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Most of these patients receive long-term
treatment with estrogenic hormones and
consequently are at increased risk for the
development of a primary breast carci
noma. In cases in which the differentia
tion of the breast tumour is poor, the
usual morphologic criteria may lead to
ambiguity in distinguishing between the
primary or secondary nature of the lesion.
This ambiguity and the difficulties in
making a correct diagnosis by the usual
methods have been discussed by McDivitt
and colleagues,8 who concluded that
many so-called primary breast cancers in
men receiving estrogens for prostate car
cinoma actually represent metastatic
growth into the mammary ducts, giving
the appearance of a primary breast lesion.
We believe that by testing this lesion
immunohistochemically for the presence
of prostate-specific antigen, most cases
can be classified as secondary or primary
tumours, depending on the presence or
absence of the marker. With proper iden
tification of the biopsy material, patients
can be spared unnecessary surgery.

*
*
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FIG. 1—Normal mammary duct surrounded by fibrous stroma with tumour cells, which
are organized in upper field and are scattered in lower field (hematoxylin and eosin, original
magnification x 10).
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BOOK REVIEWS
COLON AND RECTAL SURGERY. Marvin
L. Corman. 784 pp. Iilust. J.B. Lippincott
Company, Philadelphia, 1984. $85. (US).
ISBN 0-397-50647-3.

Ordinary surgical mortals like me have their
sense of inadequacy reinforced by a book like
this. It is a single-author effort and Dr.Cor
man must have devoted a vast amount of
energy to this project over many years. As I
read through the book I found that my initial
prejudices and expectations about one author’s
personal dogma were completely unfounded.
In many ways this book is a personal statement
by the author, but it becomes clear that not
only is he a man of enormous personal
experience in the field but also who has a great
breadth of understanding and insight.
The book is remarkable from many aspects.
It is a textbook of diseases of the colon, rec
tum and anus, and it also succeeds, as few
books do, in being a surgical textbook of such
diseases. The illustrations by Lois Barnes are
outstanding and generous to a fault. She has
the knack of setting an uncluttered stage and
then focusing the viewer’s attention on the
point to be made. There is hardly a page
without visual amplification of the text in the
form of diagrams, photographs, tables and
histologic photomicrographs. The text is clear
and concise and the author usually makes it
quite clear whether he is expressing personal
views, literature consensus or another
individual’s treasured opinion. He takes a very
balanced approach to controversial areas and
the reader is left feeling well informed on the
various sides of such issues.
A serious test of any book is for a reader
to turn to an area of personal interest and to
see by how much the author is in agreement
or otherwise. For example, I went to the sec
tion dealing with alternative operative
approaches to cancer of the rectum and I was
not disappointed. The author discusses all the
recommended approaches but he puts every
thing into perspective with a level-headed dis
cussion of indications and complications. The
reader will also find up-to-date discussions of
modern concepts in inflammatory bowel dis
ease and newer operative techniques such as
sphincter-saving procedures, pelvic pouches
and Koch pouches. Each chapter is exhaus
tively indexed and this book could form the
basis of an entire libfary on the subject.
In summary, I have been unstinting in my
admiration for this book, first because it is very
good and second because of the personal stamp
of the author. This book talks directly to
general surgeons, specialist colorectal surgeons
and surgical trainees, and they will recognize
a wealth of experience and good judgement
behind it.

C harles J. W r ig h t ,
FRCS, FRCS(EDIN)

m b , m sc , frcsc ,

Professor of Surgery,
University of Saskatchewan,
Saskatoon, Sask.
S7N 0X0

PRINCIPLES OF FRACTURE M ANAGE
MENT. Edited by C.S.B. Galasko. 234 pp.
Iilust. Churchill Livingstone, Edinburgh;
Academic Press Canada, Don Mills, Ont.,
1984. $ 4 7 .7 5 , paperbound. ISBN
0-443-02508-8.

A volume this size is obviously not intended
to describe every fracture. It is, however, an
up-to-date reminder of the well-proven basics
of fracture treatment and of more recent
developments. The general outline of fracture
management is supplemented in each chapter
by an extensive bibliography.
The first chapter on the biology of fracture
repair by S.M.L. Nade details the sequence of
events involving soft tissue and bone, includ
ing the extent of necrosis of bone ends and
fragments in fractures. The similarities and
differences of healing fractures in cancellous
and cortical bone are outlined. Nade correctly
points out that angulation in a growing bone
may be corrected but that joint malalignment
at bone ends and rotation errors may not. The
biologic advantages of loose-fitting intramedul
lary nails and the extent of injury to the
diaphyseal blood supply by reaming and tightfitting nails are mentioned. Stable but not rigid
fixation appears to be a worthy goal to pro
mote union without osteopenia. “ By and large
treatment by closed methods, skilfully applied,
causes less interference with the normal
mechanism of bone healing than any other
method.”
The second chapter, a prolonged description
of self-evident factors in manipulation and cast
immobilization o f fractures, is made worth
while by a careful description of the compli
cations associated with this method of
treatment.
The correct use of skeletal traction in the
treatment of fractures of the femur and
humerus is the treatment of choice in some cir
cumstances. The use of the halo body cast is
adequately explained but I was surprised to see
odontoid fractures being treated by traction for
12 weeks.
The chapter on fracture bracing by J. Angel
details the techniques required and summarizes
the results that proponents of this method have
achieved.
The section on fixation of fractures without
rigidity outlines conditions for which less-thanrigid fixation is expected to succeed. When
rigid fixation is impossible, the judicious use
of a small intramedullary nail, Kirschner wire
or transfixion frame may allow satisfactory
healing of fractures, and several examples are
illustrated. Conditions in which unintentional
lack of rigidity is liable to occur are also illus
trated.
J. Rush prefers early closed intramedullary
nailing of the fractures of the femur over
delayed or open nailing since the risk of infec
tion is lower and the periosteal blood supply
is protected. Use o f cross screws in either or
both ends of a fenestrated nail avoids short

ening of comminuted fractures and controls
rotation in fractures nearer bone ends. The
cross-pin method is not mentioned for treat
ing tibial fractures.
C.E. Ackroyd provides a scholarly, welldocumented explanation of the advantages and
shortcomings o f and indications for rigid inter
nal fixation. The alternative of external frame
fixation in compound fractures is encouraged.
Guidelines based on the patient’s status and
future requirements, on the fracture itself, and
on the experience and available surgical facil
ities are set out in detail. The author points out
that modern functional nonoperative methods
have such great advantages in treating tibial
fractures that rigid internal fixation should be
used only for special cases. Causes of unsta
ble and inadequate fixation and its diagnosis
and management are also outlined.
The chapter on external fixation by D.
Court-Brown and S.P.F. Hughes reports valu
able firsthand experience in the design and use
of single-bar and frame fixation. They correctly
emphasize that its use should be discontinued
as soon as its primary objective of preventing
pin loosening has been achieved.
A pioneer in his field, R.O. Becker gives a
detailed description of the historical evolution
and the theory behind electrical stimulation of
tissue for repair and regeneration. He feels it
is precedent to limit the use of all electrical
stimulation techniques to ununited fractures
that have proved refractory to standard ortho
pedic treatm ent and to avoid its use in preg
nant women.
Galasko sets out the conditions o f success
ful treatment and the pitfalls of uncomplicated
fractures in almost all areas o f the skeleton.
The compilation of no less than 120 references
relevant to the problems discussed makes fur
ther detailed study easier wherever a good
reference library is available.
The final chapter on the treatment o f com
plicated fractures gives excellent guidelines for
treating minor, moderate and severe compound
fractures. The role an orthopedic surgeon may
play when dealing with visceral injuries and
damage to nerves and vessels is adequately dis
cussed. Management of multiple injuries and
the complications of pathologic fracture are
well summarized and again a generous biblio
graphy reinforces the author’s opinion.
Although it is the work of 12 writers, the
book’s style is uniformly clear and readable.
It is an up-to-date reminder of the well-proven
principles of fracture treatment and of more
recent developments. Its reading would also be
an invaluable preparation for a fellowship oral
examination.

J.P. M o r e a u , m d , frcsc , facs
Chief of Orthopedic Surgery,
Edmonton General Hospital,
11111 Jasper Ave.,
Edmonton, Alta.
T5K 0L4
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derived from cephamycin C, results from the
in h ibition of bacterial cell wall synthesis.
Evidence suggests that the methoxy group in
th e l a p o s itio n is re s p o n s ib le fo r the
resistance of cefoxitin to degradation by
bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATM ENT

The treatment of the following infections when
due to susceptible organisms:
1 - In tra -a b d o m in a l in fe c tio n s such as
peritonitis and intra-abdominal abscess
2 - G y n e c o lo g ic a l in fe c tio n s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by S erratia m arcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus
1 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
s h o u ld be perform ed to d e term in e the
susceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
O rga n ism s p a rtic u la rly a p p ro p ria te fo r
therapy with MEFOXIN* are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactam ase producing
and non-producing strains)

E. coli
K l e b s i e l l a s p e c ie s ( in c lu d i n g
pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species

K.

Anaerobes

Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that
MEFOXIN* can be administered to patients
w h o are a lso re c e iv in g c a r b e n ic illin ,
gentam icin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable fo r
p a tie n ts w ith b a c te re m ia , b a c te r ia l
septicemia, or other severe or life-threatening
infections, or for patients who may be poor
risks because of lowered resistance resulting
fro m su ch d e b ilita tin g c o n d itio n s as
malnutrition, trauma, surgery, diabetes, heart
failure, or malignancy, particularly if shock is
present or impending.
PROPHYLACTIC USE

MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
p o stop e ra tive ly) to patients undergoing
vaginal o r abdom inal hysterectom y and
abdominal surgery when there is a significant
risk of postoperative infection or where the
o ccurrence of postoperative in fe ctio n is
considered to be especially serious.
In patients undergoing cesarean section,
intraoperative (after clamping the umbilical
cord) and postoperative use of MEFOXIN*
may reduce the incidence of surgery related
postoperative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
a d m in is tra tio n of any a n tib io tic beyond
*®Trademark

24 hours fo llo w in g surgery increases the
possibility of adverse reactions but, in the
majority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens for culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
s e n s it iv it y r e a c tio n s to M E F O X IN *,
cephalosporins, penicillins or other drugs.
MEFOXIN* should be given with caution to
penicillin-sensitive patients.
There is some clinical and laboratory evidence
o f p a rtia l c ro s s -a lle rg e n ic ity between
cepham ycins and the other beta-lactam
antibiotics, penicillins and cephalosporins.
Severe reactions (including anaphylaxis) have
been re p o rte d w ith m ost b e ta -la cta m
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is im portant to co n sid e r a diagnosis of
pseudomembranous colitis in patients who
develop diarrhea in association with antibiotic
use. W hile studies indicate that a toxin
produced by C lo strid iu m d iffic ile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form
of allergy, particularly to drugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
a d m in is tra tio n o f the drug s h o u ld be
d is c o n tin u e d . S e rio u s h y p e rs e n s itiv ity
re a ctio n s may re q u ire tre a tm e n t w ith
epinephrine and other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
with transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
high and p ro lo n g e d serum a n tib io tic
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling’s solutions
but not with the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum m ay o c c u r if serum
concentrations of cefoxitin exceed 100 j/g/mL.
Serum samples from patients treated with
MEFOXIN* sh o u ld not be analyzed fo r
creatinine if withdrawn within two hours of
drug administration.
Increased nephrotoxicity has been reported
follow ing co n co m ita n t a dm inistration of
c e p h a lo s p o rin s and a m in o g ly c o s id e
antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
e s ta b lis h e d . If th e a d m in is tr a tio n of
MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition
is essential and if super-infection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100m g/kg/day and
above) have been a sso cia ted w ith an
increased incidence of eosinophilia and
elevated SGOT.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse
re a ctio n s ra re ly re q u ire d cessation of
treatment and usually have been mild and
transient.
Local Reactions

T h r o m b o p h le b itis has o c c u rre d w ith
intravenous administration. Some degree of
pain and tenderness is usually experienced
after intramuscular injections using water.
Induration has occasionally been reported.
Allergic

M acu lo p a p u la r rash, u rticaria, pruritus,
eosinophilia, fever and otherallergic reactions
have been noted.
Gastrointestinal

Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.
Blood

T ra n s ie n t e o s in o p h ilia , le u k o p e n ia ,
neutropenia, hemolytic anemia, and thromboc y to p e n ia have been re p o rte d . Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN*.
Liver Function

Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase have
been reported.
Kidney

Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure
has been re p o rte d rare ly. The role of
MEFOXIN* in changes in renal function tests
is d i f f ic u lt to a sse ss, s in ce fa c to rs
predisposing to prerenal azotemia or to
im paired renal function have often been
present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
M EFOXIN* may be adm inistered in tra 
venously or intramuscularly when required.
(See complete monograph for full details on
ADMINISTRATION and RECONSTITUTION.)
TREATM ENT DOSAGE
Adults

The usual a d u lt dosage is 1 g or 2g of
MEFOXIN* every 6 to 8 hours. Dosage and
route of administration should be determined
by severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
Type of
of infe ctio n

D aily
D osage

Frequency
and Route

Uncom plicated
form s* o f in 
fections such as
pneum onia,
urina ry tract
infection, soft
tissue in fectio n

3-4 g

1 g every 6-8 h
I.V. or I.M.

M oderately
severe or severe
in fections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
com m o nly
needing an ti
biotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

'I n c lu d in g p a tie n ts
a b s e n t o r u n lik e ly

in w h o m

b a c te r e m ia is

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or glomerulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.
Adults with Impaired Renal Function

MEFOXIN* may be used in patients with
reduced renal function but a reduced dosage

should be em ployed and it is advisable to
m o nitor serum levels in patients w ith severe
im pairm ent.
In adults w ith renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
A f t e r a lo a d in g d o s e , th e f o l l o w i n g
re com m endations fo r maintenance dosage
may be used as a guide:
RENAL
FUNCTION
M ild
im pairm ent
M oderate
im pairm ent
Severe
im pairm ent
Essentially
no function

CREATININE
CLEARANCE
m L/m in

DOSE

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

FREQUENCY

In the patient undergoing hem odialysis, the
loading dose of 1 - 2 g should be given after
each hemodialysis, and the m aintenance dose
should be given as indicated in the Table
above.
Neonates (Including Premature Infants),
Infants and Children (See WARNINGS for
Neonates under ADMINISTRATION in the
complete monograph.)
Premature Infants
with Body Weights
Above 1500 g

20-40 m g /k g e v e ry 12 h I V.

01 w e e k o f 20-40
a g e m g /k g e v e ry 12 h I.V.
20-40 m g /k g e v e ry 8 h I.V.
1- 4 w e eks o f age

Infants
1 m o n th to 2 years
o f age

20-40 m g /k g e v e ry 6 h or
every 8 h I.M. o r I.V.

Children

20-40 m g /k g e v e ry 6 h or
eve ry 8 h I.M. o r I.V.

In severe infections, the to ta l daily dosage in
in fa n ts and c h ild re n may be in c re a s e d to
200 m g/kg, but not to exceed 12 g per day.
MEFOXIN” is not recommended for the ther
apy of meningitis. If meningitis is suspected,
an appropriate antibiotic should be used.
A t p re s e n t th e re is in s u ffic ie n t d a ta to
recom m end a specific dosage fo r children
w ith im paired renal fun ction. However, if the
adm inistration of MEFOXIN* is deemed to be
esse ntial th e dosage sh o u ld be m o dified
co n s is te n t w ith the re c o m m e n d a tio n s for
adults (see Table above).
PROPHYLACTIC USE
For p rophyla ctic use, a three-dose regimen of
MEFOXIN is recommended as follow s:
Vaginal or abdom inal hysterectom y and
abdominal surgery
2 g a d m in is te r e d i n t r a m u s c u la r ly o r
i n t r a v e n o u s l y ju s t p r io r to s u r g e r y
(approxim ately one-half to one hour before
initial incision).
The second and th ird 2 g doses should be
adm inistered at 2 -6 hour intervals after the
initial dose.
Cesarean Section
The firs t dose of 2 g should be adm inistered
intravenously as soon as the um bilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intram uscularly fo u r hours and eig h t hours
after the first dose.

AVAILABILITY
M EFO XIN ” (ste rile c efo xitin sodium , Frosst
Std.) is supplied as sterile powder in boxes of
10 vials:
No. 3356 1 g cefoxitin as sodium salt
No. 3357 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored
below 30° C.
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Ideal working conditions.
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fidence.
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ICU RESEARCH FELLOW: - Ewart Angus Intensive Care Unit, The Wellesley Hospital. Available
July 1, 1986 for a onfe year period in an academic
Medical-Surgical Unit. Research areas include clin
ical epidemiology of ICU care, nutrition and
respiratory muscle physiology. Reply to: Dr. I.M.
Fraser, Director EAICU, 247 The Jones Bldg., 160
Wellesley St. E., Toronto, ON M 4Y 1J3 (416)
92 6 -7 7 4 7 .
-S 8 6 -0 4
HEAD OF SURGERY, REGINA: SK - The College
of Medicine, University of Saskatchewan, invites
applications for the position of Head of the Regi
na section, Department o f Surgery. The success
ful candidate w ill also be Head of the Department
o f Surgery at the Plains Health Centre in Regina,
and w ill be responsible for the undergraduate and
postgraduate teaching programs there. The aca
demic rank w ill be commensurate w ith the suc
cessful candidate's qualifications and experience.
In accordance w ith Canadian immigration require
ments, this advertisement is directed to Canadi
an citizens and permanent residents. Interested
candidates should send a letter of application, cur
riculum vitae and the names of three referees to:
Dr. C.J. Wright, Department of Surgery, Univer
sity Hospital, Saskatoon, SK S7N 0W 0. Closing
date for applications is April 15, 19 86.-S 86-13
ADVANCES AND CONTROVERSIES IN VASCU
LAR SURGERY - 1986: - May 27, 28. The Con
ference w ill be held at M ount Sinai' Hospital,
Toronto, Ontario and w ill be of interest to vascu
lar and general surgeons. Category One A M A
credits. For further information contact: Continu
ing Education, University of Toronto, Room 116,
FitzGerald Building 150 College S t., Toronto, ON
M5S 1A8. Tel.: (416) 97 8-27 18.
-S 86-10
TRANSPLANTATION SURGEON: ON The
University o f Toronto seeks a surgeon to direct its
multiorgan transplant program at one of its univer
sity based hospitals. Full training in general sur
gery plus form al clinical training in multiorgan
transplantation surgery is required. The success
ful candidate w ill also be expected to have ob
tained research training w hich w ill enable him/her
to conduct an independent research program and
interact w ith other faculty in the areas of tra ns
plant im m unology and infectious diseases relat
ed to transplantation. This w ill be an annual ap
pointm ent, at the rank of Assistant Professor.
Salary to commensurate w ith qualifications and
experience. Qualifications: MD, FRCSC. Effective
date of appointm ent: Open. Closing date o f appli
cations: February 28, 1986. Enquiries, curriculum
vitae and three letters of reference should be sent
to : Dr. R.M. Stone, Surgeon in Chief, Toronto
Western Hospital, 399 Bathurst St., Toronto, ON
M 5T 2S8. In accordance w ith Canadian Imm igra
tion requirements, this advertisem ent is directed
to Canadian citizens and permanent residents.
-S86-03

PROFESSOR OF SURGERY (OPHTHALMOLO
GY): NF — Applications are invited for the po
sition of Professor of Surgery (Ophthalmology)
in the Medical School, Memorial University of
N ewfoundland. The successful candidate fo r
th is appointm ent w ill also act as chief o f the
clinical ophthalm ology services in the Health
Sciences Centre, St. John's. The medical
school and hospital have targeted ophthalmol
ogy as an area of high priority fo r academic
and clinical development. The post w ould be
o f particular interest to a physician w ho w ish 
es to plan and oversee the expansion o f a
university based ophthalmology service in clin
ical, teaching and research areas. Interested
physicians w ho would like to make application
or to seek further inform ation should contact
the Chairman of the Search Com m ittee: W il
liam Pryse-Phillips, MD, FRCP, FRCPC, Health
Sciences Centre, Memorial University of N ew
foundland, St. John's NF A1B 3V6. —S86-09
CERTIFIED OBSTETRICIAN/GYNECOLOGIST: YK
— (Permanent position to commence im m ediate
ly but short term locums w ill be accepted.) Re
quired to join ten fam ily physician group located
in W hitehorse, servicing a population of 25 0 0 0
including 27 doctors. M ust have LMCC and Cana
dian fellow ship. Colposcopy and ultrasound a
definite asset. Excellent location for someone w ho
enjoys the outdoors. A ttra ctive northern fee
schedule. Please w rite complete resume, or te le 
phone: J.L. Pollock, Business Manager, W hite
horse Medical Services Limited, 4 0 6 Lambert St.,
Whitehorse, YK Y1A 1Z7. Tel.. (403) 6 6 7 -4 4 2 1 .
-S 8 6 -0 8

ALBERTA CHILDREN S HOSPITAL
CHILD HEALTH CENTRE

PAEDIATRIC
SURGEON
Alberta Children's Hospital,
Calgary, invites applica
tio n s from paediatric
general surgeons. Both ge
ographic full-time and clin
ical affiliation with the
University of Calgary Med
ical School available.
Candidates should be eligi
ble for certification by the
Royal College of Physicians
and Surgeons of Canada
and for licensure by the
College of Physicians and
Surgeons of Alberta.
Interested surgeons are re
quested to submit a curric
ulum vitae and the names
of three references to:
Please apply to:
Dr. S.T. Myles
Chief of Staff — Surgery
Alberta Children’s Hospital
1820 Richmond Road S.W.
Calgary, Alberta
T2T 5C7

Orthopedic Surgeons

OUTSTANDING PRACTICE
OPPORTUNITIES
Midwest U.S.A.
You know what Humana stands for: quality health care
that’s second to none. That’s exactly why we are assisting
these private practice physicians in their search for new
associates.
One practice opportunity is to join a board certified Ortho
pedic Surgeon with a successful, state-of-the-art Ortho
pedic and Sports Medicine practice. Training in hand
surgery is strongly preferred, however this physician will
assist financially with a hand fellowship. The second
practice opportunity is to join a multi-specialty group.
Both practices are affiliated with a ten-year-old, ultra
modern Humana hospital located in the midwest. The
hospital is already equipped for orthopedic surgery and
will purchase any additional equipment that is required.
For specific information, send your curriculum vitae or
call: John Hollander, Director o f Professional Relations,
Humana Inc., Dept. Z-3, The Humana Building, 500
West Main, Louisville, K Y 40201-1438. C O LLE C T:
502/580-3559.
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CHAIRMAN,
DEPARTMENT OF
INTENSIVE CARE
The General Hospital, St. John's, Newfoundland is
seeking an experienced individual to chair its Depart
ment of Intensive Care. The unit is located in a modern
health sciences centre which also houses The Memori
al University Faculty of Medicine. It accommodates
both medical and surgical patients.
Applicants should hold a fellowship from the Royal
College of Physicians and Surgeons of Canada and
have demonstrated administrative ability.
Details regarding financial arrangements and an ap
propriate University appointment can be obtained from
the Chairman of the Search Committee to whom in
quiries should be addressed:
Dr. David Hawkins
Health Sciences Centre
St. Jo h n 's, Newfoundland
A1B 3V6
(709) 737-6551

-S 8 6 -1 2

Hopital GeneralSt. Boniface-General Hospital
409 Tache Avenue
W IN N IP E G , M A N IT O B A R2H 2A6

HEAD, DEPARTMENT OF SURGERY
ST. BONIFACE GENERAL HOSPITAL
The University of Manitoba and St. Boniface General Hospital have
an opening for this position which includes a geographic full-time ap
pointment in the Department of Surgery, University of Manitoba and
provides opportunity for private practice.
The hospital is a fully affiliated teaching hospital of the University
of Manitoba. Owned and operated by the Grey Nuns of the Province
of Manitoba, this 850-bed general hospital has ten clinical depart
ments with geographic full-time heads. In addition to a broad com
munity base, the hospital provides tertiary care services with
particular excellence in several areas. The hospital provides major
services and is the geographic base for the University head of family
medicine and geriatric medicine. The new Youville Research Institute
offers ample space and facilities to support major research en
deavours. The department has twenty faculty members based in fa
cilities adjacent to the hospital.
The successful candidate will be an outstanding academic surgeon
with proven clinical and medical leadership qualities who as depart
ment head will foster excellence in patient care, teaching, and espe
cially in research. Experience in recruitment and development of
medical staff will be evident from the curriculum vitae and reference.
Salary and rank commensurate with experience and ability.
The position is open to both men and women. In accordance with
Canadian immigration requirements this advertisement is directed to
Canadian citizens and permanent residents.
Written nominations or applications for the position should be accom
panied by a curriculum vitae and three references and submitted by
March 31, 1986 to: Dr. R.J.W. Blanchard — Chairman, Department
of Surgery, University of Manitoba, c/o Room A 1 160, St. Boniface
General Hospital, 409 Tache Avenue, Winnipeg, Manitoba. R2H 2A6
-S 8 6 -1 4
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